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Background: Combination antiretroviral therapy (cART) is the standard for human immunodeficiency virus
(HIV) infection treatment but can result in metabolic abnormalities, such as insulin resistance, dyslipidaemia
and lipodystrophy, which can increase the risk of cardiovascular disease.
Objective: The objective of the trial was to evaluate whether or not telmisartan, an angiotensin II receptor
antagonist and a peroxisome proliferator-activated receptor-γ partial agonist, could reduce insulin resistance
in HIV-positive individuals on cART, and affect blood and imaging biomarkers of cardiometabolic disease.
Design: A Phase II, multicentre, randomised, open-labelled, dose-ranging trial of telmisartan over a period
of 48 weeks with an adaptive design comprising two stages was used to identify the optimal dose of
telmisartan. Participants were randomised to receive one of the three doses of telmisartan (20, 40 and
80 mg) or no intervention (control).
Setting: Recruitment was from 19 HIV specialist centres in the UK.
Participants: A total of 377 patients infected with HIV who met the prespecified inclusion/exclusion criteria.
Interventions: 20-, 40- and 80-mg tablets of telmisartan.
Main outcome measures: The primary outcome measure was reduction in the homeostatic model
assessment of insulin resistance (HOMA-IR), a marker of insulin resistance, at 24 weeks. Secondary outcome
measures were changes in plasma lipid profile; Quantitative Insulin Sensitivity Check Index (QUICKI) and
revised QUICKI, alternative markers of insulin resistance, plasma adipokines (adiponectin, leptin, interleukin 8,
tumour necrosis factor alpha, resistin); high-sensitivity C-reactive protein (hs-CRP); body fat redistribution,
as measured by magnetic resonance imaging/proton magnetic resonance spectroscopy; changes in renal
markers (albumin-to-creatinine ratio, neutrophil gelatinase-associated lipocalin); and tolerability to telmisartan.
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Results: At the interim analysis, 80 mg of telmisartan was taken forward into the second stage of the study.
Baseline characteristics were balanced across treatment arms. There were no differences in HOMA-IR [0.007,
standard error (SE) 0.106], QUICKI (0.001, SE 0.001) and revised QUICKI (0.002, SE 0.002) at 24 weeks
between the telmisartan (80 mg; n = 106) and non-intervention (n = 105) arms. Longitudinal analysis over
48 weeks showed that there was no change in HOMA-IR, lipid or adipokine levels; however, but there were
significant, but marginal, improvements in revised QUICKI [0.004, 95% confidence interval (CI) 0.000 to
0.008] and plasma hs-CRP (–0.222, 95% CI –0.433 to –0.011) over 48 weeks. Substudies also showed a
significant reduction in the liver fat content at 24 weeks (1.714, 95% CI –2.787 to –0.642; p = 0.005)
and urinary albumin excretion at 48 weeks (–0.665, 95% CI –1.31 to –0.019; p = 0.04). There were no
differences in serious adverse events between the telmisartan and control arms.
Limitations: The patients had modest elevations of HOMA-IR at baseline, and our trial could have been
under-powered to detect smaller improvements in insulin resistance over time.
Conclusions: Using a novel adaptive design, we demonstrated that there was no significant effect of
telmisartan (80 mg) on the primary outcome measure of HOMA-IR and some secondary outcomes (plasma
lipids and adipokines). Telmisartan did lead to favourable, and biologically plausible, changes of the secondary
longitudinal outcome measures: revised QUICKI, hs-CRP, hepatic fat accumulation and urinary albumin
excretion. Taken collectively, our findings showed that telmisartan did not reduce insulin resistance in patients
infected with HIV on antiretrovirals.
Future work: The mechanistic basis of adipocyte regulation will be studied to allow for development of
biomarkers and interventions.
Trial registration: Current Controlled Trials ISRCTN51069819.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council and National Institute for Health Research partnership.
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PRESS point-resolved spectroscopy
QUICKI Quantitative Insulin Sensitivity
Check Index
R&D research and development
RCT randomised controlled trial
REC Research Ethics Committee
SAE serious adverse event
SAR serious adverse reaction
SD standard deviation
SE standard error
SOC system organ class
SOP standard operating procedure
SUSAR suspected unexpected serious
adverse reaction
T2DM type 2 diabetes mellitus
TMG trial management group
TNF-α tumour necrosis factor alpha
TSC Trial Steering Committee
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Plain English summary
Human immunodeficiency virus (HIV) infection in humans is now a chronic disease that is treatable by acombination of anti-HIV drugs. This has resulted in a reduction in HIV-related deaths, but it has also
led to the emergence of serious side effects, such as HIV-associated lipodystrophy, diabetes mellitus and,
importantly, an increase in the risk of ischaemic heart disease. A key abnormality seems to be insulin resistance.
There is a need to find new strategies to reduce insulin resistance in individuals infected with HIV, which would
ultimately reduce the associated cardiovascular risk.
In the current randomised clinical trial, we have investigated whether or not telmisartan, a drug that is widely
used for hypertension, can reduce insulin resistance in individuals infected with HIV on anti-HIV drugs. We
used a novel adaptive trial design to compare three different doses of telmisartan with the control group
(those individuals who do not take telmisartan) in the initial stage. We then selected the best telmisartan
dose for the second stage, in which it was tested against the control to determine the effect on insulin
resistance. We also tested the effect of telmisartan on body, liver and limb fat, blood proteins (markers of
metabolic disease) and urine proteins.
A 80-mg dose of telmisartan was taken forward into the second stage of the study. Telmisartan did not
reduce the primary marker of insulin resistance [homeostatic model assessment of insulin resistance
(HOMA-IR)] over 24 weeks. It also did not affect the levels of lipids or hormones produced by fat cells.
However, over 48 weeks, it led to marginal improvements in another marker of insulin resistance [revised
Quantitative Insulin Sensitivity Check Index (QUICKI)], a marker of inflammation (high-sensitivity C-reactive
protein) and reduced protein excretion from kidneys. Magnetic resonance imaging analysis showed a
reduction in liver fat content. Overall, we did not show an effect of telmisartan on our primary marker of
insulin resistance in individuals infected with HIV who are on antiretroviral drugs.
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Scientific summary
Background
Combination antiretroviral therapy (cART) is the mainstay of treatment for human immunodeficiency virus
(HIV) and has dramatically improved the morbidity and mortality associated with HIV, turning it into a
chronic disease. However, cART, together with the virus itself, can lead to various metabolic complications
such as obesity, type 2 diabetes mellitus (T2DM) and an increased risk of cardiovascular disease (CVD).
In the HIV DAD (Data collection on Adverse events of anti-HIV Drugs) cohort, patients with metabolic
syndrome (MS) had a fourfold increase in the incidence of T2DM and a twofold to threefold increased
risk of CVD. Long-term cART exposure also leads to an increased incidence of myocardial infarction,
intima–media thickness and carotid lesions.
Insulin resistance, a key feature of MS, is central to cardiometabolic disease and is an important link
between features of MS, obesity, dyslipidaemia, T2DM and CVD. The prevalence of insulin resistance in
cART-treated patients infected with HIV ranges from 21% to 37%. Clinical interventions that arrest or
reverse cART-associated insulin resistance represent a strategy to reduce the incidence of T2DM and CVD
in patients infected with HIV. Insulin sensitisers such as thiazolidinediones and metformin have been
investigated, but randomised clinical trials in patients infected with HIV have shown mixed results.
Therefore, there is a need for novel clinical interventions with proven safety profiles that can reduce
cART-induced insulin resistance in individuals infected with HIV.
The angiotensin II receptor blocker telmisartan also has partial agonist properties at the peroxisome
proliferator-activated receptor-γ, an important regulator of adipocyte function. Prospective randomised
clinical trials in patients with diabetes mellitus, and those with MS, have shown that telmisartan significantly
reduces insulin resistance. Telmisartan also has wide-ranging beneficial effects on various components of
the MS: it results in reductions in fasting glucose, insulin, glycosylated haemoglobin, homeostatic model
assessment of insulin resistance (HOMA-IR); increases adiponectin; improves lipid parameters; and reduces
visceral fat. This study, and others, has shown that telmisartan partially reverses the antiadipogenic effects
of antiretrovirals in vitro. This in vitro study also showed a non-monotone relationship of telmisartan on
adiponectin and lipin 1 secretion. However, whether or not telmisartan would be clinically efficacious in
reducing insulin resistance in cART-treated patients infected with HIV has not been assessed. This trial,
therefore, was designed to address this important question, coupled with an assessment of the
dose–response relationship of telmisartan in vivo.
Objectives
Primary objective
To determine the effect of telmisartan on insulin resistance in individuals infected with HIV on cART using
HOMA-IR as a measurable, validated surrogate marker of insulin resistance.
Secondary objectives
l To define the optimal dose of telmisartan that can significantly reduce insulin resistance.
l To measure HOMA-IR values at baseline (T0) and at 12, 24 and 48 weeks to provide data on time to,
and sustainability of, any reduction in HOMA-IR.
l To utilise alternative indices of insulin resistance such as Quantitative Insulin Sensitivity Check Index
(QUICKI) and revised QUICKI to determine the effect of telmisartan on insulin resistance.
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l To mechanistically evaluate whether or not telmisartan modulates the plasma concentrations of both
beneficial (adiponectin) and adverse [leptin, resistin, tumour necrosis factor alpha (TNF-α), high-sensitivity
C-reactive protein (hs-CRP)] biomarkers, which may help in further stratifying telmisartan therapy in
the future.
l To determine whether or not telmisartan improves general lipid homeostasis and reduces visceral fat
accumulation in individuals infected with HIV on cART over a 24-week period.
l To determine, in a substudy, whether or not proton magnetic resonance spectroscopy (1H-MRS)-
assessed intrahepatic and intramyocellular triglyceride content, markers of hepatic steatosis and insulin
resistance, respectively, are reduced by telmisartan therapy.
l To determine whether or not telmisartan has an effect on urinary biomarkers [albumin-to-creatinine
ratio (ACR), neutrophil gelatinase-associated lipocalin (NGAL)] of renal injury in individuals infected with
HIV on cART.
l To evaluate the tolerability of telmisartan in this patient group.
Methods
Trial design
TAILoR was a multicentre, randomised open-labelled study with an adaptive design. The adaptive design
consisted of two stages. In stage 1, eligible patients were randomised on a 1 : 1 : 1 : 1 basis to either no
treatment or 20, 40 or 80 mg of telmisartan once daily. The duration of study treatment was a maximum
of 48 weeks, with follow-up visits at 12, 24, and 48 weeks. An interim analysis was performed when half
of the planned maximum number of patients had been followed up for at least 24 weeks. A subset of
patients in the main study took part in the magnetic resonance imaging (MRI) substudy over 24 weeks.
Participants
TAILoR participants were adults (aged ≥ 18 years) with documented HIV infection who had been receiving
a stable cART for at least 6 months prior to randomisation. The backbone of therapy was based on
nucleotide reverse transcriptase inhibitors, raltegravir or maraviroc, and patients should have been on a
boosted protease inhibitor (lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir/
ritonavir, saquinavir/ritonavir) and/or efavirenz, rilpivirine or etravirine for at least 6 months.
Patients were excluded if they were diabetic, had low blood pressure, renal disease, untreated renal artery
stenosis, cholestasis, biliary obstructive disorders or severe hepatic impairment, active chronic hepatitis C
infection, were on/had been on hormone therapy, anabolics and insulin sensitisers, or any other product
likely to influence insulin sensitivity within 6 months preceding randomisation, and/or were on other
angiotensin receptor blockers, angiotensin-converting enzyme inhibitors or direct renin inhibitors within
4 weeks preceding randomisation. Patients with suspected poor compliance, pregnant or lactating women,
women of childbearing age unless using reliable contraception, and those co-enrolled into other drug trials
were also excluded.
Study settings
The trial was conducted in 19 UK sexual health clinics and/or HIV treatment centres from March 2013 to
July 2015.
Interventions
All patients were randomised to either no treatment or telmisartan (20-, 40-, or 80-mg doses taken once
daily) depending on treatment allocation. The duration of the treatment was 48 weeks. Patients were
asked to complete treatment diaries, detailing compliance.
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Sample collection
Blood and urine were collected at four time points during the trial (baseline, 12, 24 and 48 weeks/end of
trial). The samples were shipped on dry ice and stored in a category 2 laboratory equipped to handle and
store infectious samples.
Laboratory measurements
The objective measure of efficacy of trial treatment on insulin resistance was provided by a comparison
of HOMA-IR values, a validated marker of insulin resistance, for the baseline and weeks 12, 24 and 48.
Two other surrogate measures of insulin sensitivity, QUICKI and revised QUICKI using serum levels of
non-esterified fatty acids, were also assessed.
Other assessments carried out were plasma lipid profile (cholesterol, triglycerides, high- and low-density
lipoprotein cholesterol), plasma biomarkers of metabolic function (adiponectin, leptin, TNF-α, resistin
and interleukin 8) and renal markers (ACR, NGAL).
Magnetic resonance imaging substudy
Magnetic resonance imaging of total body adipose content was carried out using T1-weighted MRI scans
in 10 overlapping blocks of 1-cm slices with 1-cm gap, in upper and lower halves of the body separately.
A validated semiautomatic program was used to segment and analyse the images into total body
subcutaneous, total internal, subcutaneous abdominal and intra-abdominal adipose tissue volumes.
Pharmacovigilance
Adverse events/reactions for the TAILoR trial were monitored from the time of consent until 7 days after
the patient had taken the final dose of telmisartan.
Statistical considerations
Sample size
The original maximum total sample size of the study was 336 patients. The primary response from each
patient was the difference between the HOMA-IR score at 24 weeks and the baseline HOMA-IR score (so
that negative values indicate improvement). The design had been constructed under the assumption that
for all patients this response is normally distributed with a common standard deviation, σ. The sample size
calculation was based on a one-sided type I error of 5% and a power of 90%. To fix a power requirement,
effect sizes were specified in terms of the percentage chance of a patient on active treatment achieving a
greater reduction in HOMA-IR score than a patient on the control arm; as such, the specification did not
require knowledge of the value of the common standard deviation σ. The critical values for recommending
that a treatment was taken to further testing at the interim and final analyses (–2.782 and –2.086) had
been chosen to guarantee these properties that pertain to the whole two-stage testing procedure. The
study was designed to recruit additional patients to ensure that the target number of 24-week responses
was achieved in the presence of an anticipated 10% dropout rate (which increased the sample size to
370 patients).
Sample size for the substudy 1 (magnetic resonance imaging/proton magnetic
resonance spectroscopy)
A sample size of 10 patients per group was expected to provide sufficient data for a reliable estimate of
the within-group variance (sample size was increased to 12 to account for 10% dropout).
Interim analysis and stopping guidelines
The interim analysis was scheduled to take place once the 24-week change in HOMA-IR score was available
for at least 42 patients in each arm (n = 168, which was half of the planned maximum of 336 patients).
The sample standard deviation pooled across all four arms was used to construct test statistics expressing
the advantage of each of the three active treatments over the control arm.
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Statistical methods
Primary outcome analysis
In order to satisfy the primary objective, we evaluated three different doses against control in the first
stage of the study and conducted an interim analysis that allowed ineffective doses to be eliminated
quickly while a dose showing a reduction in HOMA-IR was taken forward. The smallest of these test
statistics was to be compared with the interim critical value (–2.782). Observing a test statistic below this
value corresponded to a significant improvement in HOMA-IR score for the corresponding dose over
control and would have led to this dose being immediately taken forward for further study, and to the trial
being stopped. Any dose corresponding to a positive test statistic would have been dropped, and if all
doses were dropped the trial would also have been stopped. If some reduction in HOMA-IR over control
was detected for at least one of the active doses (i.e. test statistic between 0 and –2.782), then the
study continued after the interim analysis. At the final analysis, if the smallest comparative test statistic
was below the final critical value (–2.086) then this dose would be recommended for further study.
Adjustments were made to allow for any discrepancies between target and actual sample sizes while still
preserving the one-sided type I error rate at 0.05.
Secondary outcome analysis
Biomarker analysis
To explore the secondary objective of identifying longitudinal change in the expression of biomarkers in
telmisartan-treated arm(s) in comparison with controls, joint models were used to fully exploit the serial
nature of these outcomes accounting for informative loss to follow-up and missingness.
Analysis of changes in body fat redistribution and intrahepatic and intramyocellular
lipid content
The change in visceral, liver and limb fat in 24 weeks was compared across the three treatment groups
and controls using multiple linear regression.
Trial procedures
The trial was managed by the Clinical Trials Research Centre at the University of Liverpool. It was conducted
in accordance with the European Clinical Trials Directive (European Commission. Directive 2001/20/EC of
the European Parliament and of the Council of 4 April 2001. Brussels: European Commission; 2001),
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
(ICH)’s Good Clinical Practice Guidelines [ICH. ICH Harmonised Tripartite Guideline: Guideline for Good
Clinical Practice E6(R1). 1996. URL: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E6/E6_R1_Guideline.pdf (accessed 24 September 2018)], the Declaration of Helsinki (World Medical
Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA
2013;310:2191–4), the NHS Research governance framework [NHS Health Research Authority. UK Policy
Framework for Health and Social Care Research. Version 3.3. 2017. URL: www.hra.nhs.uk/planning-and-
improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/ (accessed
24 September 2018)] and the Medicines for Human Use (Clinical Trials) Regulations 2004 [Great Britain.
The Medicines for Human Use (Clinical Trials) Regulations 2004. London: The Stationery Office; 2004].
Three committees oversaw the conduct of the trial: the Trial Management Group, the Trial Steering
Committee and the Independent Data and Safety Monitoring Committee. Patient representatives were
identified early in the trial and were involved in the overseeing of the trial. One representative sat on the
Trial Steering Committee and one on the Trial Management Group.
Results
Screening and participant flow
In total, 1950 patients were screened at the participating centres over the duration of the trial.
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Baseline data
The baseline characteristics were balanced across treatment arms. The study participants were
predominantly male.
Primary outcome results
Interim analysis
The t-statistic for arms B (20 mg of telmisartan) and C (40 mg of telmisartan) showed a positive value
(i.e. ≥ 0) which implied that there was no reduction in the HOMA-IR over control (arm A) and, therefore,
these active dose arms were dropped from the second stage. As some improvement over control was
detected for arm D (80 mg of telmisartan) (i.e. the t-statistic was between 0 and –2.782), this arm was
selected to progress into the second stage of the study and the patients were thereafter randomised
between arm D and the control group (arm A).
Final analysis
Given that the test statistic was not smaller than the critical value of –2.086 [estimated effect 0.007,
standard error (SE) 0.106], it was concluded that there was no significant difference in HOMA-IR between
arms D and A.
Secondary outcome results
Alternative indices of insulin resistance (Quantitative Insulin Sensitivity Check and revised
Quantitative Insulin Sensitivity Check)
For QUICKI (0.001, SE 0.001) and revised QUICKI (0.002, SE 0.002), the test statistic was not smaller than
the critical value (–2.086), suggesting no difference between arms A and D.
Longitudinal analysis of Homeostatic Model Assessment of Insulin Resistance,
Quantitative Insulin Sensitivity Check and revised Quantitative Insulin Sensitivity Check
There was no significant difference in HOMA-IR and QUICKI between the treatment and control arms over a
period of 48 weeks. However, the treatment effect of arm D compared with arm A for the longitudinal revised
QUICKI was marginally significant [0.004, 95% confidence interval (CI) 0.000 to 0.008; p = 0.05], suggesting
that telmisartan (80 mg) led to a small reduction in insulin resistance over a period of 48 weeks.
Longitudinal analysis of lipid profiles and plasma biomarkers
There were no significant differences between the treatment arm and the control arm with any of the
lipid markers over a period of 48 weeks. None of the plasma biomarkers, apart from hs-CRP, showed a
significant change (–0.222, 95% CI –0.433 to –0.011; p = 0.04) over time between the control and the
telmisartan (80-mg) treatment arm.
Substudy 1: magnetic resonance imaging
No statistically significant differences were observed in internal visceral fat or intramyocellular triglyceride
content in the soleus and tibialis anterior at 24 weeks between the treatment group (80 mg) and the
control group (p > 0.05). However, a statistically significant difference in the intrahepatic triglyceride
content was observed at 24 weeks between arm D and the control group (arm A) (1.714, 95% CI –2.787
to –0.642; p = 0.005).
Substudy 2: urine/renal biomarkers
The estimated treatment effects [arm D (80 mg) compared with arm A (control)] on NGAL were not
significant in any of the tertile subgroups tested. A telmisartan dose of 80 mg significantly reduced ACR
for the subgroup with albumin excretion of > 3 mg/mmol (–0.665, 95% CI –1.31 to –0.019; p = 0.04).
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Safety data analysis
Diarrhoea, fatigue, dizziness and pruritus were the most common adverse reactions, observed in > 2%
of patients. There was no evidence of a difference in the percentage of serious adverse events between
the telmisartan-treated arms and the control arm (p = 0.8).
Conclusions
Using a novel adaptive design, we demonstrated that there was no significant effect of telmisartan
(80 mg) on the primary outcome measure (HOMA-IR) and some secondary outcomes (plasma lipids and
adipokines). Telmisartan did lead to favourable changes of the secondary longitudinal outcome measures:
revised QUICKI, hs-CRP, hepatic fat accumulation and urinary albumin excretion. Although these changes
are biologically plausible and consistent with the literature, whether or not this would translate into
improvements in clinical outcomes in patients infected with HIV on cART is unclear. Taken collectively,
our findings showed that telmisartan did not reduce insulin resistance in patients infected with HIV
on antiretrovirals.
Trial registration
This trial is registered as ISRCTN51069819.
Funding
The project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research partnership.
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Chapter 1 Introduction
Background
Combination antiretroviral therapy (cART) is the mainstay of treatment for human immunodeficiency virus
(HIV) and has dramatically improved the morbidity and mortality associated with HIV, turning it into a
chronic disease. However, cART, together with the virus itself, can lead to various metabolic complications
such as obesity,1 type 2 diabetes mellitus (T2DM) and an increased risk of cardiovascular disease (CVD).
These metabolic complications associated with cART are particularly prominent in patients with HIV-associated
lipodystrophy (HIVLD) (also called fat redistribution syndrome), a clustering of morphological and metabolic
abnormalities comprising peripheral fat loss (lipoatrophy), visceral lipid hypertrophy, insulin resistance and
dyslipidaemia.2 HIVLD is a predictor of metabolic syndrome (MS) and associated CVD risk.3 However, metabolic
complications are also seen in patients infected with HIV without HIVLD. A recent meta-analysis of 65 studies
(n= 55,094 patients infected with HIV) utilised two of the most widely used MS criteria [Adult Treatment
Panel (ATP) III-2004 and ATP III-2005] to calculate the prevalence of MS in HIV-infected people, which
was found to be between 16.7% and 18%.4 The HIV DAD (Data collection on Adverse events of anti-HIV
Drugs) cohort, one of the largest HIV clinical cohorts (n= 33,347),5 found the prevalence of MS to increase
from 19.4% to 41.6% over a 6-year period;6 importantly, patients with MS had a fourfold increase in the
incidence of T2DM and a two to threefold increased risk of developing CVD. These results have been
confirmed by other studies such as the Multicenter AIDS Cohort Study (n= 1278),7 a more recent analysis
of the DAD cohort,8 and national representative surveys in the USA that observed a 3.8% higher T2DM
prevalence in HIV-infected adults than in the general population.9
Individuals infected with HIV show a higher risk of CVD than that observed in the general population;10
importantly, cumulative exposure to cART is also associated with an increased risk of CVD in HIV-infected
patients. The DAD study reported a linear increase in the incidence of myocardial infarction with long-term
cART exposure, with both protease inhibitors11 and nucleoside reverse transcriptase inhibitors (NRTIs).12
A recent longitudinal cohort study13 of HIV-infected US veterans selected from the Veterans Health
Administration Clinical Case Registry (n = 24,510; 164,059 person-years) observed a modestly increased
risk of CVD with both individual antiretroviral (ARV) drugs and ARV drug combinations. Long-term use of
cART also results in intima–media thickness and an increase in the prevalence of carotid lesions, making
it a risk factor for subclinical atherosclerosis.14 It is therefore clear that cART-treated HIV-infected patients
are at increased risk of cardiometabolic problems.
Insulin resistance, a key feature of HIVLD and MS, has been described as central to cardiometabolic disease
and is considered to be an important link between features of MS, obesity, dyslipidaemia, T2DM and
CVD.15 In vitro studies16 and single-drug studies in healthy individuals17 and HIV-infected patients18,19 have
shown that protease inhibitors and NRTIs cause insulin resistance. The prevalence of insulin resistance in
cART-treated HIV-infected patients ranges from 21% to 37%,20,21 indicating a significant role for cART in its
development. In the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study21 (n = 926), a
cross-sectional analysis showed the prevalence of insulin resistance to be 37%. Insulin resistance very much
remains an important problem even with some of the newer ARVs; HIV patients (n = 328) randomised to
tenofovir disoproxil fumarate/lamivudine (TDF/3TC) with either boosted atazanavir or boosted darunavir or
raltegravir showed a 1.9-fold increase in homeostatic model assessment of insulin resistance (HOMA-IR)
within 4 weeks with no change thereafter over a period of 96 weeks.22 Several mechanisms have been
suggested to be responsible for cART-induced insulin resistance, including cART-induced inhibition of
adipocyte differentiation,23 increased secretion of adipokines such as interleukin 6 (IL-6) and tumour necrosis
factor alpha (TNF-α)24 and impairment of the insulin signalling pathway.16
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Clinical intervention to arrest or reverse cART-associated insulin resistance has been suggested as a strategy to
reduce the incidence of T2DM and CVD in HIV-infected patients. Insulin sensitisers such as thiazolidinediones
and metformin have been trialled, but results from randomised clinical trials in HIV-infected patients have
been mixed.25,26 Moreover, the associated adverse effects may limit their use in HIV-infected patients.27,28
Statins have been suggested as a potential strategy to reduce cardiometabolic events in patients infected with
HIV;29 however, a recently concluded randomised, double-blinded, placebo-controlled trial in HIV-infected
individuals [the SATURN-HIV (Stopping Atherosclerosis and Treating Unhealthy bone with Rosuvastatin in HIV)
study]30 observed significant worsening of insulin resistance with 10mg of rosuvastatin. Therefore, there
is a need for novel clinical interventions with proven safety profiles that can reduce cART-induced insulin
resistance in individuals infected with HIV.
Some angiotensin receptor blockers (ARBs) have a beneficial effect on insulin resistance and T2DM, owing
to their partial agonistic activation of peroxisome proliferator-activated receptor (PPAR)-γ, an important
regulator of adipocyte function. Telmisartan shows maximal potency on PPAR-γ when compared with
other ARBs and has been reported to reduce insulin resistance in several in vitro,31,32 animal33,34 and clinical
studies.35–38 Prospective randomised clinical trials in patients with diabetes mellitus and those with MS
have shown that telmisartan significantly reduces insulin resistance: (1) in 188 T2DM patients with MS,
telmisartan significantly reduced HOMA-IR by 17% after 6 months’ treatment and by 29% after 12 months;35
and (2) in a comparison with other ARBs in non-diabetic patients (n = 151), telmisartan reduced HOMA-IR by
29% after 6 months’ treatment.38 A meta-analysis of randomised controlled trials (RCTs) where telmisartan
was compared against other antihypertensive drugs (33 RCTs; 2033 patients) found telmisartan to
significantly reduce insulin resistance, with statistically significant reductions in insulin levels and HOMA-IR
values.39 Telmisartan also has wide-ranging beneficial effects on various components of MS; a limited
meta-analysis of 10 RCTs40 (546 patients with MS) observed significant reductions in fasting glucose, insulin,
glycosylated haemoglobin and homeostasis model assessment index and a significant increase in per cent
changes of adiponectin. Telmisartan not only improved adiponectin levels,41 an important metabolic marker
of insulin resistance and atherosclerotic disease, but also improved lipid control in these patients.42 It also
had favourable effects on fasting serum insulin and high-sensitivity C-reactive protein (hs-CRP; a marker of
CVD).35,43 Telmisartan has also been shown to reduce visceral, but not subcutaneous, fat accumulation,
in patients with MS.44,45 Telmisartan reduced cardiovascular events in a broad group of at-risk patients;
one of the largest ARB outcome trials [ONTARGET (The Ongoing Telmisartan Alone and in Combination
with Ramipril Global Endpoint Trial); 120,000 patient-years of follow-up]46 established telmisartan to confer
similar cardiovascular protection as ramipril but was better tolerated. Importantly, the beneficial effects of
telmisartan on insulin sensitivity have been observed at doses lower than those used for hypertension;
20 mg/day of telmisartan significantly reduced HOMA-IR after 20 months’ treatment in patients with
non-alcoholic steatohepatitis.36 In addition to its cardiometabolic beneficial effects, telmisartan also shows
renoprotective effects;47 it has been shown to significantly reduce microalbuminuria in HIV-infected patients48
and may therefore have a positive impact on parameters of renal injury observed in cART-treated HIV-infected
patients.
Rationale for the study
There is already strong evidence for the beneficial effects of telmisartan on insulin resistance and other
markers of glycaemic control and cardiovascular health in non-HIV populations. This study, and others,
has shown that antiretroviral drugs inhibit adipocyte differentiation,23,24 reduce adiponectin secretion,23,49
increase the secretion of detrimental cytokines, IL-6 and TNF-α,23,24 and impair GLUT-4 expression,50 all of
which are suggested to contribute to the development of insulin resistance. This study has also shown that
telmisartan partially reverses the antiadipogenic effects of antiretrovirals in vitro.51 Telmisartan partially
reversed the antiretroviral drug-induced inhibition of adipocyte lipid accumulation and downregulation of
adiponectin and lipin-1. The beneficial effect of telmisartan on adipocyte function in the presence of
antiretrovirals has also been shown by Boccara et al.52 However, the clinical efficacy of telmisartan to
reduce insulin resistance in cART-treated HIV-infected patients has not been assessed; this study was
designed to address this.
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This in vitro study observed a non-monotone relationship of telmisartan on adiponectin and lipin 1
secretion. A study in non-alcoholic steatohepatitis patients also observed that telmisartan improves insulin
sensitivity at doses lower than those used for hypertension.36 This indicates the need to carefully assess the
dose–response relationship of telmisartan in vivo.
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Chapter 2 Research objectives
Primary objective
To determine the effect of telmisartan on insulin resistance in individuals infected with HIV on cART using
HOMA-IR as a measurable, validated surrogate marker of insulin resistance.
Secondary objectives
l To define the optimal dose of telmisartan that can significantly reduce insulin resistance; this dose will
then be taken forward into Phase III studies in the future.
l To measure HOMA-IR values at the baseline (T0) and at 12, 24 and 48 weeks to provide data on time
to, and sustainability of, reduction in HOMA-IR.
l To utilise alternative indices of insulin resistance such as the Quantitative Insulin Sensitivity Check Index
(QUICKI) and revised QUICKI to determine the effect of telmisartan on insulin resistance.
l To mechanistically evaluate whether or not telmisartan favourably modulates the plasma concentrations
of both beneficial (adiponectin) and adverse (leptin, resistin, TNF-α, hs-CRP) biomarkers, which may
help in further stratifying telmisartan therapy in the future.
l To determine whether or not telmisartan improves general lipid homeostasis and reduces visceral fat
accumulation in individuals infected with HIV on cART over a 24-week period.
l To determine, in a substudy, whether or not proton magnetic resonance spectroscopy (1H-MRS)-assessed
intrahepatic and intramyocellular triglyceride content, markers of hepatic steatosis and insulin resistance,
respectively, are reduced by telmisartan therapy. This will provide us with mechanistic insights into the
ability of telmisartan to beneficially affect fat redistribution, hepatic steatosis and insulin resistance.
l To determine whether or not telmisartan has an effect on urinary biomarkers [albumin-to-creatinine
ratio (ACR), neutrophil gelatinase-associated lipocalin (NGAL)] of renal injury in individuals infected with
HIV on cART.
l To evaluate the tolerability of telmisartan in this patient group.
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Chapter 3 Methods
Trial design
TAILoR was a multicentre, randomised open-labelled study with an adaptive design (Figure 1). We chose an
adaptive design for the first stage of the study because our in vitro studies had shown a non-monotone
relationship between telmisartan and various metabolic biomarkers. Furthermore, while there is a clear
dose–response relationship with telmisartan in the treatment of hypertension, it is important not to assume
that a similar relationship would exist in a repurposed indication. The adaptive trial design was thus designed
to carefully assess the dose–response relationship of telmisartan on metabolic parameters, which was the
main objective of this study.
The adaptive design consisted of two stages. In stage 1, eligible patients were randomised on a 1 : 1 : 1 : 1
basis to either no treatment or a 20-, 40- or 80-mg dose of telmisartan once daily. The duration of study
treatment was a maximum of 48 weeks, with titration visits (if applicable) at 2 and/or 4 weeks and follow-up
visits at 12, 24 and 48 weeks.
Magnetic resonance imaging: substudy 1
A subset of patients from Royal Liverpool and Broadgreen University Hospitals NHS Trust (RLBUHT) and the
Manchester Centre for Sexual Health were asked to participate in the magnetic resonance imaging (MRI)
substudy. It was necessary that these patients were also participating in the main study. The duration of
the substudy was 24 weeks, and visits took place at both baseline and 24 weeks.
Visit 1 Visit 2
Titration
2
Titration
1 Visit 3 Visit 4
Day 1
Randomisation
Sample
collection
Sample
collection
Follow-up
visits
MRI scan
Week 12Week 4Week 2
Control
Dose increase visit
for patients
randomised to
40 mg and/or 80 mg
20 mg telmisartan
40 mg telmisartan
80 mg telmisartan
Week 24
MRI scan
Week 48
FIGURE 1 Summary of the design for stage 1 of the trial. MRI, magnetic resonance imaging.
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Interim analysis
An interim analysis was performed when half of the planned maximum number of patients had been
followed up for at least 24 weeks (Figure 2). As per the adaptive design, if one active dose group was
substantially more effective than control then the study would have been stopped and the corresponding
dose would be taken directly into Phase III. Any active dose groups that showed insufficient promise at the
interim analysis would be dropped and the study would continue with the remaining doses and control.
If no dose showed sufficient promise at the interim analysis, the study would have been stopped. If some
improvement over control was detected for at least one of the doses at interim analysis, those dose(s)
would be followed up along with the control for a further 24 weeks (total duration of 48 weeks).
Participants
TAILoR participants were adults with documented HIV infection, who had been receiving a stable cART for
at least 6 months prior to randomisation.
Inclusion criteria
l Adult (aged ≥ 18 years) HIV-positive individuals receiving antiretroviral therapy containing:
¢ a boosted protease inhibitor (lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir,
fosamprenavir/ritonavir, saquinavir/ritonavir)
¢ and/or efavirenz, rilpivirine, or etravirine for at least 6 months.
l Ability to give informed consent.
l Willingness to comply with all study requirements.
Interim analysis: 50% patient complete 24-week follow-up
Outcome 1: one dose
substantially more
effective than
control
Outcome 2: all doses
less effective than
control
Outcome 3: one or more
doses are more effective
than control, but do not
meet outcome 1 criteria
Study stopped: dose
recommended for
Phase III
Study stopped Study continues with
effective dose(s)
Randomisation system
updated so that only
effective dose(s) is
carried forward
Any dose found to be
significantly better than
control is recommended
for Phase III study
Final analysis: all continuing
patients reaching 48 weeks
No dose of telmisartan
found to be significantly
better than control
Patients receiving
non-effective dose(s)
of telmisartan asked
to stop
Patients receiving effective
dose(s) are asked to continue
treatment for a maximum
of 48 weeks as per Figure 1
FIGURE 2 Schematic of stage 2 of the adaptive design following interim analysis.
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In relation to the antiretroviral therapy, the backbone was based on nucleotide reverse transcriptase inhibitors,
raltegravir or maraviroc. Patients on protease inhibitor monotherapy were also included if they met other
criteria. However, a decision was made not to include (1) patients on nevirapine or dolutegravir regimens,
without concomitant boosted protease inhibitors, (2) patients on elvitegravir which is usually administered
in combination with cobicistat [as Stribild® (Gilead Sciences Inc., CA, USA)] and (3) patients on unboosted
atazanavir.
Exclusion criteria
The exclusion criteria were as follows:
l Pre-existing diagnosis of type 1 or 2 diabetes mellitus [i.e. fasting glucose level of > 7.2mmol/l or
glycated haemoglobin (HbA1c) level of ≥ 6.5% (48 mmol/mol) or an abnormal oral glucose tolerance
test (OGTT) or random plasma glucose concentration of ≥ 11mmol/l].
l Patients known to have consistently low blood pressure (pre-existing hypotension: a reading below a
threshold of 100/60 mmHg on three separate occasions).
l Patients with renal disease [i.e. an estimated glomerular filtration rate (eGFR) of < 60ml/minute/1.73 m2
in the 6 months preceding randomisation].
l Patients with known untreated renal artery stenosis.
l Patients with cholestasis, biliary obstructive disorders or severe hepatic impairment.
l Patients with evidence of an active chronic hepatitis C infection (a previously cleared infection is not
an exclusion).
l Patients who were on/have been on hormone therapy (e.g. growth hormone), anabolics (e.g. testosterone)
or insulin sensitisers (e.g. metformin) within 6 months preceding randomisation. Patients who were on
hormonal contraception were eligible.
l Patients who were already on/had been on other ARBs, angiotensin-converting enzyme (ACE) inhibitors
or direct renin inhibitors (e.g. aliskiren) within 4 weeks preceding randomisation.
l Those with suspected poor compliance.
l Pregnant or lactating women.
l Women of childbearing age, unless using reliable contraception (e.g. coil, barrier method, hormonal
contraceptive that does not interact with their antiretroviral therapy).
l Co-enrolment in other drug trials.
l Patients who had participated in a trial of an investigational medicinal product (IMP) likely to influence
insulin sensitivity, plasma insulin, glucose levels or plasma lipid levels within 6 months preceding
randomisation.
l For the subcohort of patients undergoing MRI/magnetic resonance scanning (MRS), normal MRI
exclusion criteria applied.
Study settings
The trial was conducted in 19 sexual health clinics and/or HIV treatment centres throughout the UK
(see Appendix 1) and patients were recruited from March 2013 until July 2015.
Centre/clinician inclusion criteria
Each participating centre and principal investigator (PI) was identified on the basis of being a specialist
HIV treatment centre; having at least one lead clinician with a specific interest in, and responsibility for
supervision and management of, patients with HIV; enthusiasm to participate in the study; sufficient time,
staff and adequate facilities available for the trial; identifying that they would be able to recruit the required
number of patients; and acknowledging and agreeing to conform to the administrative, ethical and study
specific requirements.
Any centre not meeting these criteria was deemed ineligible to participate in the trial.
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Interventions
All patients either received no treatment or were treated with telmisartan as per their randomised
allocation. Telmisartan was dispensed as either a 20-, 40- or 80-mg dose, depending on treatment
allocation. All strengths of telmisartan were to be taken once daily with or without food. The duration
of the treatment was a maximum of 48 weeks. The patients were asked to complete treatment diaries,
detailing compliance, throughout the duration of treatment.
Investigational medicinal product
The IMP for the TAILoR trial was telmisartan. Telmisartan is an antihypertensive agent used to lower
blood pressure and to reduce cardiovascular events in at-risk patients. For this trial, it was used outside the
licensed indications of its different manufacturers. Telmisartan is available in doses of 20, 40 and 80 mg.
It is produced by a range of manufacturers; the generic formulations were considered to be bioequivalent
to the brand leader Micardis® (Boehringer Ingelheim Ltd, Ingelheim am Rhein, Germany). Appendix 2
details the brands of telmisartan approved for use in the trial.
The IMP was sourced through standard NHS procurement processes at each site and was dispensed to
trial participants on receipt of a valid trial specific prescription. Study drug accountability was documented
by the pharmacy teams at each site and was monitored by the trial co-ordinator/Clinical Trials Research
Centre (CTRC).
Outcomes
Primary outcome
Reduction in insulin resistance (as measured by HOMA-IR) in telmisartan-treated arm(s) after 24 weeks of
treatment in comparison with control. This was a pure efficacy outcome.
Secondary outcomes
1. Change in lipid profile at 12, 24 and 48 weeks [increase in high-density lipoprotein cholesterol (HDL-C),
reduction in total cholesterol, triglycerides and low-density lipoprotein cholesterol (LDL-C)] between
telmisartan-treated arm(s) and the control arm.
2. Change in body fat redistribution as measured by MRI/MRS at 24 weeks between telmisartan-treated
arm(s) and control arm (reduction in visceral fat, change in intrahepatic fat, change in lower leg
muscle fat).
3. Change in plasma concentrations of biomarkers [adiponectin, leptin, interleukin 8 (IL-8), TNF-α, resistin
and hs-CRP] at 12, 24 and 48 weeks between telmisartan-treated arm(s) and the control arm.
4. Change in insulin resistance, measured longitudinally, in telmisartan-treated arm(s) in comparison with
the control arm.
5. Difference in expected and unexpected serious adverse events between different telmisartan-treated
dose arm(s) and the control arm.
Two additional secondary outcome measures were added on the advice of the Independent Data Safety
and Monitoring Committee (IDSMC) and the PIs, which were added after recruitment began:
6. Reduction in insulin resistance (as measured by QUICKI and revised QUICKI) in telmisartan-treated arm(s)
after 24 weeks of treatment in comparison with control.
7. Change in urinary biomarker levels (ACR; NGAL) at 12, 24 and 48 weeks between telmisartan-treated
arm(s) and the control arm.
METHODS
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Data collection
Paper case report form
A paper case report form (CRF) was used to collect patient data at each study visit. Paper CRFs were
designed especially for the study in line with the trial protocol.
Database
On receipt of paper CRFs at the CTRC, data were entered to a good clinical practice- (GCP) compliant
database (MACRO 3, Elsevier, Amsterdam, the Netherlands) by trial staff at the CTRC. The configuration of
the database was specific for the TAILoR trial, and it had built-in validations on certain aspects of the trial
data. A full audit trail was maintained.
Timescale of evaluations
The first visit occurred on the same day as randomisation; subsequent visits took place at 12, 24 and
48 weeks. Patients randomised to higher doses of telmisartan (40 and 80 mg) also attended for dose
titration visits (see Figure 1 and Table 1).
Schedule of investigations
A summary of tests and investigations undertaken in each patient is provided in Table 1.
Sample collection
Sample collection, processing and storage at participating sites
Biological samples (blood and urine) were collected at four time points during the trial at individual clinical
sites participating in the study. For each patient, samples were collected at baseline, 12, 24 and 48 weeks/
end of trial visits. At each time point, three fasting blood samples and one urine sample were collected
from each participant. The blood samples were collected in:
1. 9-ml tripotassium ethylenediaminetetraacetic acid (K3EDTA) VACUETTE® blood tubes (Grenier Bio-One
International Ltd, Gloucestershire, UK) (for DNA extraction)
2. 9-ml Z Serum Clot Activator VACUETTE tubes (for serum separation)
3. 4-ml FX Sodium Fluoride/Potassium Oxalate VACUETTE tubes (for glucose estimation).
The K3EDTA tubes were stored at –20 °C; plasma and serum were extracted locally at each site by the
research nurses and aliquoted into two 1.8-ml cryovial tubes (STARLAB, Milton Keynes, UK) and were
immediately stored at a minimum temperature of –20 °C. The sample collection, sample processing and
storage were all performed in accordance with standardised standard operating procedures (SOPs) supplied
by the main study team at Liverpool (all laboratory SOPs can be made available on request).
Sample shipment
Packaging and shipping of all samples collected from the TAILoR study followed the Packaging Provisions
for Biological Substances, Category B, UN 3373 and UN1845 (dry ice) guidelines.53 A SOP was followed by
all sites for packaging of samples and shipment of TAILoR samples. The samples were shipped on dry ice
in sealed styrofoam™ (The Dow Chemical Company, Midland, MI, USA) boxes by a clinical trial specialist
courier with a delivery time of within 24 hours.
Sample collection, processing and storage at the co-ordinating centre (University
of Liverpool)
All samples were stored in the Bioanalytical Facility (BAF), Royal Liverpool Hospital, which is a category 2
laboratory equipped to handle and store infectious samples. All samples were stored at a minimum
temperature of –20 °C until further processing. Sample transport log sheets were completed, dated and
signed by the Wolfson Centre for Personalised Medicine, University of Liverpool, (WCPM) staff and
countersigned by the BAF analyst.
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TABLE 1 Schedule of trial procedures
Time
Time point
Premature
withdrawal
of consent
Pre T0 T0 T+ 2 weeks T+ 4 weeks
T+ 12
weeks
T+ 24
weeks
T+ 48
weeks
At each
recruitment
site
Randomisation/
baselinea
Dose titration
for 40- or 80-mg arms
(dose given: 40mg)
Dose titration
for 80-mg arm
(dose given: 80mg) Follow-up Follow-up
End of
treatment
Database search to identify potential
participants or clinic list review
✓
Information sheet provided to patient ✓
Signed informed consent ✓
Assessment of eligibility criteria by a
medically qualified person
✓
Review of medical history (including
collection of most recent blood test
results for urea and electrolytes, eGFR,
liver function, diabetes mellitus
screening, etc.
✓b ✓ ✓
Review of concomitant medications ✓ ✓ ✓ ✓ ✓ ✓
Urine pregnancy test ✓ ✓ ✓
Randomisation ✓
Study intervention ✓ ✓ ✓ ✓ ✓
Compliance with study intervention –
patient diaries and pill counting
✓ ✓ ✓ ✓ ✓
Physical examination – complete ✓
Physical examination – symptom
directed
✓ ✓ ✓ ✓ ✓ ✓
Height ✓ ✓ ✓ ✓
Weight ✓ ✓ ✓ ✓ ✓
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Time
Time point
Premature
withdrawal
of consent
Pre T0 T0 T+ 2 weeks T+ 4 weeks
T+ 12
weeks
T+ 24
weeks
T+ 48
weeks
At each
recruitment
site
Randomisation/
baselinea
Dose titration
for 40- or 80-mg arms
(dose given: 40mg)
Dose titration
for 80-mg arm
(dose given: 80mg) Follow-up Follow-up
End of
treatment
Waist/thigh circumference ✓ ✓ ✓ ✓ ✓
Heart rate, blood pressure ✓ ✓ ✓ ✓ ✓ ✓ ✓
Collection of three fasting blood
samples for bioanalysis
✓ ✓ ✓ ✓ ✓ ✓ ✓
Collection of urine sample ✓ ✓ ✓ ✓ ✓ ✓ ✓
Assessment of AEs ✓ ✓ ✓ ✓ ✓ ✓ ✓
Consent for substudy ✓ ✓ ✓ ✓ ✓ ✓
MRI/MRS scan for substudy ✓ ✓ ✓ ✓ ✓ ✓
AE, adverse event.
a Baseline assessment and randomisation visit should be within 30 days of patient giving consent.
b Liver function and diabetes mellitus screening result to be collected only at baseline.
D
O
I:10.3310/em
e06060
EFFICA
CY
A
N
D
M
ECH
A
N
ISM
EVA
LU
A
TIO
N
2019
VO
L.6
N
O
.6
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Pushpakom
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,U
K
.
13
The whole-blood samples collected in K3EDTA vacuettes were initially subjected to viral inactivation by
incubating the samples at 58 °C in a water bath for 40 minutes. The inactivated samples were transferred to
the WCPM for DNA extraction using a magnetic bead-based method on a chemagen chemagic MSM I
platform (Perkin Elmer, Waltham, MA, USA). Briefly, a 4.5-ml whole-blood sample was added into 50-ml
tubes containing lysis buffer and protease enzyme for cell lysis. Once lysis was completed, binding buffer and
magnetic beads were added to elute the extracted DNA. The DNA was dissolved in Tris buffer and its quality
and quantity were ascertained using a NanoDrop™ spectrophotometer (ThermoFisher Scientific Ltd, Paisley,
UK). The DNA samples were stored at –20 °C for future use. The urine samples were aliquoted into cryovials
and stored at –20 °C.
Investigations
A detailed laboratory analysis plan is provided in Appendix 3. All laboratory investigations specified below
were conducted using SOPs, which can be made available on request.
Assessment of efficacy
Assessment of Homeostatic Model Assessment of Insulin Resistance
The objective measure of efficacy of trial treatment on insulin resistance was provided by a comparison
of HOMA-IR values at baseline and at weeks 12, 24 and 48. HOMA-IR is a known surrogate marker for
measuring insulin resistance.
For HOMA-IR, serum and plasma aliquots were sent to the Liverpool Clinical Laboratories (LCL), Royal
Liverpool Hospital, for the estimation of insulin and glucose levels respectively. LCL is a Clinical Pathology
Accredited (CPA) clinical laboratory that participates in the external quality assessment for the analysis of a
number of analytes [UK National External Quality Assessment Service (NEQAS)].
Estimation of insulin
Serum insulin was measured using an electrochemiluminescence immunoassay on the Roche Modular e 602
analyzer (Roche Diagnostics Ltd, West Sussex, UK). The assay has a dynamic range of 0.2–1000mU/l, with a
lower detection limit of 3 mU/l. It has an intra-assay precision of between 1.5% and 2.0% for concentrations
between 6.36 and 88.3 mU/l. The assay is unaffected by icterus, lipaemia, bilirubinaemia or drugs. However,
haemolysis is known to interfere and no results were accepted for samples with a haem index exceeding 50.
Internal quality control (IQC) assessments were conducted for the insulin assay and included analysis of three
separate IQCs (Technopath Multichem IA Levels 1, 2 and 3, Technopath Clinical Diagnostics, Tipperary,
Ireland) at the start of the day once the daily maintenance and any calibrations had been performed. The
results for the IQCs had to fall within 2 standard deviations (SD) of the mean to be considered as acceptable
performance to allow acceptance of the results. For External Quality Assessment (EQA), LCL received three
samples for analysis every 6 weeks and these were processed as per the SOP for the Analysis of External
Assessment Samples.
Estimation of glucose
Fluoride EDTA plasma was used for the estimation of glucose using a Roche cobas® c systems assay on a
Roche cobas analyzer (Roche Diagnostics Ltd, West Sussex, UK). The assay has a range of 0.11–41.6 mmol/l in
serum, with a lower detection limit of 0.11 mmol/l (2 mg/dl). The assay is unaffected by interference from
lipaemia, haemolysis or bilirubinaemia. Two IQCs were used and the results for the IQCs had to fall within
2 SD of the mean to be considered as acceptable performance for the results to be included. LCL also takes
part in EQA for glucose analysis on a fortnightly basis.
METHODS
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Calculation of Homeostatic Model Assessment of Insulin Resistance
Homeostatic model assessment of insulin resistance was calculated using the equation:
Fasting plasma insulin (mU/l) × fasting plasma glucose (mmol/l)  22:5: (1)
Other assessments
Quantitative insulin sensitivity check index
Fasting glucose and insulin levels were measured as stated in the section above. QUICKI was calculated
using the equation:
1  ½log(fasting insulin in µU/ml) + log(fasting glucose in mg/dl). (2)
Revised quantitative insulin sensitivity check index
Revised QUICKI was calculated using the equation:
1 ½log-fasting insulin (µU/ml) + log-fasting glucose (mg/dl)
+ log-fasting non-esterified fatty acids (mmol/l). (3)
Non-esterified fatty acids (NEFAs) were measured in serum samples at time points T0, T + 12, T + 24,
and T + 48. Serum NEFA analysis was performed in the GCP Laboratory, University of Liverpool using a
colorimetric assay on a RX Daytona analyser (Randox Laboratories Limited, UK). The serum was subjected
to viral inactivation by treating with 1% Triton™ X-100 solution (Sigma-Aldrich Company Ltd, Dorset, UK)
for 60 minutes at room temperature and then analysed. IQC assessments were conducted for the NEFA
assay and included analysis of two separate IQCs (Multisera QC Levels 2 and 3, Randox Laboratories Ltd,
County Antrim, UK) at the start of the day once the daily maintenance and any calibrations had been
performed. The results for the IQCs had to fall within ± 2 standard deviations of the mean to be considered
as acceptable performance to allow the results to be included in the analysis. All samples were analysed in
triplicate. Results for any samples with a value outside the detection range or that failed in more than one
replicate were not accepted.
Assessment of lipid profile
Fasting serum samples obtained at T0 and at the 12-, 24- and 48-week visits were analysed by the LCL
for total cholesterol, triglycerides, LDL-C and HDL-C levels on the Roche modular e 602 analyzer.
The Roche Modular e 602 analyzer utilises an enzymatic colourimetric method for the analysis of total
cholesterol. The assay has a measuring range of 0.1–20.7 mmol/l, with a lower detection limit of 0.1 mmol/l.
For triglycerides, measuring range of the assay is 0.1–10.0 mmol/l, with a lower limit of detection (LLOD)
at 0.1 mmol/l. For the high-density lipoprotein (HDL) assay, the measuring range is 0.08–3.12 mmol/l,
with a lower detection limit of 0.08 mmol/l.
Assessment of high-sensitivity C-reactive protein
High-sensitivity C-reactive protein (hs-CRP) in the serum was measured at T0 and at the 12-, 24- and
48-week visits by LCL. The hs-CRP was measured using a particle enhanced immunoturbidimetric assay
on a Roche cobas modular analyzer. The assay has a measuring range of 0.15–20.0 mg/l, with a lower
detection limit of 0.15 mg/l. The assay is not affected by icterus (up to an I index of 60), haemolysis
(up to a H index of 1000) and lipaemia (up to an L index of 600).
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Assessment of novel biomarkers of metabolic function
We originally intended to measure the serum concentration of six biomarkers (adiponectin, leptin, IL-6, TNF-α,
resistin and IL-8) at T0 and at the 12-, 24- and 48-week visits. However, following validation, the IL-6 assay was
found not to meet the desired criteria and, hence, the marker was removed from the protocol (details given
in the sample analysis plan in Appendix 3). The biomarker analyses were performed in the WCPM utilising
human singleplex and/or multiplex kits using electrochemiluminescence-based immunoassays (Meso Scale
Discovery, Rockville, MD, USA) as per the manufacturer’s protocol on a Meso Scale Discovery Sector Imager
2400A (Meso Scale Discovery, Rockville, MD, USA). Meso Scale Discovery assays use electrochemiluminescent
labels called SULFO-TAG that are conjugated to detection antibodies and allow for ultrasensitive detection.
The detection antibody for a specific protein target is coated on one electrode (or ‘spot’) per well. Once the
biofluids are added to the detection wells, electricity is applied to the plate electrodes by a Meso Scale
Discovery Sector Imager, leading to light emission by SULFO-TAG labels. Light intensity is then measured to
quantify analytes in the sample. Investigators performed all analyte measurements blindly and were unaware
of the patients’ clinical characteristics.
Assay validation
All assays obtained from the manufacturer were initially subjected to one or more validation runs in order to
make sure that the assay was working to acceptable standards. Assays for each analyte were tested for a
number of parameters such as sensitivity, reproducibility, linearity and analyte recovery. All analytes were
quantified using an eight-point logarithmic standard curve that included a zero calibrator and each standard
was run in triplicate. The detection range and the LLOD were assessed for each analyte. All validation
experiments included 10 healthy control samples and 10 study specific samples (five each from two different
time points). All samples were run in duplicate to assess the sensitivity of the assay. Only those values that
were within the detection range (above the LLOD) were considered acceptable. For assessing reproducibility,
six replicates of a pooled healthy volunteer sample (pooled serum from 10 healthy volunteers) were run on
the same detection plate and the values were considered acceptable if the coefficient of variation was
< 10%. Linearity was assessed by using at least two serial dilutions of the same sample. Selected samples
were spiked with known concentrations of the standard analyte and percentage recovery was assessed;
only those with a recovery of > 80% were considered acceptable. A universal plate plan was used for
validation of all biomarkers. The dilutions (linearity) and spike concentrations (recovery) used for individual
biomarkers are given in Table 2.
Adiponectin
Adiponectin was analysed using a single-spot human adiponectin sandwich immunoassay kit (K151-BXC3;
Meso Scale Discovery, Rockville, MD, USA) using a seven-point standard curve run with fivefold serial
dilution and a zero calibrator. The calibrator for the human adiponectin assay was supplied at 100 µg/ml.
Briefly, the serum samples were diluted 1000-fold (1 : 1000) using Diluent 100 (Meso Scale Discovery,
Rockville, MD, USA) and were added onto wells coated with the SULFO-TAG-labelled antibody within the
detection plates and incubated. The labelled detection antibody bound to adiponectin was then detected
using electrochemiluminescence. The LLOD for adiponectin was 0.005 ng/ml.
TABLE 2 Dilutions (linearity) and spike concentrations (recovery) used for individual biomarkers
Biomarker Dilutions used (linearity) Spike concentrations (recovery)
Adiponectin 1 : 500, 1 : 1000, 1 : 2000, 1 : 4000 20–50 µg/ml
Leptin Undiluted sample, 1 : 2, 1 : 4 5.56–50 µg/ml
IL-6 1 : 2, 1 : 4, 1 : 8 1.56–25 pg/ml
TNF-α 1 : 2, 1 : 4, 1 : 8 0.99–15.885 pg/ml
Resistin 1 : 20, 1 : 40, 1 : 80, 1 : 160 7.81–125 pg/ml
IL-8 – 1.56–25 pg/ml
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Leptin
Leptin was analysed using a single-spot human leptin sandwich immunoassay kit (K151-BYC3; Meso Scale
Discovery, Rockville, MD, USA) using a seven-point standard curve run with threefold serial dilution and a
zero calibrator. The calibrator for the human leptin assay was supplied at 10 µg/ml. Briefly, undiluted
serum samples were added to wells coated with the SULFO-TAG-labelled antibody within the detection
plates and incubated. The labelled detection antibody bound to leptin was then detected using
electrochemiluminescence. The LLOD for leptin was 43 pg/ml.
Resistin
Resistin was analysed using a single-spot human resistin sandwich immunoassay kit (K151FND4; Meso
Scale Discovery, Rockville, MD, USA) using a seven-point standard curve run with fourfold serial dilution
and a zero calibrator. The calibrator for the human resistin assay was supplied at 50,000 pg/ml. Briefly, the
serum samples were diluted 100-fold (1 : 100) using Diluent 2 (Meso Scale Discovery, Rockville, MD, USA)
and were added onto wells coated with the SULFO-TAG-labelled antibody within the detection plates
and incubated. The labelled antibody bound to resistin was then detected using electrochemiluminescence.
The LLOD for resistin was 0.2 pg/ml.
Proinflammatory markers (tumour necrosis factor alpha and interleukin 8)
The proinflammatory markers TNF-α and IL-8 were analysed using a multispot V-PLEX human Proinflammatory
Panel II (4-Plex) sandwich immunoassay (K15053D-1; Meso Scale Discovery, Rockville, MD, USA). A seven-point
standard curve run with threefold serial dilution and a zero calibrator was used for the assay. The calibrator
for the V-PLEX Human Proinflammatory Panel II was supplied at 500 pg/ml (IL-8) and 317 pg/ml (TNF-α),
respectively. Briefly, the serum samples were diluted twofold (1 : 2) using Diluent 2 and were added onto wells
coated with the SULFO-TAG-labelled antibody within the detection plates and incubated. The labelled antibody
bound to individual proinflammatory analytes was then detected using electrochemiluminescence. The LLOD
range for IL-8 was 0.01–0.11 pg/ml and for TNF-α was 0.01–0.13 pg/ml.
Assessment of renal biomarkers
Urine ACR and urinary NGAL levels were measured at T0 and at the 12-, 24- and 48-week visits. ACR was
analysed by LCL, Royal Liverpool Hospital, and NGAL analysis was performed in the WCPM, utilising
human singleplex kits (Meso Scale Discovery, Rockville, MD, USA) as specified in Assessment of novel
biomarkers of metabolic function.
Urine albumin
Urine albumin was estimated using an immunoturbidimetric assay on a Roche cobas c systems analyzer.
A six-point calibration curve was run using water and a Roche CFAS PUC calibrator (Roche Diagnostics
Ltd, West Sussex, UK). IQC assessments were conducted for urine albumin using two separate IQCs (MAS
UriChemTrak Human Level 1 and Level 2, ThermoFisher Scientific Ltd, Paisley, UK) at the start of the day once
the daily maintenance and any calibrations had been performed. The results for the IQCs had to fall within
2 SDs of the mean to be considered as acceptable performance to allow the results to be included. LCL
also participates in the EQA for urine albumin on a monthly basis. The assay has a range of 3–400mg/l (for
undiluted samples), with a lower detection limit of 3 mg/l. No significant interference is observed with icterus
(up to 855 µmol/l of conjugated bilirubin) or haemolysis (haemoglobulin concentration up to 248 µmol/l).
Urine creatinine
Urine creatinine was estimated using a kinetic colorimetric assay based on the Jaffe method54 on a Roche
cobas c analyzer. Calibration was conducted using a two-point calibration curve using deionised water and
Roche CFAS reagent (Roche Diagnostics Ltd, West Sussex, UK). Calibration is performed every 4 weeks, if
there is reagent lot change or if there is requirement as indicated by the IQCs. IQCs (UrichemTrak 1 and 2)
were analysed at the start of the day following any maintenance and daily start up, and approximately
every 3 hours throughout the day. The assay has got a range of 375–55,000 µmol/l, with a lower limit of
detection of 375 µmol/l. No significant interference is observed with an I index of 10 (bilirubin concentration
of 171 µmol/l), H index of 1000 (approximate haemoglobin concentration of 621 µmol/l) or L index of 800.
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Urinary neutrophil gelatinase-associated lipocalin
A validation experiment was performed for NGAL to ensure the assay was working to acceptable standards.
The assay was tested for several parameters such as sensitivity, reproducibility, linearity and analyte recovery.
A seven-point logarithmic standard curve and a zero calibrator was utilised and each standard was run in
triplicate. The detection range and the LLOD were assessed for NGAL. The validation experiment included
20 healthy control samples and 10 study-specific samples (five each from two different time points) in the
analysis, with all samples being run in duplicate to assess the sensitivity of the assay. Only those values that
were within the detection range (above LLOD) were considered to be acceptable. For assessing reproducibility,
six replicates of a pooled healthy volunteer sample (pooled urine from 20 healthy volunteers) were run on the
same detection plate and the values were considered acceptable if the %CV was < 10%. Linearity was
assessed by using at least two serial dilutions of the same sample. Selected samples were spiked with a
known concentration of standard analyte and percentage recovery was assessed; only those with a
percentage recovery of > 80% were considered acceptable.
Neutrophil gelatinase-associated lipocalin was analysed with a single spot custom human NGAL sandwich
immunoassay kit (N45CA-1; Meso Scale Discovery, Rockville, MD, USA) using a seven-point standard curve
run and a zero calibrator. The calibrator for the human NGAL assay was supplied at 10,000 pg/ml. Briefly,
the urine samples were diluted 250-fold (1 : 250) using Diluent 37 (Meso Scale Discovery, Rockville, MD,
USA) and were added onto wells coated with the SULFO-TAG-labelled antibody within the detection plates
and incubated. The labelled detection antibody bound to NGAL was then detected using electrochemiluminescence.
The LLOD range for NGAL was 0.1–10 pg/ml.
Magnetic resonance imaging substudy
Magnetic resonance scanning was undertaken at the Magnetic Resonance Imaging and Analysis Research
Centre, University of Liverpool, on the Siemens 1.5 T Symphony scanner (Siemens, Erlangen, Germany),
using well-established methods.55
Liver 1H-MRS spectra were acquired with the Siemens body coil (Siemens, Erlangen, Germany), using a
point-resolved spectroscopy (PRESS) sequence [repetition time (TR) 1500 milliseconds/echo time (TE)
135 milliseconds] without water saturation, 64 signal averages.55 Transverse magnetic resonance (MR)
images were used to ensure accurate positioning of three 20 × 20 × 20 mm voxels, avoiding blood vessels,
the gall bladder and fatty tissue.
Skeletal muscle 1H-MRS spectra were acquired using the Siemens CP extremity coil (Siemens, Erlangen,
Germany) using PRESS (TR 1500 milliseconds /TE 135 milliseconds) without water saturation, 64 signal
averages.56 Transverse MR images were used to ensure accurate positioning of a 20- × 20- × 20-mm voxel
in each of the soleus and tibialis anterior. Spectra were analysed in the time domain using the AMARES
(advanced method for accurate, robust, and efficient spectra) algorithm included in the jMRUI 3.0 software
package. Intramyocellular lipid is expressed as methylene relative to creatine signal.56 Intrahepatic lipid is
expressed as methylene relative to unsuppressed water.
Magnetic resonance imaging of total body adipose content was carried out by a method adapted from
Thomas et al.55 using T1-weighted MR images (TR 705 milliseconds, TE 12 milliseconds) in 10 overlapping
blocks of 1-cm slices with a 1-cm gap, in upper and lower halves of the body separately. A validated
semiautomatic program was used to segment and analyse the images into total body subcutaneous, total
internal, subcutaneous abdominal and intra-abdominal adipose tissue volumes. This work was outsourced
to a commercial analysis service, Vardis Group (London, UK).
The scanner was supported by the manufacturers’ top-level service contract, which incorporates specific
elements of quality control for MRI.
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Pharmacovigilance definitions and procedures
The following were used for the pharmacovigilance procedures in the trial:
Adverse event – any untoward medical occurrence in a subject to whom a medicinal product has been
administered, including occurrences that are not necessarily caused by or related to that product.
Adverse reaction (AR) – any untoward and unintended response in a subject to an IMP that is related to
any dose administered to that subject.
Unexpected AR – an AR, the nature and severity of which is not consistent with the information about the
medicinal product in question set out in:
l the summary of product characteristics for that product (in the case of a product with a marketing
authorisation)
l the investigator’s brochure relating to the trial in question (in the case of any other IMP product).
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected unexpected serious adverse
reaction (SUSAR) is any of the aforementioned that:
l Results in death.
l Is life-threatening (subject at immediate risk of death). Life-threatening in the definition of ‘serious’
refers to an event in which the patient was at risk of death at the time of the event; it does not refer to
an event which hypothetically might have caused death if it were more severe.
l Requires inpatient hospitalisation or prolongation of existing hospitalisation. Hospitalisation was
defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a
precautionary measure for continued observation. Hospitalisations for a pre-existing condition,
including elective procedures that have not worsened, do not constitute a SAE.
l Results in persistent or significant disability or incapacity, or consists of a congenital anomaly or
birth defect.
l Other important medical events that may not result in death, be life-threatening or require
hospitalisation may be considered a SAE/experience when, based on appropriate medical judgement,
they may jeopardise the subject and may require medical or surgical intervention to prevent one of the
outcomes listed in this definition.
Causality
Unrelated: there is no evidence of any causal relationship, where an alternative cause for the adverse event
(AE) is provided.
Unlikely: there is little evidence to suggest there is a causal relationship (e.g. the event did not occur within
a reasonable time after administration of the trial medication). There is another reasonable explanation for
the event (e.g. the participant’s clinical condition, other concomitant treatment).
Possibly: there is some evidence to suggest a causal relationship (e.g. because the event occurs within a
reasonable time after administration of the trial medication). However, the influence of other factors may
have contributed to the event (e.g. the participant’s clinical condition, other concomitant treatments).
Probably: there is evidence to suggest a causal relationship and the influence of other factors is unlikely.
Almost certainly: there is clear evidence to suggest a causal relationship and other possible contributing
factors can be ruled out.
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Period of observation
Adverse events/reactions for the TAILoR trial were monitored from the time of consent until 7 days after
the patient had taken the final dose of telmisartan (wash-out period of telmisartan) after the patient’s
participation in the trial was concluded.
Reporting procedures
Adverse reactions and all SAEs (regardless of causality) were reported. The reporting procedures detailed in
Figure 3 and below were followed.
Unrelated, non-serious adverse events
Given the patient group that we were recruiting in this clinical trial, it was assumed that there would be a
high number of unrelated, non-serious AEs. It was therefore agreed early in the trial set up by the IDSMC,
Trial Management Group (TMG) and Trial Steering Committee (TSC) that these types of AEs would not be
reported as part of the trial processes.
Non-serious adverse reactions
All ARs (non-serious events suspected to be related to any dose of telmisartan) were reported.
Serious adverse reactions/adverse events/suspected unexpected serious adverse reactions
All events that met the serious criteria were reported (regardless of causality). SARs, SAEs and SUSARs
were reported within 24 hours of the local site becoming aware of the event. The SAE form asked for the
nature of event, date of onset, severity, corrective therapies given, outcome and causality. The responsible
investigator signed the causality form. Additional information was required to be sent within 5 days if the
reaction had not resolved at the time of reporting.
The CTRC was responsible for notifying the Medicines and Healthcare products Regulatory Agency (MHRA)
and main Research Ethics Committee (REC) of any SUSARs that occurred during the study according to the
following timelines: fatal and life-threatening within 7 days of notification and non-life-threatening within
15 days. All investigators were informed of all SUSARs occurring throughout the study. Local investigators
were asked to report any SUSARs and/or SAEs as required by their local research and development
(R&D) office.
Annual safety reports
Annual safety reports were prepared and provided to the MHRA and main REC on an annual basis. As per
the regulatory guidelines, reports were submitted on an annual basis within 60 days of the Clinical Trial
Authorisation anniversary. A total of four reports were submitted (in 2013, 2014, 2015 and 2016).
Statistical considerations
Sample size
Original aim
The original maximum total sample size of the study was 336 patients. The primary response from each
patient was the difference between the HOMA-IR score at 24 weeks and the baseline HOMA-IR score
(so that negative values indicate improvement). The design had been constructed under the assumption
that for all patients this response is normally distributed with a common standard deviation, σ. The sample
size calculation was based on a one-sided type I error of 5% and a power of 90%.
In a conventional comparison of one active treatment against a control treatment, a criterion was set so that
if the measure of advantage of the active over the control exceeded some critical value, the outcome was
declared positive. As a negative outcome was indicative of an improvement here, we wanted the measure of
advantage to be lower than some critical value. It was required that a positive outcome (i.e. a reduction in
METHODS
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FIGURE 3 Schematic of pharmacovigilance reporting procedures.
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HOMA-IR) should occur with probability α if the effects of the treatments were identical (α is the one-sided
type I error rate), and with probability 1 – β if the true treatment advantage takes some negative value (1 – β
is the power of the study). Here, we adopted a generalisation of this power requirement to multiple active
treatments following Dunnett.57 If there was no difference between the mean response on any treatment
and that on control, then a probability of α = 0.05 was set for the risk of erroneously ending the study
with a recommendation that any treatment be tested further. To fix a power requirement, effect sizes were
specified in terms of the percentage chance of a patient on active treatment achieving a greater reduction in
HOMA-IR score than a patient on the control arm; as such, the specification did not require knowledge of
the value of the common standard deviation σ. The requirement was that if a patient on the best of the
active doses had a 65% chance of showing a better response than a patient on control, whereas patients on
either of the other two active treatments had a 55% chance of showing a better response than a patient on
control, then the best active dose was to be recommended for further testing with probability 1 – β = 0.90.
This condition demanded a high power of making the correct choice if one active dose was substantially
better than control, whereas the others showed some advantage, albeit not enough to be recommended
for use. The critical values for recommending that a treatment was taken to further testing at the interim
and final analyses (–2.782 and –2.086) had been chosen to guarantee these properties using a method
described by Magirr and Whitehead,58 generalising the approach of Whitehead and Jaki.59 These properties
pertain to the whole two-stage testing procedure.
A 55% chance of achieving a better response on active dose relative to control corresponded to a reduction
in mean HOMA-IR score of about one-sixth of the standard deviation (0.178 σ), whereas the clinically relevant
effect of 65% corresponded to a reduction of about half a standard deviation (0.545 σ). The standard
deviation was reported to be around 5.60,61 Although this value was not felt to be sufficiently reliable to base
the design on, were it to be true, and if the changes in HOMA-IR were normally distributed, then the 55%
and 65% chances of better outcomes corresponded to mean changes in HOMA-IR of –0.890 and –2.725,
respectively.
Although the original maximum sample size of the study was 336 evaluable patients, it was acknowledged
that the interim analysis could reduce both the sample size and the study duration, as outlined above. The
study was designed to recruit additional patients to ensure that the target number of 24-week responses
was achieved in the presence of an anticipated 10% dropout rate (which increased the sample size to
370 patients).
Post-interim analysis
Interim analysis showed that there was a higher than anticipated rate of withdrawals and/or missing
primary outcome data. To ensure that we had the required number of patients for the final analysis,
the sample size was increased to 377 patients.
Sample size for the substudy 1 (magnetic resonance imaging/proton magnetic
resonance spectroscopy)
To explore the secondary objective of using MRI/1H-MRS in a subset of patients to identify the effect of
telmisartan on visceral fat distribution and hepatic and muscle fat, we intended to recruit 48 patients
locally (12 each in telmisartan dose arms and 12 in the control arm) to undergo whole-body MRI scans and
liver and calf MRS at baseline and at 24 weeks. There is limited information44,45 on the effect of telmisartan
on visceral fat distribution for the dose groups considered and no reliable estimates of the within-group
variance were available to carry out a formal power calculation. A sample size of 10 patients per group
was expected to provide enough data for a reliable estimate of the within-group variance (sample size was
increased to 12 to account for 10% dropout). To put this into context, the proposed sample size would
allow the detection of a linear reduction in visceral fat of at least 10 cm2/20 mg with an 80% power at
the 5% significance level, assuming a within-group standard deviation of visceral fat reduction, σ = 27 cm2.
Even if deviations from the sample standard deviation (σ = 27 cm2) occurred (e.g. σ increases to 40 cm2),
the sample size proposed would still have been sufficient to detect a linear reduction in visceral fat
distribution ≥ 15 cm2/20 mg (nQuery calculator, version 6; Statistical Solutions Ltd, Cork, Ireland). The final
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sample size achieved was affected by a lower recruitment rate than initially expected and by the decision
to stop recruitment for the main study for treatment arms B and C.
Sample size for substudy 2 (renal biomarkers)
To explore the secondary objective of whether or not there was a change in urinary biomarker levels at 12,
24 and 48 weeks between telmisartan-treated arm(s) and the control arm, we used the same sample size
as for the main study.
Interim analysis and stopping guidelines
The interim analysis was scheduled to take place once the 24-week change in HOMA-IR score was available
for at least 42 patients in each arm (n = 168, which was half of the planned maximum of 336 patients).
The sample standard deviation pooled across all four arms was used to construct test statistics expressing
the advantage of each of the three active treatments over the control arm. The prespecified analysis was
as follows:
1. If the largest of these statistics is below a critical value (equal to –2.782), this would mean that one
active dose group shows a substantially higher mean reduction of 24-week HOMA-IR score than
the control group and, therefore, the study will be stopped and the corresponding dose will be
recommended for further testing.
2. If any active dose shows no improvement over control (i.e. has an increase in HOMA-IR), that active dose
will be dropped from the second stage.
3. If all three active doses satisfy this criterion, then the study will be stopped and no significant
improvement over control will be claimed for any of the active doses.
4. If some improvement over control is detected for at least one of the doses (i.e. if at least one test
statistic is between 0 and –2.782), then the study will progress to the second stage.
Consequently, if arms are dropped after the interim analysis, randomisation will continue to be in an equal
ratio (i.e. 1 : 1 or 1 : 1 : 1).
Effect of interim analysis on the sample size and study duration
At the interim analysis, doses may be dropped from the trial, or the trial may be stopped altogether.
Consequently, the sample size when the decision is reached could be smaller than the maximum stated
number of 336 patients. Given the structure of the design, the values 168 patients (if the study is stopped
following interim analysis), 252 patients (if one active dose arm is promoted to the second stage), 294
patients (if two active dose arms are promoted to second stage) and 336 patients (if all three active dose
arms are promoted to second stage) are possible. Under the situation in which one treatment has a 65%
chance of giving a better outcome than control, while the others achieve 55%, the four sample sizes occur
with probabilities of 0.40, 0.08, 0.19 and 0.33, respectively. In this same situation, the probability of
dropping the best treatment at the interim analysis is 0.006 and it is even smaller for treatments with larger
effects. The reduced sample sizes of 168, 252 and 294 patients mentioned above refer to the numbers of
patients with 24-week HOMA-IR scores that are included in the analysis. There will be additional patients
who have been recruited and treated during the 24 weeks prior to extracting the data for interim analysis
and during the time when the analysis take place, and their number will depend on the recruitment rate
achieved. Nevertheless, taking these patients into account, it can be deduced that the impact of the interim
analysis will be to shorten the study duration by about 12 months if the conclusion is clear-cut and to reduce
the sample size by an expected 40 patients (this figure is calculated by taking into account the number of
patients recruited during the conduct of interim analysis from months 24 to 26 and, therefore, does not
actually contribute to the analysis).
The IDSMC remit included giving advice on whether or not the accumulated data from the interim analysis
justified continuing recruitment of further patients and further follow-up. If a decision was made to continue,
the IDSMC were tasked to advise on the frequency of future reviews of the data on the basis of accrual and
event rates. The IDSMC was to make recommendations to the TSC regarding continuation of the trial.
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A decision to discontinue recruitment, in all patients or in selected subgroups, would be made by the IDSMC
on the basis of results from the interim analysis.
Blinding
The TAILoR trial was an open trial, with the investigators and patients not blinded to the allocated treatment.
However, allocation concealment was possible as participants were randomised using a secure (24-hour)
web-based randomisation program controlled centrally by the CTRC.
Method of assignment to treatment
In the first stage of the study, patients were randomised in a 1 : 1 : 1 : 1 ratio to receive 20, 40 or 80 mg
of telmisartan or no intervention (control) using a secure (24 hour) web-based randomisation program
controlled centrally by the CTRC CTU.
Randomisation lists were generated in a 1 : 1 : 1 : 1 ratio using simple block randomisation with random
variable block length. For each recruiting centre, randomisation was stratified by ethnicity (black or
non-black). Following the interim analysis, as the trial continued, those eligible that consented to take
part in the study were randomised in an equal ratio to receive one of the remaining doses or no
intervention (control).
During both stages of the trial, patients were enrolled to the study by clinicians and/or research nurses at
each individual site who were delegated to do so by the PI.
Sequence and duration of all study periods
A schematic of the study design can be found in Data collection, including descriptions and timings of all
assessments and procedures that were needed throughout. In summary, follow-up assessments occurred
at 12, 24 and 48 weeks after randomisation.
Statistical analysis plan
Statistical analysis plans were developed for the interim and final analyses of the trial by the trial
investigators and trial statistician, and were reviewed and agreed by the TSC and Data Monitoring and
Ethics Committee prior to the end of the recruitment period at each stage of the trial. The complete detail
of all statistical analysis plans are given in Appendix 4.
Statistical methods
Primary outcome analysis
In order to satisfy the primary objective, we evaluated three different doses against control in the first stage
of the study and conducted an interim analysis that allowed ineffective doses to be eliminated quickly while
a dose showing a reduction in HOMA-IR was taken forward. At the interim analysis, the sample standard
deviation pooled across all four arms was determined and used to construct test statistics expressing
the advantage of each of the three active treatments over control. These statistics were adjusted for the
stratification factor (ethnicity). The smallest of these test statistics was to be compared with the interim critical
value (–2.782). Observing a test statistic below this value corresponded to a significant improvement in
HOMA-IR score for the corresponding dose over control and would have led to this dose being immediately
taken forward for further study, and to the trial being stopped. Any dose corresponding to a positive test
statistic would have been dropped and if all doses were dropped, the trial would also have been stopped.
If some reduction in HOMA-IR over control was detected for at least one of the active doses (i.e. test statistic
of between 0 and -2.782), then the study would continue after the interim analysis. At the final analysis,
if the smallest comparative test statistic was below the final critical value (–2.086) then this dose would be
recommended for further study. Adjustments were made to allow for any discrepancies between target and
actual sample sizes while still preserving the one-sided type I error rate at 0.05.
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The design was constructed under the assumption that for all patients the response (HOMA-IR score) is
normally distributed with a common standard deviation, σ. If HOMA-IR score was not normally distributed,
then a log with base e transformation was used.
Sensitivity analyses
Missing HOMA-IR values at 24 weeks were imputed by the MICE (Multivariate Imputation by Chained
Equations)62 algorithm (MICE package; version 3.3.0) conditional on HOMA-IR values at baseline, HOMA-IR
values at 12 weeks and stratification factor (ethnicity). A compliance-adjusted primary outcome analysis
was undertaken using instrumental variable (IV) regression, in order to estimate the effect of actual dose
on outcome. Further IV regression was carried out but additionally accounting for baseline HIV viral load.
More information on sensitivity analyses is provided in the statistical analysis plans (see Appendix 4).
Secondary outcome analysis
Biomarker analysis
To explore the secondary objective of identifying longitudinal change in the expression of biomarkers in
telmisartan-treated arm(s) in comparison with controls, joint models63,64 were used to fully exploit the serial
nature of these outcomes accounting for informative loss to follow-up and missingness. The models are
adjusted for ethnicity, the stratification factor at randomisation. The joint model was constructed under the
assumption that longitudinal outcomes were normally distributed. If any biomarker value was not normally
distributed, then a log with base e transformation was used.
Analysis of changes in body fat redistribution and intrahepatic and intramyocellular
lipid content
The aim of this analysis was to identify the effect of telmisartan on visceral fat distribution and hepatic and
muscle fat. The change in visceral fat at 24 weeks was compared across the three treatment groups and the
control using multiple linear regression. A multiple linear regression model was considered to explore the
differences in visceral fat change between the treatment groups while accounting for potential confounders.
The model was adjusted for the relative change of total external fat to account for any confounding effect.
The standard error of each estimator of the model coefficients, p-values, as well as the 95% confidence
intervals (CIs) for the coefficient parameters were provided. A similar strategy was adopted for the analysis of
liver and calf MRS data.
Evaluation of alternative methods of insulin resistance (Quantitative Insulin Sensitivity
Check Index and Revised Quantitative Insulin Sensitivity Check Index)
The aim of this analysis was to see if telmisartan showed a similar direction of change in insulin resistance
measured by QUICKI and revised QUICKI to that observed with HOMA-IR. We used the same analysis as
that described in Primary outcome analysis for the two alternative measures.
Renal biomarker analysis
Longitudinal measurements of urinary biomarkers were analysed using linear mixed-effect models adjusting
for age, weight change and sex, which were included in the final model if found significant. For analysis of
NGAL, the sample set was divided into tertiles. For analysis of ACR, the sample set was divided into two
subsets based on the KDIGO (Kidney Disease Improving Global Outcomes) 2012 clinical practice guideline
for the evaluation and management of chronic kidney disease65 (i.e. an ACR of < 3 mg/mmol, normal; an
ACR of > 3 mg/mmol, microalbuminuria).
Additional analysis
All analyses were undertaken adjusting for weight change. Joint models included data from the dropped
arms at the interim analysis and were fitted with longitudinal measurements from all four arms to adjust
for informative dropout further and to account for changes in weight over time. Bivariate joint models were
fitted using the joineRML package in R (The R Foundation for Statistical Computing, Vienna, Austria).66,67
Two additional ad hoc exploratory compliance-adjusted analysis were undertaken for HOMA-IR at 24 weeks
to address some selection bias.
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Trial organisation
Trial management
The trial was managed by the CTRC at the University of Liverpool, which is a UK Clinical Research
Collaboration (UKCRC) – Registered Clinical Trial Unit (CTU), a part of the Liverpool Trials Collaborative.
The CTRC was responsible for trial management, quality assurance, data management and trial statistics.
A dedicated trial manager, data manager and statistician were appointed to the CTRC.
Trial sponsor
The TAILoR trial was co-sponsored by the University of Liverpool and the Royal Liverpool and Broadgreen
University Hospitals NHS Trust.
Ethical considerations, regulatory requirements, and research governance framework
The TAILoR trial was conducted in accordance with the European Clinical Trials Directive, ICH GCP
Guidelines, the Declaration of Helsinki, NHS Research governance framework, and the Medicines for
Human Use (Clinical Trials) Regulations 2004.
The trial was authorised to proceed by the MHRA on 29 June 2012. Its EudraCT number is 2012-000935-18.
The trial also received REC (National Research Ethics Service committee – North West – Liverpool Central)
approval prior to the start of the study (original approval dated 2 April 2012).
Prior to beginning research at each participating site, REC approval was sought as were local permissions
from the R&D departments at each site.
Trial registration
National Institute for Health Research portfolio
The TAILoR trial was adopted onto the National Institute for Health Research (NIHR) portfolio and fulfilled
the criteria for UK Clinical Research Network support.
Summary of protocol amendments
During the course of the trial, a number of amendments were made to the TAILoR protocol. Each
amendment was assessed by the TMG, Trial Steering Group and the funder. Each amendment was approved
by the REC and, if appropriate, by the MHRA. A full list of amendments and summarises can be found in
Appendix 5.
Trial committees
Trial Management Group
A TMG was set up to be responsible for the day-to-day management of the TAILoR trial. The TMG met on
a monthly basis to discuss the conduct and progress of the trial. The TMG membership was as follows:
l Professor Sir Munir Pirmohamed (chief investigator)
l Claire Taylor (trial co-ordinator)
l Catherine Spowart (until June 2016) (supervisory trial manager)
l Dr Ruwanthi Kolamunnage-Dona (study statistician)
l Professor Thomas Jaki (senior study statistician)
l Professor Paula Williamson (senior statistician and co-applicant)
l Dr Sudeep Pushpakom (co-applicant and scientist)
METHODS
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l Professor Saye Khoo (co-applicant and PI at RLBUHT)
l Professor John Whitehead (until retirement in 2014; co-applicant and statistician)
l Helen Reynolds (research nurse at RLBUHT)
l Jenny Harrison (until October 2015; research nurse at RLBUHT)
l Dr Duncan Churchill (PI at the Elton John Centre)
l Dr Gabriel Schembri (PI at the Manchester Centre for Sexual Health)
l Steve Earle (patient representative).
Trial Steering Committee
The TSC was established to provide overall supervision of the trial and to ensure that the trial was conducted
to ICH GCP guidelines. The TSC met annually throughout the course of the trial via both teleconference and
e-mail. Copies of the minutes were provided to the study funder (NIHR). The TSC were also consulted about
any amendments to the trial protocol. The TSC membership was as follows:
l Professor Stephane de Wit (chairperson)
l Professor Lucinda Billingham (independent member)
l Professor Mahesh Parmar (independent member)
l Simon Collins (independent member, patient representative)
l Professor Sir Munir Pirmohamed (chief investigator)
l Professor Paula Williamson (co-applicant).
Meetings were also attended by members of the TMG and sponsor representatives:
l Claire Taylor (trial co-ordinator)
l Catherine Spowart (until June 2016; supervisory trial manager)
l Dr Ruwanthi Kolamunnage-Dona (study statistician)
l Professor Thomas Jaki (senior study statistician)
l Dr Sudeep Pushpakom (co-applicant and scientist)
l Professor Saye Khoo (co-applicant and PI at RLBUHT)
l Professor John Whitehead (until retirement in 2014; co-applicant and statistician)
l Heather Rogers (RLBUHT sponsor representative)
l Lindsay Carter (April 2012–March 2013; University of Liverpool sponsor representative)
l Karen Wilding (University of Liverpool sponsor representative).
Independent Data and Safety Monitoring Committee
An Independent Data and Safety Monitoring Committee (IDSMC) was established at the start of the trial.
Its purpose was to review trial data, assess safety issues and/or address any ethics concerns. The IDSMC
met annually throughout the course of the trial by both teleconference and e-mail. The IDSMC also
received safety reports on a quarterly basis. The IDSMC assessed the interim analysis to decide on the
ongoing format of the trial. The IDSMC members were:
l Professor Sir Ian Weller (chairperson)
l Dr Adrian Mander (independent statistician)
l Professor Jacqueline Capeau (independent member).
Risk assessment, monitoring and data management
Risk assessment
A risk assessment was performed by the CTRC team in collaboration with the chief investigator and sponsor
at the beginning of the trial. The risk assessment indicated that the TAILoR study was a low-risk study and
that monitoring would take place centrally, with site visits taking place if required to resolve issues.
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Monitoring and data management
Monitoring was performed centrally. The MACRO database (version 3) contained predefined ranges that
flagged queries to the study data manager if data outside the ranges were entered. In addition, the trial
statistician performed regular checks on the data to produce IDSMC and trial monitoring reports to look
for errors and inconsistencies and to highlight any protocol deviations.
Sites were requested to fax consent forms to the trial co-ordinator within 7 days of completion and these
were then checked by the trial co-ordinator to ensure that they were valid.
Site training/initiation visits took place at all participating sites. On site monitoring visits took place if
central monitoring indicated a need (e.g. CRFs not being returned/returned late, inconsistencies in CRFs).
Patient and public involvement
Patient representatives were identified early on in the trial and were involved in the oversight of the trial.
One representative sat on the TSC and one on the TMG. Both attended regular meetings throughout
the course of the trial. The patient representatives reviewed the study website, clinic poster, participant
information sheets and consent forms. The design and format of the patient information sheets was
altered in response to their feedback. They also gave opinions on how recruitment process could be
improved.
METHODS
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Chapter 4 Results
Participant recruitment
Screening and participant flow
In total, 1950 patients were screened at the participating centres over the duration of the trial. Of the
1118 patients meeting the eligibility criteria, 698 declined to participate. Tables 14–16 in Appendix 6
summarise the numbers screened and eligible patients recruited to the trial. Further details of screening
are given in Appendix 6, with Table 16 summarising the reasons for non-recruitment. The flow of
patients is summarised in Figure 4, including the numbers of patients screened, randomised, followed up
and analysed.
Randomisation checking
Randomisation numbers were sequential by date randomised, and there were no missing randomisation
numbers. The last day of randomisation was 20 July 2015. Treatments were balanced across strata
(ethnicity) (Table 3).
Recruitment and retention
Recruitment took place from March 2013 until July 2015, taking a total of 28 months. This was longer
than the originally allocated recruitment period of 1 year. There were a number of delays in starting the
trial and in the opening of sites to recruitment. The major issues encountered were:
l lack of funding for excess treatment costs (ETCs)
l slower recruitment
l increased participant dropout and subsequent need to increase from the original sample size
l high staff turnover at some participating sites, which further contributed to delay/interruption
in recruitment.
The TAILoR team took a number of measures to counter the above cited impediments:
1. A waiver to underwrite the ETCs was negotiated with the trial sponsor (University of Liverpool) to get
the trial started. Over the course of the trial, all participating sites were contacted to cover ETCs and
this was eventually agreed by all sites by the time the last patient was recruited.
2. Setting up of additional sites to reach the recruitment target in the same time frame – the number of
recruitment sites was increased from the originally planned eight sites to 19 sites.
3. Encouraging patient participation and increasing publicity for the trial among the patient population –
the trial team held discussions with the patient and public involvement representatives in the TMG and
the TSC on ways to increase recruitment rates. As a result of this, the participant information sheet was
altered to make them more reader friendly; we also developed posters for use in participating clinics,
and developed a recommended recruitment pitch for researchers. A study website (www.tailortrial.org)
was also created to increase visibility and to update the participants of the various developments related
to the trial.
4. Ensuring recruiter engagement – to increase recruitment, we continued to engage with research teams
at sites holding regular PI and research nurse meetings, and having regular newsletter updates.
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Randomised
(n = 379)
Discontinued intervention with no further data collection
(n = 14)
•  Lost to follow-up, n = 6
•  Death, n = 1
•  Withdrew consent for follow-up, n = 1
•  Other, n = 6f
Discontinued intervention with continued data collection
(n = 0)
Fo
llo
w
-u
p
A
llo
ca
ti
o
n
Arm A: non-intervention
(n = 105)
Assessed for eligibility
(n = 1950)
En
ro
lm
en
t
Arm B: telmisartan 20 mg
(n = 84)
Arm C: telmisartan 40 mg
(n = 82)
Arm D: telmisartan 80 mg
(n = 106)
Excluded
(n = 1574)
• Did not meet inclusion criteria, n = 832
• Decline to participate, n = 698
• Not randomised, n = 44
Discontinued intervention with no further data collection
(n = 21)
•  Lost to follow-up, n = 5, with AE, n = 1
•  Related AE, n = 2
•  Patient preference, n = 1
•  Withdrew consent for follow-up, n = 3, with AE, n = 1
•  Other, n = 8g
Discontinued intervention with continued data collection
(n = 18)
•  Related AE, n = 4
•  Patient preference, n = 4
•  Serious AE, n = 1
•  Failure to comply with protocol, n = 2
•  Other, n = 7h
Final analysis
Analysed for primary outcome
(n = 85)
Analysed for primary outcome
(n = 78)
Excluded
(n = 2)
• Randomised the same patient in error, n = 1
• Patient was not present at the randomisation,
   n = 1b
Discontinued intervention with no further data collection
(n = 47)
•  Lost to follow-up, n = 2, with AE, n = 1
•  Patient preference, n = 1
•  Patient preference, then lost to follow-up, n = 1
•  Related AE, n = 3
•  Arm dropped, n = 38
•  Other, n = 1c
Discontinued intervention with continued data collection
(n = 6)
•  Related AE, n = 2
•  Failure to comply with protocol, n = 1
•  Other, n = 3e
Discontinued intervention with no further data collection
(n = 51)
•  Lost to follow-up, n = 5, with AE, n = 1
•  Withdrew consent for follow-up, n = 2, with AE, n = 2
•  Related AE, n = 2
•  Serious AE, n = 1
•  Arm dropped, n = 36
•  Other, n = 2d
Discontinued intervention with continued data collection
(n = 12)
•  Related AE, n = 5, serious AE, n = 1
•  Patient preference, n = 2
•  Failure to comply with protocol, n = 1
•  Other, n = 3i
Missing screening logs for those randomised, n = 3a
Excluded from analysis (n = 20)
•  Did not attend 24 weeks, n = 4
•  Haemolysed samples collected 24 weeks, n = 0
•  Haemolysed samples collected baseline, n = 3
•  Samples not collected/un-fasted 24 weeks, n = 1
•  Samples not collected/un-fasted baseline, n = 1
•  Withdrew before 24 weeks , n = 11
Excluded from analysis (n = 28)
•  Did not attend 24 weeks, n = 4
•  Haemolysed samples collected 24 weeks, n = 2
•  Haemolysed samples collected baseline, n = 3
•  Samples not collected/un-fasted 24 weeks, n = 2
•  Samples not collected/un-fasted baseline, n = 2
•  Withdrew before 24 weeks, n = 15
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Recruitment rate
The target recruitment rate for the study was two to five patients per month per site, based on the original
eight sites recruiting and a target recruitment figure of 370 patients. Monthly and cumulative monthly
accrual of patients was slower than anticipated and is shown in Figure 5.
Baseline data
The baseline characteristics of all randomised patients are summarised by treatment arms (see Tables 4
and 5). Baseline characteristics were balanced across treatment arms. The median ages were comparable
between all arms (Table 4). The study participants were predominantly male (ranging between 81.0% and
84.1% across the four arms; see Table 4). The body mass index (BMI) and other vital parameters of the
participants were comparable between all four arms (see Table 4), as was the cluster of differentiation 4
(CD4) cell count (ranging between 580 and 598 cells/mm3; see Table 18 in Appendix 6). The baseline liver
function and full blood count were also comparable between participants in all four arms (see Tables 19
and 20 in Appendix 6). The median HOMA-IR values ranged between 0.408 and 17.495 for the entire
cohort (Table 5) and were comparable between all four arms. There was also no difference in baseline
values for the secondary outcome measures (Table 5).
Numbers analysed
In total, 307 (81%) of the patients attended all study assessment visits, and 72% of patients had complete
records of longitudinal outcome as planned. Table 21 (see Appendix 6) shows the numbers for missed
visits and missing data because of sample issues, and reasons for missingness are given in Table 22
(see Appendix 6).
FIGURE 4 Consolidated Standards of Reporting Trials flow diagram. a, Screening data are missing for three patients.
b, A patient was randomised in arm B, even before they attended the clinic, because of a communication error.
c, Patient concerned about leg swelling (not an AE) and decided to stop study drug. d, Patient has left the country;
patient preference. e, Medication ran out 2 days before final visit; appointment was missed, as patient misunderstood
the follow-up schedule; patient lost study medication and failed to inform research team until 48-week follow-up visit.
f, Patient moved to London with no forwarding address; did not wish to continue the study because of organisational
reasons; because of advice from study team following MRI incidental finding; to enter another clinical trial; eGFR
< 60ml/minute/1.73 m2 at screening; on nevirapine. g, Patient developed a cough and wanted to discontinue
study medication; taking Rampiril (general practitioner’s orders); switch in ARV; not able to commit to study; eGFR
< 60ml/minute/1.73 m2 at baseline; did not meet eligibility criteria; did not return for appointment and did not
respond to contacts; decided to become pregnant. h, Patient ran out of study medication; eGFR < 60ml/minute/1.73m2;
patient ran out of study medication but did not collect extra medication; forgot to take study medication when on
holiday abroad; ran out of study medication; ran out of study medication but was unable to come to collect extra
medication; did not take study medication as required. i, All three patients had run out of study drug.
TABLE 3 Ethnicity distribution of treatment/non-intervention arms
Ethnicity
Treatment arm, n (%)
Arm A (control)
(N= 105)
Arm B (20mg)
(N= 84)
Arm C (40mg)
(N= 82)
Arm D (80mg)
(N= 106)
Black 22 (20.9) 18 (21.4) 16 (19.51) 22 (20.8)
Non-black 83 (79.0) 66 (78.6) 66 (80.49) 84 (79.2)
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FIGURE 5 Monthly and cumulative monthly accrual of patients. Post interim analysis: interim analysis has shown that there was a higher than anticipated rate of withdrawals
and/or missing primary outcome data. In order to have the required number of patients for final analysis, a total of 377 patients was required.
RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
32
TABLE 4 Baseline characteristics of patients by treatment arm
Characteristic
Treatment arm
Arm A (N= 105) Arm B (N= 84) Arm C (N= 82) Arm D (N= 106)
Age (years)
Median (IQR); min.–max. 47.2 (39.8–52.4);
20.4–70.5
46.0 (41.0–52.2);
21.6–74.6
47.9 (43.3–51.5);
31.5–70.8
45.8 (38.2–51.7);
22.5–67.3
Sex, n (%)
Female 20 (19.0) 15 (17.9) 13 (15.9) 17 (16.0)
Male 85 (81.0) 69 (82.1) 69 (84.1) 89 (84.0)
BMI (kg/m2) (n= 103) (n= 81)
Median (IQR); min.–max. 25.4 (23.1–29.2);
16.7–42.0
25.6 (23.3–29.2);
18.8–52.2
26.3 (24.4–29.6);
16.7–46.3
25.4 (23.0–27.8);
7.9–43.7
Systolic blood pressure (mmHg) (n= 81)
Mean (SD); min.–max. 126.8 (13.9);
100.0–160.0
124.4 (14.2);
100.0–162.0
126.9 (14.3);
92.0–158.0
124.8 (15.4);
100.0–172.0
Diastolic blood pressure (mmHg)
Mean (SD); min.–max. 80.0 (10.7);
60.0–122.0
78.2 (11.2);
56.0–107.0
79.7 (9.9);
54.0–102.0
78.6 (11.1);
55.0–107.0
Heart rate (beats per minute) (n= 82) (n= 80)
Mean (SD); min.–max. 73.0 (11.5);
50.0–101.0
72.5 (11.7);
51.0–105.0
71.6 (13.1);
39.0–113.0
72.8 (12.2);
51.0–115.0
Temperature (°C) (n= 99) (n= 78) (n= 78) (n = 102)
Mean (SD); min.–max. 36.3 (0.5); 35–38 36.3 (0.4);
35.3–37.8
36.4 (0.3);
35.5–37.1
36.3 (0.5);
34.5–37.8
Respiratory rate (breaths per minute) (n= 102) (n= 83) (n= 76) (n = 103)
Mean (SD); min.–max. 15.6 (2.9);
10.0–28.0
15.9 (4.0);
10.0–41.0
16.0 (4.2);
10.0–37.0
16.5 (3.4);
10.0–28.0
Waist circumference (cm) (n= 101) (n= 83) (n= 79) (n = 102)
Mean (SD); min.–max. 93.5 (11.8);
65.0–137.0
94.6 (14.7);
66.0–145.0
97.1 (12.2);
70.0–143.0
93.0 (11.6);
67.5–122.0
Thigh circumference (cm) (n= 101) (n= 82) (n= 77) (n = 102)
Mean (SD); min.–max. 50.8 (7.5);
33.5–80.0
52.3 (7.7);
39.0–90.5
51.8 (6.0);
37.0–69.0
49.6 (8.5);
22.7–84.0
eGFRa (ml/minute/1.73 m2) (n= 50) (n= 41) (n= 38) (n = 54)
Mean (SD); min.–max. 79.8 (13.6);
45.0–129.0
79.9 (10.8);
60.0–105.0
77.9 (10.5);
62.0–107.6
81.4 (14.5);
53.0–122.0
< 60, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9)
< 90, n (%) 0 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
> 60, n (%) 24 (22.9) 23 (27.4) 25 (30.5) 22 (20.8)
> 90, n (%) 28 (26.7) 19 (22.6) 19 (23.2) 28 (26.4)
IQR, interquartile range; max., maximum; min., minimum.
a Some data are presented in both continuous and categorical form as a result of there being upper and lower limits
of measurement.
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TABLE 5 Baseline values of primary and secondary outcome data by treatment arm
Characteristic
Treatment arm
Arm A (N= 105) Arm B (N= 84) Arm C (N= 82) Arm D (N= 106)
Insulin (pmol/l) (n= 102) (n= 81) (n= 78) (n= 100)
Median (IQR); min.–max. 54 (35–90);
11–279
57 (37–87);
21–319
61 (40–85);
21–432
51 (36.5–75.5);
21–454
Glucose (mmol/l) (n= 104) (n= 83) (n= 80) (n= 104)
Mean (SD); min.–max. 5.2 (0.5);
4.2–6.9
5.2 (0.58);
4.0–7.6
5.29 (0.7);
3.2–8.5
5.22 (0.54);
4.1–6.8
NEFAs (mmol/l) (n= 104) (n= 82) (n= 79) (n= 102)
Median (IQR); min.–max. 0.42
(0.27–0.615);
0.08–1.21
0.385
(0.25–0.58);
0.07–1.08
0.35 (0.25–0.55);
0.05–0.84
0.40 (0.30–0.59);
0.08–1.21
HOMA-IR (n= 100) (n= 81) (n= 78) (n= 100)
Median (IQR); min.–max. 1.808
(1.120–2.903);
0.408–10.775
1.860
(1.208–3.508);
0.578–9.800
2.117
(1.223–3.297);
0.618–17.495
1.628
(1.175–2.490);
0.591–16.852
QUICKI (n= 100) (n= 81) (n= 78) (n= 100)
Mean (SD); min.–max. 0.117 (0.009);
0.097–0.142
0.116 (0.009);
0.098–0.135
0.116 (0.010);
0.093–0.134
0.118 (0.009);
0.093–0.135
Revised QUICKI (n= 100) (n= 81) (n= 78) (n= 99)
Mean (SD); min.–max. 0.132 (0.017);
0.101–0.184
0.134 (0.019);
0.100–0.211
0.134 (0.019);
0.100–0.212
0.133 (0.016);
0.096–0.178
HDL-C (mmol/l) (n= 104) (n= 82) (n= 79) (n= 103)
Median (IQR); min.–max. 1.15 (0.9–1.4);
0.5–3.0
1.1 (1.0–1.4);
0.3–2.7
(0.9–1.4);
0.2–2.8
(1.0–1.4);
0.5–2.9
Cholesterol (mmol/l) (n= 104) (n= 82) (n= 79) (n= 103)
Mean (SD); min.–max. 5.01 (0.99);
2.2–8.2
5.0 (1.11);
2.6–8.3
4.83 (1.04);
2.5–7.1
4.97 (1.04);
2.9–7.64
Triglycerides (mmol/l) (n= 104) (n= 82) (n= 79) (n= 103)
Median (IQR); min.–max. 1.4 (1.0–2.0);
0.5–6.5
1.25 (0.9–1.8);
0.4–4.8
1.4 (1.0–1.9);
0.5–6.1
1.2 (0.9–1.8);
0.4–6.7
LDL-C (mmol/l) (n= 103) (n= 81) (n= 78) (n= 102)
Mean (SD); min.–max. 3.1 (0.91);
1.1–6.4
3.14 (0.97);
1.1–6.2
2.97 (0.9);
0.8–5.2
3.12 (0.91);
0.8–5.6
Adiponectin (µg/ml) (n= 104) (n= 82) (n= 78) (n= 101)
Median (IQR); min.–max. 14.62
(10.11–20.50);
3.14–44.34
16.27
(12.05–21.84);
1.73–60.49
13.69
(9.22–20.31);
2.01–66.19
13.47
(8.28–18.51);
2.74–129.01a
Leptin (pg/ml) (n= 104) (n= 81) (n= 78) (n= 103)
Median (IQR); min.–max. 4856.7
(1885.9–13,879);
253.64–123,299
4688.7
(2149–15,786);
388.38–192,842
5227.2
(2271.4–9710);
168.11–119,430
4492.2
(2126.5–10,192);
502.59–104,002
IL-8 (pg/ml) (n= 104) (n= 82) (n= 78) (n= 102)
Median (IQR); min.–max. 17 (12.98–22.7);
5.67–744.98a
14.38
(11.65–18.67);
5.18–166.7
16.32
(11.83–25.12);
6.04–187.86
18.57
(12.75–29.53);
4.51–368.69
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Primary outcome results
Interim analysis
There were 48, 49, 47 and 45 patients who were randomised to arms A, B, C and D, respectively, with
a total of 189 patients available for interim analysis. However, only 154 patients had a complete set of
baseline and 24-week HOMA-IR data and were therefore included in the interim analysis. A total of
32 patients did not have a HOMA-IR value at the 24-week time point, and three patients did not have
baseline HOMA-IR data. In 31 out of 32 cases, the 24-week HOMA-IR data were unavailable because of
withdrawal from the study, visit not attended and loss to follow-up. There were seven patients (14.6%) in
arm A, four patients (8.2%) in arm B, 11 patients (23.4%) in arm C and nine patients (20.0%) in arm D
who were unavailable for interim analysis. Figure 6 shows the box plots for HOMA-IR at baseline and
24 weeks by treatment arm and the summary statistics are given in Table 23 (see Appendix 6).
The HOMA-IR data were not normally distributed; hence the analysis was performed in log-scale. The
model estimates are presented in Table 6; the t-statistic for arms B and C showed a positive value (i.e.
higher than 0), which implied that there was no reduction in the HOMA-IR over control (arm A) for arms B
and C and, therefore, these active dose arms were dropped from the second stage. As some improvement
over control was detected for arm D (i.e. the t-statistic was between 0 and –2.782), this arm was selected
to progress into the second stage of the study and the patients were thereafter randomised between arm D
and the control arm (arm A).
Final analysis
At the end of the study, there were 105 patients randomised in arm A and 106 patients in arm D (total
n = 211). One patient from arm D had an extreme HOMA-IR value at 24 weeks (62.0). This was because of
a high insulin value of 1242 (glucose value was 7.8). The summary statistics for HOMA-IR at baseline and
TABLE 5 Baseline values of primary and secondary outcome data by treatment arm (continued )
Characteristic
Treatment arm
Arm A (N= 105) Arm B (N= 84) Arm C (N= 82) Arm D (N= 106)
TNF-α (pg/ml) (n= 103) (n= 82) (n= 78) (n = 101)
Median (IQR); min.–max. 2.31 (1.69–3.49);
0.58–12.61
2.1 (1.74–2.49);
1.04–6.27
2.39 (1.71–2.99);
0.49–8.11
2.35 (1.77–3.09);
0.85–56.89*
Resistin (pg/ml) (n= 104) (n= 82) (n= 78) (n = 101)
Median (IQR); min.–max. 5602.7
(3936.6–7998.5);
1667.2–30,299
4790.2
(3713.7–6966.3);
1288.2–20,357
5114
(3656.4–6861);
1180–13,781
5684.9
(4590.9–8367.2);
1607.7–19,692
hs-CRP (mg/ml) (n= 104) (n= 82) (n= 78) (n = 103)
Median (IQR); min.–max. 2.24 (1.03–4.04);
0.31–98.12a
1.4 (0.71–3.93);
0.35–18.97
1.32 (0.59–4.17);
0.25–91.56a
1.32 (0.66–3.14);
0.28–41.74
NGAL (pg/ml) (n= 99) (n= 82) (n= 72) (n = 101)
Median (IQR); min.–max. 5.99
(1.98–15.31);
0.46–160.79
5.59
(2.38–15.76);
0.59–325.54
6.30
(1.70–17.59);
0.49–282.04
5.48
(1.85–15.85);
0.61–160.50
ACR (mg/mmol) (n= 40) (n= 34) (n= 31) (n = 40)
Median (IQR); min.–max. 0.8 (0.4–3.6);
0.2–37.0
0.9 (0.6–1.8);
0.2–8.5
0.9 (0.5–2.0);
0.2–7.4
0.5 (0.4–1.65);
0.3–38.8
IQR, interquartile range; max., maximum; min., minimum.
a Confirmed correct.
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24 weeks by treatment arm are given in Table 7, and the model estimates are presented in Table 8. As
the HOMA-IR was not normally distributed, all analyses were performed in log scale. Since the test statistic
(t-value 0.065) was not smaller than the critical value of –2.086, it was concluded that there was no
significant difference in HOMA-IR between arms D and A (t-value 0.007, SE 0.106).
We have investigated the effect of inclusion of this extreme value further by plotting the change in HOMA-IR
at 24 weeks from baseline against HOMA-IR at baseline; this is presented in Figure 10 (see Appendix 6). This
patient was considered to be a statistical outlier and was therefore excluded from the analyses shown below.
A total of 85 patients from arm A and 78 patients from arm D with both baseline and 24-week HOMA-IR
measurements were included in the final analysis. Figure 7 shows the box plots for HOMA-IR at baseline
and 24 weeks by treatment arm, and the summary statistics are given in Table 24 (see Appendix 6).
The model estimates are presented in Table 25 (see Appendix 6). Since the test statistic (–0.347) was not
smaller than the critical value of –2.086, it was concluded that there was no significant difference in
HOMA-IR between arms D and A (–0.034, SE 0.099).
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FIGURE 6 Box plots for HOMA-IR at baseline and 24 weeks by treatment arm at the interim analysis. A refers to
the control arm; B, C and D refer to arms treated with 20, 40 and 80mg of telmisartan, respectively. 0, baseline;
24, 24 weeks.
TABLE 6 Model estimates for log-HOMA-IR and decision at the interim analysis
Variable Parameter estimate Standard error t-value for treatment Decision
Intercept 0.3799 0.1414 – –
Log(HOMA-IR) at baseline 0.5529 0.0681 – –
Ethnicity –0.0164 0.1228 – –
Arm B vs. arm A 0.0486 0.1300 0.3738 Drop arm B
Arm C vs. arm A 0.1009 0.1383 0.7297 Drop arm C
Arm D vs. arm A –0.0247 0.1386 –0.1778 Keep arm D
RESULTS
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TABLE 7 Summary statistics for HOMA-IR at baseline and 24 weeks by treatment arm
Summary statistic
Time point
HOMA-IR at baseline HOMA-IR at 24 weeks
Arm A (control) Arm D (80mg) Arm A (control) Arm D (80mg)
Number of patients (%) 100 (95.2) 100 (94.3) 89 (84.8) 82 (77.4)
Mean (SD), min.–max. 2.5 (2.08),
0.4–10.8
2.5 (2.79),
0.6–16.9
3.0 (3.25),
0.6–19.6
3.4 (6.89),
0.6–62.0
Median (IQR) 1.8 (1.1–2.9) 1.6 (1.2–2.5) 2.1 (1.3–3.2) 2.0 (1.1–3.6)
Missing (%) 5 (4.8) 6 (5.7) 16 (15.2) 24 (22.6)
Number of patients randomised 105 106 105 106
IQR, interquartile range; max., maximum; min., minimum.
TABLE 8 Model estimates for log-HOMA-IR and test statistic (including the extreme HOMA-IR value at 24 weeks)
Variable Parameter estimate Standard error t-value for treatment
Intercept 0.428 0.135 –
Log-(HOMA-IR) at baseline 0.594 0.079 –
Ethnicity (non-black) 0.010 0.132 –
Arm D vs. arm A 0.007 0.106 0.065
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FIGURE 7 Box plots for HOMA-IR at baseline and 24 weeks by treatment arm at the final analysis for continued
treatment arms. A refers to the control arm; D refers to arm treated with 80mg of telmisartan. 0, baseline;
24, 24 weeks.
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The model was further adjusted for change in weight between 24 weeks and baseline in a post hoc
analysis. A total of 84 patients from arm A and 77 patients from arm D (one patient was excluded because
of unavailability of weight at baseline data) were included in this analysis. The test statistic, –0.399, was
still not smaller than the critical value (–2.086), and thus there was no significant difference in HOMA-IR
between the two arms (–0.039, SE 0.097; see Appendix 6, Table 26).
Sensitivity analyses were also carried out to adjust for (1) potential missing HOMA-IR values and (2) treatment
compliance. The parameter estimates in each of these sensitivity analyses [imputation for missing HOMA-IR,
test statistic= –0.393, effect size –0.038, SE 0.096; treatment compliance, –0.010 (95% CI –0.028 to 0.008;
p = 0.3] showed that there was no significant difference between arms A and D. Details of these analyses
are presented in Appendix 6, Tables 27–30.
Secondary outcome results
Alternative indices of insulin resistance (Quantitative Insulin Sensitivity Check and
revised Quantitative Insulin Sensitivity Check)
We used two alternative measures of insulin resistance, QUICKI and revised QUICKI, to further investigate
the effect of telmisartan. Figure 8 shows the box plots for QUICKI and revised QUICKI at baseline and
24 weeks by treatment arm, and the summary statistics are given in Tables 31 and 32 (see Appendix 6).
For QUICKI, the test statistic (0.4471) was not smaller than the critical value (–2.086), suggesting no
difference between arms A and D (0.0006, SE 0.0013), a result similar to that observed with HOMA-IR
(see Table 33 in Appendix 6). Similarly, for revised QUICKI, the test statistic (0.6882) was not smaller than
the critical value (–2.086), again showing no difference between arms A and D (0.0017, SE 0.0025;
see Table 34 in Appendix 6).
The model diagnostics related to the above models are shown in Appendix 6.
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FIGURE 8 Box plots for QUICKI and revised QUICKI at baseline and 24 weeks by treatment arm. A refers to the
control arm; D refers to arm treated with 80mg of telmisartan. 0, baseline; 24, 24 weeks.
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Longitudinal outcomes
Longitudinal analysis of Homeostatic Model Assessment of Insulin Resistance,
Quantitative Insulin Sensitivity Check and revised Quantitative Insulin Sensitivity Check
The longitudinal profiles of HOMA-IR, QUICKI and revised QUICKI at weeks 12, 24 and 48 for all four arms
were analysed using a bivariate joint model, adjusted for weight changes over time. A total of 321 patients
and 812 individual measurements (320 patients and 808 individual measurements in the case of revised
QUICKI) were included in this analysis.
There was no significant difference in HOMA-IR (treatment effect of arm D compared with arm A for the
longitudinal log-HOMA-IR was –0.083, 95% CI –0.247 to 0.082; p = 0.3) and QUICKI (0.001, 95% CI
–0.001 to 0.003; p = 0.3426) between the treatment and control arms over a period of 48 weeks.
However, the treatment effect of arm D compared with arm A for the longitudinal revised QUICKI was
marginally significant (0.004, 95% CI 0.000 to 0.008; p = 0.05), suggesting that telmisartan (80 mg)
led to a small reduction in insulin resistance over a period of 48 weeks. The complete set of estimated
parameters from the model is given in Appendix 6.
Longitudinal analysis of lipid profiles (high-density lipoprotein cholesterol, total
cholesterol, triglycerides and low-density lipoprotein cholesterol)
The bivariate joint models included 328 patients and 845 individual measurements on average for the lipid
profiles; HDL-C and triglycerides were fitted in log-transformed scale for normality. There was no significant
difference between the treatment arm and the control arm with any of the lipid markers over a period of
48 weeks. The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal profiles
of HDL-C, total cholesterol, triglycerides and LDL-C was 0.001 (95% CI –0.046 to 0.047: p = 1.0), 0.013
(95% CI –0.173 to 0.199; p = 0.9), 0.030 (95% CI –0.056 to 0.116; p = 0.5) and 0.000 (95% CI –0.145
to 0.144; p = 1.0), respectively. The longitudinal profiles and complete set of parameter estimates are given
in Appendix 6.
Longitudinal analysis of plasma biomarkers
The longitudinal profiles of plasma biomarkers (adiponectin, leptin, IL-8, TNF-α, resistin and hs-CRP) at
weeks 12, 24 and 48 were analysed using a bivariate joint model. The joint models included 326 patients
and 840 individual measurements on average for each of the above plasma biomarkers and all were fitted
in log-transformed scale for normality.
None of the plasma biomarkers apart from hs-CRP showed a significant change over time between the
control and the telmisartan (80-mg) treatment arm. The estimated treatment effect on the longitudinal
profiles of adiponectin, leptin, IL-8, TNF-α and resistin was 0.035 (95% CI –0.078 to 0.148; p = 0.5), 0.004
(95% CI –0.179 to 0.187; p = 1.0), 0.041 (95% CI –0.111 to 0.193; p = 0.6), –0.025 (95% CI –0.133 to
0.082; p = 0.6) and –0.066 (95% CI –0.171 to 0.039; p = 0.2), respectively. However, hs-CRP showed a
significant change over time (treatment effect of –0.222, 95% CI –0.433 to –0.011; p = 0.04), with patients
in the treatment arm showing significantly lower plasma hs-CRP levels over 48 weeks than those in the
control arm. The longitudinal profiles and complete set of parameter estimates are given in Appendix 6.
An interaction between treatment and time was not considered as both treatment and time effects were
not found to be significant in any outcome. In cases where only time effect was significant, a trend was
revealed (i.e. the longitudinal outcome was changing over time) despite a significant treatment effect.
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Substudy 1: magnetic resonance imaging
We assessed the effect of telmisartan (80 mg) on internal visceral fat and intrahepatic and intramyocellular
(soleus and tibialis anterior) lipid content over a period of 24 weeks using MRI and 1H-MRS. The summary
statistics for these are presented in Table 48 (see Appendix 6) and Figure 9. Other related outcome
measures such as external abdominal fat, total internal fat, total external fat and total body fat were also
assessed and the summary statistics are given in Table 49 (see Appendix 6).
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FIGURE 9 Box plots for the MRI and 1H-MRS measurements at baseline and 24 weeks by treatment arm (with
individual data points). (a) Internal visceral fat; (b) intramyocellular triglyceride (soleus); (c) intrahepatic triglyceride;
and (d) intramyocellular triglyceride (tibialis anterior). In all figures, A refers to the control arm; B, C and D refer to
arms treated with 20, 40 and 80mg of telmisartan, respectively; 0 refers to baseline and 24 refers to 24 weeks.
(continued )
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All models were adjusted for the baseline value of the outcome and for weight change between baseline
and 24 weeks. No statistically significant differences were observed in internal visceral fat at 24 weeks
between the treatment arm (80 mg) and the control arm (p = 0.9).
A statistically significant difference in the intrahepatic triglyceride content was observed at 24 weeks between
arm D and arm A (the control group) (mean reduction 1.74, 95% CI –2.787 to –0.642; p = 0.005). Although
the model was adjusted for differences in baseline, these results should be interpreted with caution given
the large within-group variability and low sample size (as reflected by the wide 95% CIs). No statistically
significant differences were observed in intramyocellular triglyceride content in the soleus and tibialis anterior
at 24 weeks between the treatment (80 mg) and control groups (p = 0.8). The complete set of parameter
estimates are shown in Appendix 6.
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FIGURE 9 Box plots for the MRI and 1H-MRS measurements at baseline and 24 weeks by treatment arm (with
individual data points). (a) Internal visceral fat; (b) intramyocellular triglyceride (soleus); (c) intrahepatic triglyceride;
and (d) intramyocellular triglyceride (tibialis anterior). In all figures, A refers to the control arm; B, C and D refer to
arms treated with 20, 40 and 80mg of telmisartan, respectively; 0 refers to baseline and 24 refers to 24 weeks.
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Substudy 2: urine/renal biomarkers
The longitudinal profiles of biomarkers NGAL and ACR were considered in subgroups defined by tertiles
(for NGAL) and thresholds (for ACR) at baseline. For analysis of ACR, the sample set was divided into three
subsets based on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic
kidney disease65 (ACR < 3 mg/mmol, normal; ACR 3–30 mg/mmol, microalbuminuria; ACR > 30 mg/mmol,
macroalbuminuria). Given the lower number of dropout in each subgroup (< 20), linear mixed-effect
models were used rather than joint models to analyse the longitudinal variations. The models were
adjusted for ethnicity, age and sex.
The three tertile subgroups for NGAL included 106, 106 and 105 patients, respectively, and NGAL scores
were fitted in log-transformed scale for normality. The changes in weight from baseline were not significant
and the final models were adjusted for age and sex, and information from dropped arms. The estimated
treatment effects [arm D (80 mg) compared with arm A (control)] on NGAL were not significant in any of
the tertile subgroups: –0.215 (95% CI –0.627 to 0.196; p = 0.3), –0.065 (95% CI –0.512 to 0.382; p = 0.8)
and –0.347 (95% CI –0.893 to 0.198); p = 0.3).
The subgroup of ACR < 3 mg/mmol included 70 patients; 21 were included in the subgroup of ACR
3–30 mg/mmol and just one patient had an ACR of > 30 mg/mmol. Therefore, subgroups of ACR
3–30 mg/mmol and ACR > 30 mg/mmol were combined. ACR scores were fitted in log-transformed scale
for normality. The changes in weight from baseline or sex were not significant, and the final models for
the subgroups ACR < 3 mg/mmol and ACR > 3 mg/mmol were adjusted for age and information from
dropped arms. The treatment effect on the longitudinal ACR for the subgroup with an ACR of > 3mg/mmol
was –0.665 (95% CI –1.310 to –0.019; p= 0.04), suggesting a significant but marginal treatment effect in
arm D compared with the control arm.
There was no evidence of significant correlations between NGAL and ACR at baseline or at any other
follow-up time points (p < 0.05). The longitudinal profiles, complete set of parameter estimates and
scatterplots of ACR versus NGAL are shown in Appendix 6.
Safety data analysis
Each AR was categorised using the Medical Dictionary for Regulatory Activities (MedDRA)’s coding system
organ class (SOC) terms (version 19.0) by the chief investigator. The number of ARs and number and
percentage of patients affected in each category by treatment arm are presented in Table 9. Diarrhoea,
fatigue, dizziness and pruritus were the most common ARs, observed in > 2% of patients. The number of
occurrences of diarrhoea and dizziness was proportionately higher in the higher-dose arms. The number of
ARs and number and percentage of patients affected in each category by treatment arm and by severity
are shown in Table 58 (see Appendix 6).
Serious adverse events
From a total of 377 patients, 21 SAEs were reported from 19 (5.0%) patients: five patients (4.8% of
the allocated 105 patients; six events) in arm A (control), three patients (3.6%; three events) in arm B
(20 mg), four patients (4.9%; four events) in arm C (40 mg) and seven patients (6.6%; eight events) in
arm D (80 mg). No SUSARs were reported (see Table 59 in Appendix 5 for full details). We compared the
percentage of patients who had one or more SAEs between telmisartan-treated arms and the control
arm using the Fisher’s exact test. There was no evidence of difference in percentage of SAEs between
telmisartan-treated arms and the control arms (p = 0.8).
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TABLE 9 Adverse reactions (by SOC and preferred terms according to the Medical Dictionary for Regulatory Activities)
Category of events
(SOC term) AR description (PT)
Treatment arm
Total randomised (N= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Blood and lymphatic
system disorders
Neutropenia 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Cardiac disorders Palpitations 0 0 0.0 0 0 0.0 3 3 2.8 3 3 0.8
Congenital, familial
and genetic disorders
Double ureter 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Ear and labyrinth
disorders
Ear pain 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Eye disorders Dry eye 0 0 0.0 0 0 0.0 2 1 0.9 2 1 0.3
Lacrimation increased 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Vision blurred 1 1 1.2 1 1 1.2 2 2 1.9 4 4 1.1
Visual impairment 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Gastrointestinal
disorders
Abdominal distension 0 0 0.0 3 3 3.7 1 1 0.9 4 4 1.1
Abdominal pain
(upper)
0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Constipation 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Diarrhoea 1 1 1.2 3 2 2.4 6 6 5.7 10 9 2.4
Dry mouth 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Dyspepsia 2 2 2.4 1 1 1.2 1 1 0.9 4 4 1.1
Faeces (soft) 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Mouth ulceration 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Nausea 1 1 1.2 3 2 2.4 2 1 0.9 6 4 1.1
Tongue coated 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Vomiting 0 0 0.0 2 2 2.4 1 1 0.9 3 3 0.8
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TABLE 9 Adverse reactions (by SOC and preferred terms according to the Medical Dictionary for Regulatory Activities) (continued )
Category of events
(SOC term) AR description (PT)
Treatment arm
Total randomised (N= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
General disorders
and administration
site conditions
Asthenia 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Chest pain 0 0 0.0 1 1 1.2 1 1 0.9 2 2 0.5
Fatigue 5 4 4.8 4 4 4.9 6 6 5.7 15 14 3.7
Feeling cold 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Feeling hot 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Influenza-like illness 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Malaise 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Pyrexia 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Infections and
infestations
Acute sinusitis 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Campylobacter
gastroenteritis
0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Influenza 2 2 2.4 1 1 1.2 4 4 3.8 7 7 1.9
Lower respiratory
tract infection
0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Nasopharyngitis 0 0 0.0 1 1 1.2 2 2 1.9 3 3 0.8
Onychomycosis 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Rhinitis 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Sinusitis 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Upper respiratory
tract infection
1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Urinary tract infection 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Injury, poisoning
and procedural
complications
Fall 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Investigations Hepatic enzyme
increased
0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Weight increased 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
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Category of events
(SOC term) AR description (PT)
Treatment arm
Total randomised (N= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Metabolism and
nutrition disorders
Increased appetite 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Musculoskeletal and
connective tissue
disorders
Arthralgia 1 1 1.2 1 1 1.2 0 0 0.0 2 2 0.5
Back pain 2 2 2.4 0 0 0.0 1 1 0.9 3 3 0.8
Myalgia 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Neck pain 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Osteopenia 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Pain in jaw 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Nervous system
disorders
Ageusia 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Amnesia 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Burning sensation 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Disturbance in
attention
0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Dizziness 6 6 7.1 7 6 7.3 17 16 15.1 30 28 7.4
Dysgeusia 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Headache 6 6 7.1 7 7 8.5 11 9 8.5 24 22 5.8
Loss of consciousness 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Paraesthesia 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Somnolence 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Syncope 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Tension headache 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Tremor 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Trigeminal neuralgia 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
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TABLE 9 Adverse reactions (by SOC and preferred terms according to the Medical Dictionary for Regulatory Activities) (continued )
Category of events
(SOC term) AR description (PT)
Treatment arm
Total randomised (N= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Psychiatric disorders Anxiety 0 0 0.0 3 3 3.7 1 1 0.9 4 4 1.1
Confusional state 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Depressed mood 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Depression 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Insomnia 1 1 1.2 0 0 0.0 3 3 2.8 4 4 1.1
Morbid thoughts 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Renal and urinary
disorders
Chromaturia 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Haematuria 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Renal impairment 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Reproductive system
and breast disorders
Ejaculation failure 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Respiratory, thoracic
and mediastinal
disorders
Cough 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Epistaxis 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Oropharyngeal pain 0 0 0.0 1 1 1.2 1 1 0.9 2 2 0.5
Pulmonary fibrosis 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Sinus congestion 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Skin and
subcutaneous tissue
disorders
Angioedema 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Dry skin 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Hyperhidrosis 2 2 2.4 1 1 1.2 0 0 0.0 3 3 0.8
Photosensitivity
reaction
0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Pruritus 4 4 4.8 1 1 1.2 3 3 2.8 8 8 2.1
Rash 1 1 1.2 1 1 1.2 4 4 3.8 6 6 1.6
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Category of events
(SOC term) AR description (PT)
Treatment arm
Total randomised (N= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Vascular disorders Haematoma 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Hypertension 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Hypotension 1 1 1.2 2 1 1.2 1 1 0.9 4 3 0.8
Orthostatic
hypotension
0 0 0.0 3 2 2.4 1 1 0.9 4 3 0.8
Total 50 28 33.3 69 28 34.1 104 49 46.2 223 105 27.9
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Compliance with study drug schedule
Any unused drug was collected during the follow-up and study medication compliance was assessed by
counting the number of pills returned and entries made in the treatment diary. Table 57 (see Appendix 6)
presents a descriptive summary of compliance of the total dose consumed according to the treatment diary
and according to the number of pills returned at each visit (at weeks 2, 4, 12 and 24) split by treatment
arm. The baseline characteristics of those who provided compliance information were compared with
the characteristics of patients who did not provide compliance information (see Table 61 in Appendix 6).
There were no clinically important differences observed in the systolic or diastolic blood pressure, CD4 cell
count and eGFR between those with compliance data and those without. However, on average, HIV viral
load was higher in those who provided compliance data than in those who did not (see Table 61 in
Appendix 6). Analysis according to compliance (dose received) was carried out as a sensitivity analysis using
IV regression (with randomisation as the instrument). We also carried out two additional exploratory
compliance-adjusted analyses for HOMA-IR at 24 weeks to address the selection bias, given the above
observation on HIV viral load. The results remained the same as the original sensitivity analysis (see Appendix 6,
Tables 28–30).
RESULTS
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Chapter 5 Discussion
A number of small clinical studies in the non-HIV-infected population31,68–71 and meta-analyses oftelmisartan’s effect on insulin resistance39 and other markers of glycaemic control41 have suggested that
telmisartan has a beneficial effect on glucose and lipid homeostasis. This study51 and others52 have shown
that telmisartan results in partial reversal of metabolic toxicity induced by antiretrovirals in vitro, suggesting
a potential beneficial effect of telmisartan in individuals infected with HIV, in whom cART-induced
cardiometabolic toxicity is a concern. Based on these observations, in order to determine whether or not
telmisartan has clinical utility, a robust, methodologically sound, adequately powered, randomised clinical
trial was needed in individuals infected with HIV to investigate the effect of telmisartan on various metabolic
parameters. Our in vitro study51 also suggested a need for defining the dose–response of telmisartan; hence,
a clinical trial with a novel adaptive design to investigate the effect of multiple doses of telmisartan was
adopted. This was also considered to be necessary because it should not be assumed that the dose–response
of telmisartan in hypertension (i.e. telmisartan is already licensed for use in the treatment of hypertension)
would be equivalent in a repurposed indication (i.e. reduction of insulin resistance).
To the best of our knowledge, the TAILoR trial is the only RCT to date which has assessed the effect of
telmisartan on insulin resistance in individuals infected with HIV. It is also important to note that this trial
is also the largest RCT to investigate the effect of telmisartan on insulin resistance and other metabolic
parameters in any clinical setting (HIV positive or negative).
Main findings
Primary outcome
The primary objective of the trial was to investigate whether or not telmisartan, at any of the doses
tested, resulted in a reduction in HOMA-IR, a validated marker of insulin resistance, in individuals infected
with HIV over a period of 24 weeks. Using a novel adaptive design, the trial was divided into two stages;
the first was to identify the best dose(s) of telmisartan (20, 40 or 80 mg) when compared with current
standard of care, and the second stage was to compare one or more doses of telmisartan for a further
24 weeks. The first stage, conducted in 154 patients, identified one dose (80 mg of telmisartan) that met
the prespecified end point and was subsequently tested in the second stage. The final analysis, conducted
in 211 individuals, demonstrated that telmisartan (80 mg) did not result in a statistically significant
reduction in HOMA-IR when compared with the control arm over 24 weeks.
Secondary outcomes
We used QUICKI and revised QUICKI, two alternative indices of insulin resistance, to confirm the effect of
telmisartan on HOMA-IR. Telmisartan did not show a statistically significant increase (QUICKI and revised
QUICKI are log measures and, therefore, are expected to increase if there is any reduction in insulin
resistance) in these indices at 24 weeks in comparison with the control arm.
A longitudinal analysis of the effect of telmisartan on HOMA-IR, QUICKI and revised QUICKI over a period
of 48 weeks, when compared with the control arm, showed that while there was no change in HOMA-IR
and QUICKI, there was a significant, but marginal, improvement in revised QUICKI (p = 0.05). Telmisartan
(80 mg) did not have any effect on serum lipids (cholesterol, triglycerides, HDL-C and LDL-C) and adipokines
(markers of homeostasis and inflammation: adiponectin, leptin, resistin, IL-8, TNF-α), but there was a
significant decrease in hs-CRP over 48 weeks.
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Two different substudies were conducted as part of this trial:
l Substudy 1 was an exploratory evaluation of the effect of telmisartan on total body, liver (intrahepatic)
and limb (intramyocellular) fat distribution using MRI and 1H-MRS. Telmisartan did not show any
significant reduction in total body fat or limb fat, but significantly reduced liver fat over a period of
24 weeks.
l Substudy 2 investigated the effect of telmisartan on renal parameters. Telmisartan (80 mg) showed a
significant decrease in ACR (p = 0.04) over a period of 48 weeks in patients with microalbuminuria
(ACR > 3 mg/mmol), but did not affect urinary NGAL, a marker of kidney disease.
There were no safety concerns with any of the doses of telmisartan and, although 21 SAEs were reported
throughout the study, these were similar between the treatment arms and the non-intervention arm,
and there was no dose-dependent increase in AEs. Of course, telmisartan has been used in a significant
number of patients with hypertension, and it was not expected that this study would find any new,
previously unreported, AEs. However, the finding of no decrease in blood pressure, even in patients
without hypertension, was reassuring.
Interpretation and comparison with other studies
Telmisartan does not result in the reduction of Homeostatic Model Assessment of
Insulin Resistance
Most of the evidence for telmisartan’s beneficial effect on insulin resistance and other glycaemic markers
has so far come from non-HIV clinical studies.35,38 Since the inception of this trial, three studies have
reported in patients infected with HIV:
l two observational studies showed a reduction in insulin resistance with telmisartan48,72 with smaller
sample sizes (18 and 13 participants)
l a single-arm open-label trial conducted in 35 individuals infected with HIV (the MATH trial73) that failed
to find a significant change in HOMA-IR over 24 weeks.
Telmisartan has two main modes of action: it acts as an angiotensin II receptor antagonist and is a partial
agonist at the adipocyte nuclear receptor PPAR-γ. Its effects have been attributed to the activation of
PPAR-γ,74 but its anti-angiotensin effects may also play a role.52
Human immunodeficiency virus causes disruption in glucose metabolism; in particular, the HIV viral protein
inhibits PPAR-γ.75 Adipose tissue, a major mediator of insulin sensitivity in the body, acts as a reservoir for
HIV.76 HIV infection causes inflammation that can lead to dysregulation of insulin signalling. HIV replication
also causes upregulation of fatty acid synthase, an enzyme responsible for fatty acid synthesis;77 this increases
the production of fatty acids, which could result in lipotoxicity and insulin resistance. In addition to the
effect of HIV, cART is known to be toxic to adipose tissue, with cART-induced inhibition of PPAR-γ well
documented.52,78,79 Therefore, both HIV and cART, independently, have a direct effect on PPAR-γ. Therefore,
our decision to trial telmisartan to reduce insulin resistance had a biological basis. The reason that we did
not any reduction in HOMA-IR find may have been either because (1) telmisartan was not potent enough to
compete with the adverse effects of HIV and cART on adipocytes and/or (2) the cause of the rise in insulin
resistance in HIV is dependent on many other pathways, and blocking one is not adequate enough to lead
to an improvement.
In the non-HIV setting, there have only been a handful of RCTs to assess the effect of telmisartan on insulin
resistance as a primary outcome measure. Two of the largest RCTs compared telmisartan with other ARBs
but in the presence of either rosiglitazone35 or rosuvastatin,38 two drugs with independent effects on glucose
and lipid homeostasis. Derosa et al.’s study35 in 188 T2DM patients with MS who were on rosiglitazone
demonstrated that telmisartan (40 mg) significantly reduced HOMA-IR by 17% at 24 weeks and by 29% at
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48 weeks. Rizos et al.’s comparison38 of telmisartan (80 mg) with olmesartan and irbesartan (n = 151) in
hypertensive individuals with impaired glucose function demonstrated that telmisartan reduced HOMA-IR by
29% (whereas the other ARBs resulted in an increase in HOMA-IR). It is important to note that the patients
studied in these trials were highly insulin resistant at baseline (median baseline HOMA-IR was 7.2 in the
telmisartan arm in Derosa et al.;35 and 2.6 in the telmisartan arm in Rizos et al.38). By contrast, in the present
trial, the median baseline HOMA-IR was 1.6 in arm D. Therefore, detecting a reduction in HOMA-IR even
further with telmisartan would be improbable without a much larger trial. It is also important to note that
patients infected with HIV are treated with different cART combinations, each with a differing propensity to
cause insulin resistance; this heterogeneity may have masked any positive effect, given the small numbers
of patients in each drug combination group. Recruitment restricted to patients with higher HOMA-IRs may
have been beneficial, but the feasibility of recruiting to such a trial would have been difficult.
Finally, it is important to highlight that 80 mg of telmisartan did have a positive impact on HOMA-IR. Even
though patients in both the treatment and the control arms showed an increase in HOMA-IR between
baseline and 24 weeks, the increase was of lesser magnitude in the treatment arm (+0.18; 7% increase)
when compared with the control arm (+0.5; 20% increase). This was also observed at 48 weeks: HOMA-IR
increased less with telmisartan (+0.74; 29% increase) than in the control arm (+1.2; 49% increase). It is
not clear from the literature whether or not the effects of telmisartan increase with duration of treatment;
we chose a 24-week time period based on observations in the non-HIV literature. A longer duration of
treatment may have been more ideal but previous studies have shown that HOMA-IR changes within
4 weeks of starting antiretrovirals.22
Telmisartan showed a marginal beneficial effect on revised QUICKI (p = 0.05) in a longitudinal analysis over
48 weeks. Although HOMA-IR has been most commonly used as an index of insulin resistance under fasting
conditions, a meta-analysis of surrogate measures of insulin resistance/sensitivity under fasting conditions
identified revised QUICKI as the index that has the strongest correlation (r = 0.68) with the gold standard,
the hyperinsulinaemic–euglycaemic clamp.80 Revised QUICKI takes into account fasting serum NEFA levels,
in addition to plasma glucose and serum insulin, which has been suggested to improve its correlation with
the clamp-based index of insulin sensitivity and its discriminatory power, particularly in non-obese individuals
who present with mild insulin resistance.81 Given that the TAILoR cohort had a median baseline BMI of
26.7 kg/m2 (marginally overweight as per NICE Clinical Guidelines82), revised QUICKI may be a more a
sensitive indicator of the effect of telmisartan than HOMA-IR.
Telmisartan significantly reduced liver fat, but not total body or limb fat
A limited meta-analysis of three RCTs83 with telmisartan treatment duration of 16–24 weeks (combined
sample size of 62 participants) showed that telmisartan caused a significant reduction in visceral, but not in
subcutaneous, fat suggesting a beneficial effect on body fat. However, the current study did not observe
any significant reduction in internal visceral fat with any of the telmisartan doses over a period of 24 weeks.
This is in line with the findings from the only other study that assessed the effect of telmisartan in patients
infected with HIV on cART.73 It is possible a longer timeframe may be required to reduce visceral fat in
patients infected with HIV.
Our trial did find a significant reduction in liver, but not limb, fat in the 80 mg of telmisartan arm over a
period of 24 weeks. This is the first time a positive effect on liver fat has been reported with telmisartan
in patients infected with HIV, but given the small numbers (n = 10 in each of the three treatment arms;
n = 13 in the non-intervention arm), the findings have to be interpreted with caution. Indeed, intrahepatic
fat has been suggested to be a better marker of metabolic disease than visceral fat,84 and may provide a
better estimate of ectopic fatty acid deposition, which is one of the main reasons for the development
of insulin resistance. However, our finding contrasts with a previous randomised trial85 in obese adult
individuals using 160 mg of telmisartan that did not find any changes in total, liver or limb fat.
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Telmisartan did not change any of the plasma markers except high-sensitivity
C-reactive protein
Telmisartan treatment did not improve lipids (total cholesterol, triglycerides, HDL and LDL-C) or plasma
adipokines (adiponectin, leptin, resistin, IL-8 and TNFα) over a period of 48 weeks. This is in line with results
from the MATH trial,73 which also did not find any change in lipids or adipokines with the exception of a
marginal increase in TNFα. However, meta-analyses of non-HIV clinical studies have shown that telmisartan
results in a reduction in lipids42 and adiponectin.41 The effect of telmisartan on leptin, resistin, IL-8 and TNFα
in patients not infected with HIV, however, has been contradictory and may be primarily because of small
scale studies with limited generalisability.35,86,87 The lack of effect of telmisartan on lipids in our trial may be
because of the more complex clinical picture in patients infected with HIV (interaction with HIV and cART,
duration of treatment) and because 58 (15.4%) of our patients were already on statins.
Many non-HIV clinical studies,38,88 and a meta-analysis43 (n = 2632 patients), have shown that telmisartan
reduces hs-CRP levels. We observed a similar effect of telmisartan on hs-CRP over a period of 48 weeks
in this trial. C-reactive protein promotes the proatherogenic activity of angiotensin, directly and indirectly
stimulates structural and functional modification of arterial walls, heart and vascular remodelling and is
considered to be an inflammatory marker.89 In patients infected with HIV, hs-CRP may be an independent
predictor of CVD;90 the anti-inflammatory effect of telmisartan, through its direct blockade of angiotensin
action, may be responsible for the reduction in hs-CRP in patients infected with HIV, and may thus have
the potential to reduce the associated CVD risk.
Telmisartan and effect on microalbuminuria
There is already some preliminary evidence of the renoprotective effect of telmisartan in patients infected
with HIV; Ucciferri et al.48 showed that telmisartan reduced microalbuminuria in patients infected with HIV.
A meta-analysis of 20 RCTs, including > 12,000 patients not infected with HIV on telmisartan, by Takagi et al.47
also showed that telmisartan results in a significant reduction in urinary ACR. Our study was not designed to
investigate renal outcomes, but telmisartan (80 mg) did result in a significant reduction (p= 0.04) in ACR
over 48 weeks in patients with microalbuminuria (defined by an ACR of > 3 mg/mmol) when compared with
the current standard of care. However, it should be noted that this effect was observed in a small sample
size of only 22 participants who had microalbuminuria and, therefore, the results should be interpreted with
caution. Telmisartan did not have an effect on NGAL, another marker of renal health. It may also be important
to note that NGAL did not show any correlation with urinary ACR. ACR is a marker of glomerular injury,
whereas NGAL is a marker of tubular damage.
Strength and weaknesses
Design of the study
The study used a novel adaptive design in order to investigate the optimal dose of telmisartan, with the
potential to cause a reduction in HOMA-IR. Adaptive designs are allowed to incorporate a prospectively
planned opportunity for modification of one or more specified aspects of the study design and hypotheses
based on analysis of the interim data.91 Adaptive trial designs are innovative designs recommended by both
the US Food and Drug Administration92 and the European Medicines Agency93 for clinical R&D because
they offer flexibility in identifying the optimal clinical benefit of the test treatment under study without
undermining the validity and integrity of the study. In the current study, the adaptive design allowed for
testing three different doses of telmisartan simultaneously and dropping two different ‘loser doses’ so that
a potential ‘winner dose’ could be taken into the second stage of the study. Such a design also took into
account the fact that the dose–response profile of telmisartan, when used, as in our study, to reduce insulin
resistance, may differ from its dose–response profile when used for its licensed indication, which is to reduce
hypertension. This design also provided an opportunity to stop the study at the interim analysis stage if the
required benefit was not identified with any of the doses.
Given that no further data were collected on dose arms dropped at interim analysis, a potential weakness is
our incomplete understanding of the effect of these dose arms.
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Recruitment and retention
Despite positive results from feasibility assessments, recruitment to the study was slower than expected.
Recruitment was also beset by delays in funding for extra treatment costs, which led to delays in the study
set-up at various sites. We overcame these limitations, as described, but this nevertheless had an impact
on the start of recruitment at different sites. The trial was supported by the Comprehensive Local Research
Networks, which helped promote the trial nationally; this had a positive impact on recruitment.
Outcome measures and effect size
We used HOMA-IR as our primary outcome measure, which is the most commonly used measure of
insulin resistance. In addition, several other markers of insulin resistance/sensitivity were used as secondary
outcome measures. Ideally, an insulin clamp should have been used as the primary outcome measure, but
the invasiveness and complexity of undertaking this in a large-scale trial ruled it out. Although there was
no significant effect on HOMA-IR longitudinally over 48 weeks, there was a significant increase in revised
QUICKI, which is biologically plausible, and perhaps is indicative of its greater sensitivity than HOMA-IR in
evaluating changes in insulin action. Using QUICKI as a primary outcome measure may therefore have
been preferable. A 24-week time point was selected for the primary outcome and 48 weeks for the total
duration of drug treatment based on data on patients not infected with HIV. Whether or not a longer
duration of treatment may show an effect is debatable. Furthermore, our patient group had relatively
modest elevations in HOMA-IR and, it is possible, on the basis of data from patients not infected with HIV,
that its effects may have been greater if the patients had been stratified to higher HOMA-IR elevations.
The likely effect of HIV and cART on insulin resistance is likely to be complex and rely on multiple
pathways; thus, blocking one pathway to overcome this may have been over simplistic.
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Chapter 6 Conclusions and recommendations
In conclusion, this trial used a novel adaptive design to assess the effect of different doses of telmisartanon insulin resistance in patients infected with HIV on cART. There was no significant effect of telmisartan
on our primary outcome measure, which was a reduction in HOMA-IR after 24 weeks’ treatment, although
we found a smaller elevation in HOMA-IR in patients on telmisartan than in the control arm. Interestingly,
a longitudinal analysis over 48 weeks showed telmisartan increased revised QUICKI, a sensitive surrogate
marker of insulin sensitivity, indicating that it may have potential beneficial metabolic effects in this
population. This is also consistent with the positive effects of telmisartan on hs-CRP and hepatic fat
accumulation. Consistent with the vast body of literature, telmisartan also reduced ACR, even though we
had only a small number of patients who were albuminuric at baseline. It is, however, important to note
that many of the positive effects of telmisartan we identified in this trial were marginally significant and thus
could be false positives as a result of multiple testing. This has to be balanced against the fact that all the
effects are biologically plausible, and the combination of effects taken together, particularly at 48 weeks,
suggests that telmisartan’s use in patients infected with HIV may have some benefits. However, whether or
not improvement in these surrogate markers, which were secondary outcomes in our trial, would have any
effect on clinical outcomes, including a reduction in cardiovascular events and mortality, is unclear.
Implications for clinical practice
Despite the use of newer agents and newer combinations, insulin resistance, related metabolic disease
manifestations and the increased risk of CVD remain key problems in HIV-infected individuals on cART.
Currently, these metabolic manifestations in patients infected with HIV are treated symptomatically using
various drug classes such as statins (to reduce lipids), antidiabetic drugs such as metformin or glitazones
(to lower glucose) and the growth hormone-releasing factor analogue tesamorelin.94 Telmisartan is not used
in current clinical practice for the prevention or treatment of metabolic disease, despite the accumulating
evidence in the non-HIV setting. This trial does show some positive findings, such as telmisartan’s effect on
revised QUICKI (a surrogate for insulin sensitivity), hs-CRP (a marker of CVD) and intrahepatic fat (a marker
of metabolic disease). Based on the results of the trial, telmisartan did not affect our primary outcome
measure, reduction in insulin resistance, in HIV-infected individuals.
Recommendations for future research
l All the markers used in this trial, although clinically acceptable, are relatively crude. It is important to
undertake detailed analysis in this patient group, for example of the lipidome, to understand in more detail
the derangements that occur in adipocyte function with HIV infection and cART, and to understand more
about the biology of this adipocyte dysfunction and whether or not drugs may be able to improve this.
l The detrimental effect of HIV infection and cART may be complex and dependent on multiple pathways.
Given that less toxic cART is now available, and widely used, any future studies should be adequately
powered to evaluate improvements in milder degrees of insulin resistance and should consider the use of
multiple drugs, affecting different biological pathways. The duration of the study should be dependent
on the drug(s) studied and outcome measures, and should be determined carefully during study design.
l Although the trial did not show any effect in our primary outcome measure over 24 weeks, there were
improvements in some secondary outcome measures (revised QUICKI, hs-CRP and urinary albumin
excretion over 48 weeks and hepatic fat accumulation over 24 weeks), all of which are biologically plausible
and consistent with the literature. Whether or not telmisartan use would therefore lead to improvement in
clinical outcomes is unclear. This remains an area of unmet medical need, not only in the HIV population,
but also in the general population given the increasing prevalence of obesity and insulin resistance. Any
future novel interventions, which may be individual therapies of novel targets or combination therapies
(with or without telmisartan), should be powered on clinical outcome measures, with validation of some of
the surrogate end points that have been used in this trial as well as novel biomarkers.
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Appendix 1 Trial sites and principal investigators
TABLE 10 List of participating centres, PIs and initiation dates
Trial site PI Date opened
Brighton and Sussex Hospital Dr Duncan Churchill 23 September 2013
Coventry and Warwickshire Dr Satyajit Das 20 September 2013
George Eliot Hospital Dr David Loay 26 January 2015
Guy’s and St Thomas’ Dr Barry Peters 14 June 2013
Harrogate District Hospital Dr Fabiola Martin 10 June 2014
James Cook University Hospital Dr David Chadwick 29 October 2013
King’s College Dr Frank Post 4 June 2013
Manchester Royal Infirmary Dr Gabriel Schembri 30 May 2014
New Croft Clinic (Royal Victoria Infirmary) Dr Mayur Chauhan 15 April 2015
North Middlesex Hospital Dr Jonathan Ainsworth 24 March 2014
Royal Bournemouth and Christchurch Hospitals Dr Elbushra Herieka 2 May 2013
Royal Free, London Professor Margaret Johnson 26 July 2013
Royal Liverpool Hospital Professor Saye Khoo 21 February 2013
Southmead Hospital Dr Mark Gompels 14 January 2015
St Helens Hospital Dr Mas Chapomda 18 November 2014
St James’s University Hospital Dr Jane Minton 19 September 2013
St Stephen’s Trust at Chelsea and Westminster Dr Graeme Moyle 6 June 2014
Western General Hospital Professor Clifford Leen 19 September 2013
YorClinic Dr Fabiola Martin 4 December 2013
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Appendix 2 List of approved brands of
telmisartan
TABLE 11 Approved brands of telmisartan for use in the TAILoR trial
Brand/manufacturer Date approved by TMG Date approved for use in trial
Actavis 17 February 2014 4 April 2014 (needed MHRA approval to use generics)
Teva 17 February 2014 4 April 2014 (needed MHRA approval to use generics)
Pritor 20 February 2014 4 April 2014 (needed MHRA approval to use generics)
Tolura 7 May 2014 7 May 2014
Glenmark 22 June 2014 22 June 2014
Mylan 10 November 2014 7 May 2014
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Appendix 3 Sample analysis plan
Sample shipment and storage
1. The TAILoR trial will use a specialist clinical trial courier for shipping of samples at a cost of £80 per
shipment. A definitive timetable for shipment of samples is not provided here; the aim is to have
regular shipments of samples from all sites so that:
i. The shipment fits in with the analysis timelines presented in the progress reports and all outcome
measures are analysed in time for statistical analysis.
ii. There is always a readily available set of samples for transfer to the LCL for analysis.
iii. Wherever possible, a full courier load is available so that the shipment is cost-effective.
iv. All samples are shipped as soon as any site finishes the last follow-up of the last patient.
2. Shipments will also depend on individual site’s storage capacity.
3. The Trial Co-ordinator, in liaison with sites and the TAILoR team in the Wolfson Centre, will arrange
shipment of samples to Liverpool.
4. All samples will be stored in the –40 °C and –20 °C freezers in the BAF in the Royal Liverpool Hospital.
5. Both BAF and TAILoR SOPs will be followed to verify the samples on receipt at the BAF and appropriate
records for sample receipt and transfer will be retained by all parties concerned (BAF, Wolfson Centre
and CTRC).
Standard operating procedures and log sheets relevant to shipping and storage:
l SOP1 _ TAILoR Sample Processing and Storage. Version 1.0; dated 12 February 2013.
l SOP2 _ TAILoR Sample Processing and Storage for Samples Processed Offsite. Version 1.0; dated
11 July 2013.
l SOP3 _ TAILoR SOP _ Packaging and Shipment of Samples. Version 4.0; dated 24 March 2014.
l TAILoR SOP _ Sample Reception. Version 3.0; dated 25 March 2014.
l TAILoR Sample Transfer Log Sheet (BAF to Aintree Labs). Version 3.0; dated 10 April 2014.
l TAILoR Sample Transfer Log Sheet (BAF to LCL and back). Version 1.0; dated 15 January 2015.
l TAILoR Sample Transfer Log Sheet (BAF to WCPM). Version 1.0; dated 10 April 2014.
Laboratory analysis: primary outcome measure (Homeostatic Model
Assessment of Insulin Resistance)
l The primary outcome measure, HOMA-IR, is calculated using plasma glucose and serum insulin levels;
both of these will be analysed in the LCL, Royal Liverpool Hospital.
l Plasma glucose and serum insulin will be measured using standard clinical chemistry kits and analysers.
l All samples will be analysed in duplicates.
l Plasma and serum aliquots will be routinely batched and transferred to LCL. All samples will be
analysed for plasma glucose, serum insulin, serum lipid profile and hs-CRP simultaneously.
l Results will be uploaded by LCL in batches directly on to the designated folder in the VOCAL (UoL)
for further analyses.
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Laboratory analysis: secondary outcome measures
1. Lipid profile (high-density lipoprotein cholesterol, total cholesterol, triglycerides and low-density
lipoprotein cholesterol).
l High-density lipoprotein cholesterol, total cholesterol, triglycerides and LDL-C will be analysed by LCL
using routine clinical chemistry methods.
2. Blood biomarkers (exploratory biomarkers).
l High-sensitivity C-reactive protein: this will be analysed by LCL using routine clinical chemistry methods.
l Adiponectin: this will be performed in the WCPM utilising electrochemiluminescence immunoassays
(Meso Scale Discovery, Rockville, MD, USA) as per the manufacturer’s protocol and analysed on a
Meso Scale Discovery Sector Imager 2400A (Meso Scale Discovery, Rockville, MD, USA).
¢ All samples will be analysed in duplicate.
¢ Appropriate validation of the assay will be conducted and parameters such as accuracy,
precision, linearity, reproducibility, sample recovery after spiking, inter and intra-assay variability
will be measured before undertaking full sample analysis.
l Interleukin 6, TNF-α and resistin: this analysis will be performed in the WCPM, utilising
electrochemiluminescence immunoassays as per the manufacturer’s protocol and analysed on a Meso
Scale Discovery Sector Imager 2400A.
¢ All samples will be analysed in duplicate.
¢ Appropriate validation of the assay will be conducted and parameters such as accuracy,
precision, linearity, reproducibility, sample recovery after spiking, inter and intra-assay variability
will be measured before undertaking full sample analysis.
Following validation, the IL-6 mesoscale assay was found not to meet desired criteria and hence the marker
has been removed from the protocol. An amendment of the protocol to this effect has been submitted.
l Lipin 1: lipin 1 was originally included in the grant application on the assumption that it is secreted
outside the adipose tissue and, therefore, measurable in plasma or serum using an enzyme-linked
immunosorbent assay (ELISA). There is only one ELISA kit available in the market for human lipin 1 and
this has been tested in-house but does not work. The current knowledge specifies that lipin 1 is integral
to the cell and does not get secreted outside the cell. Therefore, the TMG has decided to replace lipin 1
with an alternative marker, leptin. An amendment of the protocol to this effect has been submitted.
l Leptin: this will be performed in the WCPM utilising electrochemiluminescence immunoassays as per
the manufacturer’s protocol and analysed on a Meso Scale Discovery Sector Imager 2400A.
¢ All samples will be analysed in duplicate.
¢ Appropriate validation of the assay will be conducted and parameters such as accuracy, precision,
linearity, reproducibility, sample recovery after spiking, inter and intra-assay variability will be
measured before undertaking full sample analysis.
l Non-esterified fatty acids: NEFAs are a new marker included following discussion with the IDSMC.
Serum NEFA levels will be analysed using a colorimetric method on Randox RX daytona (Randox
Laboratories Ltd, County Antrim, UK) in the GCLP facility, Royal Liverpool Hospital.
¢ All samples will be analysed in triplicate.
¢ Appropriate validation of the assay will be conducted and parameters such as accuracy, precision,
linearity, reproducibility, sample recovery after spiking, inter- and intra-assay variability will be
measured before undertaking full sample analysis.
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Standard operating procedures relevant to biomarker analyses
l SOP _ Preparation of TAILoR Samples Master Plate. Version 2.0; dated 25 March 2016.
l SOP _ Adiponectin Assay – TAILoR samples. Version 1.0; dated 25 March 2016.
l SOP _ Resisitn Assay – TAILoR Samples. Version 2.0; dated 27 April 2016.
l SOP _ Leptin Assay – TAILoR Samples. Version 2.0; dated 27 April 2016.
l SOP _ Proinflammatory markers Assay – TAILoR Samples. Version 3.0; dated 25 April 2016.
3. Urinary biomarkers:
l Neutrophil gelatinase-associated lipocalin: this will be performed in the WCPM utilising
electrochemiluminescence immunoassays as per the manufacturer’s protocol and analysed on a
Meso Scale Discovery Sector Imager 2400A.
¢ All samples will be analysed in duplicate.
¢ Appropriate validation of the assay will be conducted and parameters such as accuracy,
precision, linearity, reproducibility, sample recovery after spiking, inter and intra-assay variability
will be measured before undertaking full sample analysis.
l Albumin-to-creatinine ratio: this will be carried out in the LCL, Royal Liverpool Hospital.
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Appendix 4 Statistical analysis plans
Interim analysis
Patient groups for analysis
The principle of intention to treat (ITT), as far as is practically possible, will be the main strategy of the
analysis adopted for the primary outcome. The analysis will be conducted on all patients randomised to the
treatment arms.
Patients who withdrew consent for trial continuation will contribute outcome data up until the point of
withdrawal, unless the patient specifically requests that the data not to be used.
The membership of the analysis set will be determined and documented, and reasons for participant
exclusion will be given prior to the randomisation lists being requested. Reasons may include missing data,
loss to follow-up and treatment withdrawal (not excluded for ITT analysis set).
Analysis of primary outcome
The primary analysis will use the principle of ITT based on all the randomised participants, as far as is
practically possible.
Homeostatic model assessment of insulin resistance was calculated by:
HOMA-IR = ½fasting insulin (µU/ml) × fasting glucose (mmol/l)  22:5: (1)
The conversion factor for fasting insulin is 0.144 to convert from pmol/l to µU/ml.
In order to satisfy the primary objective, we will evaluate three different doses against control in the first
stage of the study. We will conduct an interim analysis that will allow ineffective doses to be eliminated
quickly, while a dose showing a positive effect can be taken forward.
At the interim analysis, an analysis of covariance (ANCOVA) model is used by fitting the regression model:
HOMA-IR 24 = HOMA-IR 0 + treatment + stratification factor (black/non-black). (2)
Analysis of covariance is a more efficient approach when dealing with small group numbers and when
there is imbalance in baseline HOMA-IR.
The test statistics are given by the t-values for each active dose treatment.
The largest of these test statistics will be compared with the interim critical value (2.782). The above ANCOVA
model means that the coefficient related to treatment is positive for an increase in HOMA-IR. Therefore, we
look at the negative of the test statistic and use in the decision below. Exceeding this value would correspond
to a significant improvement in HOMA-IR score for the corresponding dose over control and would lead to
this dose being immediately taken forward for further study, and to the trial being stopped.
The analysis will be proceeding as follows:
l If the largest of these statistics exceeds a critical value (equal to 2.782), this would mean that one active
dose group shows a substantially higher mean reduction of 24-week HOMA-IR score than the control
group and, therefore, the study will be stopped and the corresponding dose will be recommended for
further testing.
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l If any active dose show no improvement over control (i.e. has a negative measure of advantage), then
that active dose will be dropped from the second stage*.
l If all three active doses satisfy this criterion, then the study will be stopped and no significant
improvement over control will be claimed for any of the active doses.
l If some improvement over control is detected for at least one of the doses (i.e. if at least one test
statistic is between 0 and 2.782), the study will progress to the second stage and the patients will
be randomised between these dose(s) and control.
The design has been constructed under the assumption that for all patients the response (HOMA-IR score) is
normally distributed with a common standard deviation, σ. These assumptions will be checked at the interim
analysis stage (Levene’s test for checking equal group variances and histogram for checking normality).
If any arm is dropped and the study progresses to the second stage, then the patients in the dropped arm(s)
will stop the medication and will not be involved in second stage of the study.
Analysis of secondary efficacy outcomes
This analysis will not be presented in the interim analysis report.
Analyses of missing data/withdrawals
A summary table of the missing data will be presented, detailing the proportion of missing assessments
overall and for each visit split by each treatment arm.
No sensitivity analyses will be carried out at this interim analysis stage.
The decision to drop treatments at the interim analysis stage will be based only on observed data at
24 weeks. The non-fasting samples data will be excluded from the analysis as they could interfere with
the primary outcome (PI clinical judgement).
Final analysis
Data sets analysed
The principle of ITT, as far as is practically possible, will be the main strategy of the analysis adopted for
the primary outcome. The analysis will be conducted on all patients randomised to the treatment arms,
and for whom the outcome(s) of interest have been observed/measured. No imputations will be made.
The membership of the analysis set will be determined and documented, and reasons for participant
exclusion will be given prior to the randomisation lists being requested. Reasons may include missing data,
loss to follow-up and treatment withdrawal (not excluded for ITT analysis set).
Per-protocol analysis will not be considered.
Demographic and other baseline characteristics
Patients in each arm will be described separately with respect to sex, ethnicity, age, BMI, waist
circumference (cm), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), CD4 cell count
(cells/mm3), HIV viral load (copies/ml), urea (mmol/l), potassium (mmol/l), creatinine (mmol/l), eGFR
(ml/minute/1.73 m2), ALT (IU/l), albumin (g/l) and sodium (mmol/l).
Categorical data will be presented using counts and percentages, and continuous data will be presented
using number of patients, mean, mode, median, SD, minimum, maximum and interquartile range (IQR).
Tests of statistical significance will not be undertaken for baseline characteristics; rather, the clinical
importance of any imbalance will be noted.
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Compliance with treatment
A descriptive summary of compliance will be presented. Total dose consumed according to the treatment
diary is summarised by mean, mode, median, SD, minimum, maximum and IQR and split by site and
by treatment.
Total dose will also be calculated according to the number of pills returned at each visit (week 2, 4, 12 and 24).
Discrepancies between these two estimates of total dose will be summarised by mean, mode, median, SD,
minimum, maximum and IQR and split by site and by treatment.
Analysis of the primary outcome
Derivation
HOMA-IR was calculated by:
HOMA-IR =
fasting insulin (µU /ml) × fasting glucose (mmol/l)
22:5
. (3)
The conversion factor for fasting insulin to convert from pmol/l to µU/ml is 0.144.
Analysis
In order to satisfy the primary objective, we will evaluate all doses remaining after the interim analysis
against control. An ANCOVA model is used by fitting the regression model:
HOMA-IR 24 = HOMA-IR 0 + treatment + stratification factor (black/non-black), (4)
where HOMA-IR _ 0 is the HOMA-IR value at the baseline prior to randomisation and HOMA-IR _ 24 is the
HOMA-IR value at 24 weeks. The treatment variable is categorical with control as the reference level.
The test statistics are given by the t-values for each active dose treatment. The smallest of these test
statistics will be compared with the final critical value (–2.086). A test statistic below the critical value
would correspond to a significant improvement in HOMA-IR score for the corresponding dose over control.
If the smallest of these statistics is below a critical value (equal to –2.086), this would mean that (at least)
one active dose group shows a substantially higher mean reduction of 24-week HOMA-IR score than the
control group.
The design has been constructed under the assumption that for all patients the response (HOMA-IR score)
is normally distributed with a common standard deviation, σ. These assumptions will be checked at the
final analysis (Levene’s test for checking equal group variances and histogram for checking normality).
If HOMA-IR score is not normally distributed, then a log with base e transformation is used.
The primary decision will be based only on observed data at 24 weeks. The non-fasting sample data will
be excluded from the primary analysis as HOMA-IR calculation required the fasting insulin and glucose to
be a valid measurement.
Secondary outcome analyses
Longitudinal markers and outcomes
To identify change in the expression of the markers in telmisartan-treated arms remaining after the interim
analysis in comparison with the control, a joint model of the longitudinal marker will be fitted adjusting for
the dropout from the study. Patients who had a missing marker were considered as ‘dropouts’ and the first
time point (t = 12, 24, or 48) at which the marker is missing will be taken as the time of dropout. Those who
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did not drop out from the study before t = 48 (i.e. had complete record of biomarker) were censored at
48 weeks.
Adjusting for the dropout, a joint model with random intercept and slope will be fitted to fully exploit the
serial nature of the longitudinal marker data. The longitudinal submodel is defined by:
Y (t) = β0 + β1t + β2X +W1(t) + ε(t), (5)
where Y(t) is the marker measurement at time t = 0 (baseline), T + 12 (t = 12), T + 24 (t = 24) and T + 48
(t = 48) weeks, and X includes categorical variables representing the treatment arm and stratification factor
(black/non-black). β0, β1 and β2 = {β21, β22} are regression coefficients related to intercept, slope and the two
covariates. ϵ(t) denotes the measurement error process and assumes Gaussian distribution with mean zero
and variance σ2e. The hazard for dropout is modelled by:
λ(t) = λ0(t)eγW1(t)+β3X , (6)
where λ0(t) is an unspecified baseline hazard and β3 = {β31, β32} and γ are regression coefficients related to
covariates and association between dropout and longitudinal HOMA-IR outcome over time (0 and 48
weeks). We assume W1(t) = U0 + U1t is an unobserved zero-mean Gaussian random process. β21 indicates
the average treatment effect for each treatment arm compared with the control, once adjusted for
potential informative dropout or missingness in the longitudinal marker outcome.
Difference in expected and unexpected serious adverse events
We compare the percentage of patients who had one or more SAEs using a chi-squared or Fisher’s exact
test of independence (if numbers are below five).
Change in Quantitative Insulin Sensitivity Check Index and revised Quantitative Insulin
Sensitivity Check Index after 24 weeks of treatment in comparison with control
The two alternative measures of insulin resistance are calculated as:
QUICKI = 1/(log G + log I), (7)
Revised QUICKI =1/(log G + log I + log NEFA), (8)
where G is fasting glucose (mg/dl), I is fasting insulin (µU/ml) and NEFA is plasma NEFAs concentration
(mmol/l). Fasting glucose is recorded in mmol/l for the primary analysis and the conversion factor for
fasting glucose to convert from mmol/l to mg/dl is 18 (1 mmol/l = 18 mg/dl; Blood Sugar Converter,
www.diabetes.co.uk/blood-sugar-converter.html; accessed 23 February 2016).
The ANCOVA model (see Analysis of the primary outcome) is used to analyse the two alternative measures.
If the measures were not normally distributed, then a log with base e transformation will be used.
Unlike HOMA-IR, the log-insulin and log-glucose values are in the denominator for QUICKI/revised QUICKI.
If there is a reduction in insulin resistance (i.e. increased insulin sensitivity), the above two measures will be
increased at 24 weeks as compared with that at the baseline. Therefore, the largest of the test statistics
from the ANCOVA of each active treatment arm (against the control arm) will be compared with the final
critical value of 2.086. A test statistic above the critical value would correspond to a significant improvement
in the score for the corresponding dose over control.
The fasting insulin and glucose are required to be valid measurements.
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Substudy 1: magnetic resonance imaging/magnetic resonance scanning
Change in visceral, hepatic and muscle fat will be calculated by subtracting the visceral, hepatic and
muscle fat values at baseline visit from those at the 24-week visit.
Summary estimates of location and variability will be reported for all treatment arms. Mean, median, SD,
IQR and maximum and minimum values will be reported at each time point (at baseline and at 24 weeks)
for the MRI measurements of internal visceral fat (dm3), external abdominal fat (dm3), total internal fat
(dm3), total external fat (dm3) and total body fat (dm3) and for the following 1H-MRS measurements:
intrahepatic and intramyocellular triglyceride content in liver, soleus and tibialis anterior (without dimensions,
measured as a percentage).
In addition, three separate multiple linear regression models will be fitted to explore the differences in outcomes
between treatment arms with control as the reference level, while accounting for potential confounders:
1. Model 1: internal visceral fat at 24 weeks will be the outcome variable. A multiple linear regression model
will be fitted. The relative change of total external fat [(value at 24 weeks – value at baseline) ÷ value at
baseline] will be added to the model to account for this potential confounder.
2. Model 2: intrahepatic triglyceride content in liver at 24 weeks will be the outcome variable. A multiple
linear regression model will be fitted.
3. Model 3: intramyocellular triglyceride content in the soleus and tibialis anterior at 24 weeks will be
treated as a bidimensional outcome. A multivariate multiple regression model will be fitted.
The treatment arm (as a factor) and the corresponding baseline values will be added in all models and sex
will be included as covariates. Model assumptions regarding residuals will be assessed and non-parametric
models will be considered, if appropriate. Summary statistics for patients with baseline measurements but
with missing measurement at 24 weeks will be described.
Substudy 2: longitudinal expressions of urinary biomarkers
Change in urinary biomarker levels [creatine, urea, total protein and novel biomarkers such as kidney injury
molecule-1 (KIM-1), NGAL and retinol-binding protein (RBP)] at 12, 24 and 48 weeks between telmisartan-
treated arm(s) and the control arm will be determined by a joint longitudinal biomarker. The dropout
model with random intercept and slope will be fitted to fully exploit the serial nature of the longitudinal
biomarker data.
Sensitivity analyses
A summary table of the missing primary outcome data will be presented detailing the proportion of
missing assessments overall and for each visit split by each treatment arm.
Sensitivity analyses 1: imputing values for missing Homeostatic Model Assessment of
Insulin Resistance at 24 weeks
Missing HOMA-IR at 24 weeks values will be imputed using the MICE algorithm, conditional on HOMA-IR
values at baseline, HOMA-IR values at 12 weeks and stratification factor (black/non-black). This analysis of
missing data will be restricted to the primary outcome only; no imputation methods will be used on any of
the secondary outcomes.
Sensitivity analyses 2: joint modelling for missing Homeostatic Model Assessment of
Insulin Resistance at 24 weeks
The problem of non-ignorable missingness for HOMA-IR at 24 weeks is addressed through joint modelling
of the longitudinal HOMA-IR and the time to dropout from the study. In this analysis, time to dropout is
defined by patients who withdrew from the study or had missing HOMA-IR for any other reason at times
t = 0, 12, or 24. Those who did not drop out from the study before t = 24 and those who had complete
record of HOMA-IR will be censored at 24 weeks.
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Sensitivity analyses 3: compliance-adjusted analysis
A compliance-adjusted primary outcome analysis will be undertaken using IV regression, in order to
estimate the effect of actual dose on outcome. In the event of a discrepancy between the two measures
of total dose for a given patient, the average of these two total doses will be used. When compliance
information is missing for a given patient for some (but not the entire) treatment period, doses will be
imputed for the missing weeks using simple imputation (i.e. based on patient average compliance over the
whole treatment period for which compliance data are available). If compliance data are missing entirely
for a given patient, they will be excluded from any further compliance analyses.
The suitability of randomisation as the sole instrument will be assessed using tests of exogeneity, redundancy
and under/weak identification. The IV regression analysis will be undertaken using data from only those
patients who provided some compliance information. Thus, the baseline characteristics of patients without
any compliance information (in particular, in terms of blood pressure, CD4 cell count, HIV viral load, eGFR)
will be presented and compared with those who provided any compliance information, in order to aid
interpretation (in terms of likely bias and generalisability) of the results of the IV regression.
Safety evaluations
Data sets analysed
The safety analysis dataset will contain all participants that are randomised and commenced treatment.
Presentation of the data
All ARs reported by the clinical investigator will be presented in a table. The number (and percentage)
of patients experiencing each AR (in terms of MedDRA coding of PT and SOC) will be presented for
each treatment arm categorised by severity (mild, moderate, severe). For each patient, only the maximum
severity experienced of each type of AR will be displayed. The number (and percentage) of occurrences of
each AR will also be presented for each treatment arm. No formal statistical testing will be undertaken.
Total number of SAEs/SUSARs will be presented for each treatment arm, along with line listings for each
case, including the following: randomisation number, SAE number, report type (final/initial), description
(PT), description (SOC), SAE number, seriousness, additional description if medically significant, treatment,
severity, expectedness, relationship (PI assessment, chief investigator’s assessment), outcome and patient
status in trial (continuing in trial/withdrawn from treatment).
All safety analyses will have independent quality control checking by an independent statistician.
Deviations from the final statistical analysis plan
Homeostatic Model Assessment of Insulin Resistance, Quantitative Insulin Sensitivity
Check Index and revised Quantitative Insulin Sensitivity Check Index between 24 weeks
and baseline
Analyses were undertaken adjusting for the weight change.
Change in weight (kg) is computed by: weight change =weight at 24 weeks – weight at baseline. Weight
change is fitted as a continuous variable and fitted the ANCOVA model:
HOMA-IR 24 = HOMA-IR 0 + treatment +weight change + stratification factor (black/non-black) (9)
where HOMA-IR _ 0 is the HOMA-IR value at the baseline prior to randomisation and HOMA-IR _ 24 is the
HOMA-IR value at 24 weeks.
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Longitudinal outcomes
Analyses were undertaken adjusting for the weight change. Joint models for longitudinal outcomes also
included data from the dropped arms.
We have used a bivariate joint model to simultaneously include longitudinal measurements of the marker
and longitudinal weight as outcomes adjusting for the dropout. Data from the two dropped arms (B and C)
were also included to further adjust for informative dropout and assumed that these patients completed the
trial as planned. The fitted model takes the following form:
Y 1(t) = β01 + β11t + β21X +W11(t) + ε1(t) (10)
Y 2(t) = β02 + β12t + β22X +W12(t) + ε2(t) (11)
λ(t) = λ0(t)eγ1W11(t)+γ2W12(t)+β3X , (12)
where Y1(t) is the marker measurement and Y2(t) is the weight at time t, where t = 12, 24 or 48 weeks,
and X includes categorical variables representing the treatment arm (A, B, C and D), stratification factor
(black/non-black) and marker or weight value at the baseline. β0, β1 and β2 are regression coefficients
related to intercept, slope and the covariates. ϵ(t) denotes independent measurement error process. λ(t)
models the hazard for dropout, λ0(t) is an unspecified baseline hazard and β3 and γ = {γ1,γ2} are regression
coefficients related to covariates and association parameters. The dependence between the marker and
weight was accounted for by correlated random-effects W11 and W12. We assumed W1(t) = U01 + U11t and
W12(t) = U02 + U12t with {U01, U11, U02, U12} ∼ N4(0,Σ).
The treatment effect coefficient in β21 indicates the average treatment effect for each treatment arm
compared with the control, once adjusted for potential informative dropout, while accounting for the
weight changes over time. Approximate standard errors and 95% CIs were produced. The joineRML
package in R was used for this analysis.
Magnetic resonance imaging/magnetic resonance scanning substudy
Models were fitted adjusted for weight change between baseline and 24 weeks. Change in weight is
added as a covariate in the current model.
Longitudinal expressions of urinary biomarkers
Data were available for NGAL and ACR only.
The longitudinal profiles of the biomarker NGAL were considered in subgroups defined by tertiles at
baseline (tertiles divide an ordered distribution of baseline NGAL into three parts, so each subgroup
contains one-third of the sample).
For analysis of ACR, the subgroups were based on an ACR of < 3 mg/mmol, an ACR of 3–30 mg/mmol
and an ACR of > 30 mg/mmol at baseline.
Given the lower number of dropouts in each subgroup (< 20), linear mixed-effect models were used to
analyse the longitudinal variations rather than joint models. The models were adjusted for age. Weight
change and sex were also added and, if found significant, they were included in the final model.
Sensitivity analyses 2: joint modelling for missing Homeostatic Model Assessment of
Insulin Resistance at 24 weeks
The proposed joint model of random intercepts and random slopes was failed because the number of
random effects and parameters requiring estimation exceeds the total number of observation points.
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Although fitting a joint model with random intercepts is possible in principle, the model may not fully
initialise the parameter estimates for the baseline hazard function. Hence, the proposed analysis was not
carried out.
Sensitivity analyses 3: compliance-adjusted analysis
Two additional ad hoc exploratory compliance-adjusted analyses were carried out for HOMA-IR at 24 weeks
to address the selection bias that is evident in original compliance-adjusted analysis (see Sensitivity analyses),
given that patients who provided some compliance data had higher HIV viral load at baseline than those
who did not provide any compliance data.
1. Instrumental variable regression was as for sensitivity analysis 3 (i.e. using complete case population),
but additionally accounting for baseline HIV viral load.
Assumption: baseline HIV viral load is missing at random and there are no other factors (i.e. other than HIV
viral load) that influence whether or not patients provide compliance data.
2. Multiple imputation was used to impute missing compliance information prior to carrying out IV
regression, with HIV viral load at baseline as the key predictor in the imputation model (i.e. imputed
compliance information used for all participants who had missing compliance information but who had
baseline HIV viral load data). The same conditions as above using multiple imputation (20 imputations
per patient using predictive mean matching with baseline HIV viral load as predictor variable) rather
than including baseline HIV viral load in model.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
Appendix 5 Protocol amendments
TABLE 12 List of amendments to the TAILoR trial
Amendment
number Details of amendment
Original application Protocol version 1, 29 February 2012
Modified submission Additional exclusion criteria added to protocol (version 2, 14 June 2012)
Amendment 1
(substantial)
Additional exclusion criteria added to protocol (version 2, 14 June 2012)
Changes to PISC (version 3, 1 August 2012) to reflect transfer of data to a private company
Change of PI at Brighton and Sussex Hospital
Amendment 2
(substantial)
Number of changes to protocol (version 3, 2 November 2012) including change in central
laboratory, change in exclusion criteria, change in number and type of biological samples
to be collected
Changes to PISC (version 4.0, 2 November 2012)
Addition of further site
Amendment 3
(substantial)
Addition of Royal Bournemouth and Christchurch Hospitals as a participating site
Amendment 4
(non-substantial)
Minor amendments to treatment diary
Amendment 5
(substantial)
Addition of St James’s University Hospital Leeds
Margaret Johnson replaces Dr Mike Youle as PI at the Royal Free London
Amendment 7 (minor) Admin changes to protocol (version 4.0, 18 October 2013) including:
l Travel expenses
l Time windows for visits
l Rewording of exclusion criteria
l Clarification of what is meant by ‘medical history’ (test results to be included)
l Removal of addresses
l Change to contact details
l Addition of website
l Addition of clinic poster (version 1.0, 24 October 2013)
l Change to main and substudy PISC (version 5.0, 29 October 2013) (contact details of trial
co-ordinator)
l Change to treatment diary (version 3.0, 29 October 2013)
l Change to contact card (version 2.0, 24 June 2013)
Amendment 8
(substantial)
Addition of participating sites:
l North Middlesex Hospital
l Manchester Royal Infirmary
l North Bristol NHS Trust
l St Helens Hospital
l Harrogate District Hospital
Amendment 9
(substantial)
Change to protocol (version 5.0, 24 February 2014) to allow the use of generic IMP
Change to PISC (main study) (version 6.0, 3 February 2014)
Amendment 10
(substantial)
Addition of participating site:
l George Eliot Hospital Nuneaton
continued
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Protocol deviations
The number of protocol deviations are summarised by treatment arm and presented in Table 13.
TABLE 12 List of amendments to the TAILoR trial (continued )
Amendment
number Details of amendment
Amendment 11
(substantial)
Change to protocol (version 6.0, 19 August 2014) to clarify drugs in inclusion criteria, to allow
substudy to be performed at other sites
Change to PISC (version 7.0, 19 August 2014) main study
Change to substudy PISC (version 6.0, 19 August 2014)
Amendment 12
(substantial)
Addition of Newcastle Upon Tyne Foundation Trust as a participating site
Amendment 13
(substantial)
Change to PISC to reflect potential interim analysis results (version 8a, 8b, 8c, 8d, 8e, 8f, 8g,
16 March 2015)
Amendment 14
(substantial)
Change to PISC (version 9.0, 20/05/2015)
Production of additional information sheet (version 1.0, 29 May 2015)
Increase in number of patients to be recruited (protocol version 7.0, 13 May 2016)
Notification of
extension
Notification of extension to recruitment period
Amendment 15
(substantial)
Letter to notify sub-study patients of typo in version 4 substudy PISC
Amendment 16
(substantial)
Update to serum biomarker tests to be performed
Urinary biomarkers to become a substudy
Protocol version 8.0
TABLE 13 Number of protocol deviations
Protocol deviation Impact
Treatment arm, n (%)
Total number
of patients,
n (%)
Arm A
(N= 105)
Arm B
(N= 84)
Arm C
(N= 82)
Arm D
(N= 106)
Inclusion criteria – patients recruited that
are not on an accepted drug treatment
Major 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Exclusion criteria – eGFR of < 60ml/minute/
1.73 m2
Major 1 (1.0) 0 (0.0) 0 (0.0) 2 (1.9) 3 (0.8)
Exclusion criteria – patients who are already
on/have been on other ARBs and/or ACE
inhibitors within 4 weeks preceding
randomisation
Major 1 (1.0) 0 (0.0) 0 (0.0) 1 (0.9) 2 (0.5)
Treatment regime – premature
discontinuation of randomised treatment
for safety reasons
Major 1 (1.0) 6 (7.1) 12 (14.6) 9 (8.5) 28 (7.4)
Treatment regime – use of non-protocol
dosing regime
Major 0 (0.0) 0 (0.0) 0 (0.0) 11 (10.4) 11 (2.9)
Study assessments at 12 weeks – missing
or visits that occur outside the 2-week
window
Minor 25 (23.8) 4 (4.8) 16 (19.5) 17 (16.0) 62 (16.4)
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TABLE 13 Number of protocol deviations (continued )
Protocol deviation Impact
Treatment arm, n (%)
Total number
of patients,
n (%)
Arm A
(N= 105)
Arm B
(N= 84)
Arm C
(N= 82)
Arm D
(N= 106)
Study assessment at 48 weeks – missing or
visits that occur outside the 2-week window
Minor 30 (28.6) 3 (3.6) 25 (30.5) 36 (34.0) 94 (24.9)
Study assessment at 24 weeks – missing or
visits that occur outside the 2-week window
Major 31 (29.5) 5 (6.0) 19 (23.2) 26 (24.5) 81 (21.5)
Titration visit at 2 weeks – missing or visits
that occur outside the 4-day window
Major 0 (0.0) 0 (0.0) 13 (15.9) 13 (12.3) 26 (13.8)a
Titration visit at 4 weeks – missing or visits
that occur outside the 4-day window
Major 0 (0.0) 0 (0.0) 0 (0.0) 23 (21.7) 23 (21.7)b
Study assessments – samples not collected/
unfasted at 12 weeks
Minor 1 (1.0) 1 (1.2) 0 (0.0) 4 (3.8) 6 (1.6)
Study assessments – samples not collected/
unfasted at 48 weeks
Minor 3 (2.9) 4 (4.8) 3 (3.7) 2 (1.9) 12 (3.2)
Study assessments – haemolysed samples
collected at 12 weeks
Minor 2 (1.9) 0 (0.0) 2 (2.4) 1 (0.9) 5 (1.3)
Study assessments – haemolysed samples
collected at 48 weeks
Minor 2 (1.9) 0 (0.0) 3 (3.7) 1 (0.9) 6 (1.6)
Study assessments – samples not collected/
unfasted at 24 weeks
Major 1 (1.0) 1 (1.2) 1 (1.2) 2 (1.9) 5 (1.3)
Study assessments – haemolysed samples
collected at 24 weeks
Major 0 (0.0) 1 (1.2) 2 (2.4) 2 (1.9) 5 (1.3)
Study assessments – samples not collected/
unfasted at baseline
Major 1 (1.0) 1 (1.2) 0 (0.0) 2 (1.9) 4 (1.1)
Study assessments – haemolysed samples
collected at baseline
Major 3 (2.9) 2 (2.4) 2 (2.4) 3 (2.8) 10 (2.7)
Blood pressure not being checked at
baseline and follow-up visits
Major 0 (0.0) 1 (1.2) 1 (1.2) 0 (0.0) 2 (0.5)
a Titration visit at 2 weeks occurred for arm C and arm D only.
b Titration visit at 4 weeks occurred for arm D only.
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Appendix 6 Further details of results
Screening and participant flow
TABLE 14 Summary of screening data for all sites
Site
Date Number of patients
Opened
First patient
randomised
Last patient
randomised Screened Recruited
Brighton and Sussex
Hospital
23 September 2013 1 November 2013 15 June 2015 43 39
Coventry and
Warwickshire
20 September 2013 23 September 2013 14 November 2014 50 22
George Eliot Hospital 26 January 2015 27 January 2015 26 June 2015 60 15
Guy’s and St Thomas’ 14 June 2013 25 July 2013 26 May 2015 109 47
Harrogate District Hospital 10 June 2014 11 June 2014 13 July 2015 10 6
James Cook University
Hospital
29 October 2013 14 November 2013 14 May 2015 68 27
King’s College 4 June 2013 25 July 2013 3 July 2015 84 24
Manchester Royal
Infirmary
30 May 2014 26 June 2014 17 June 2015 42 20
New Croft Clinic
(Royal Victoria Infirmary)
15 April 2015 11 June 2015 9 July 2015 3 2
North Middlesex Hospital 24 March 2014 1 April 2014 18 May 2015 94 11
Royal Bournemouth
Hospital
2 May 2013 25 July 2013 29 June 2015 525 14
Royal Free, London 26 July 2013 18 September 2013 28 April 2015 104 24
Royal Liverpool Hospital 21 February 2013 19 March 2013 10 April 2015 143 41
Southmead Hospital 14 January 2015 22 January 2015 20 July 2015 9 8
St Helens Hospital 18 November 2014 30 January 2015 7 July 2015 7 4
St James’s University
Hospital
19 September 2013 28 November 2013 28 May 2015 134 11
St Stephen’s Trust at
Chelsea and Westminster
6 June 2014 20 June 2014 16 June 2015 40 40
Western General Hospital 19 September 2013 10 March 2014 14 May 2015 287 12
YorClinic 4 December 2013 23 January 2014 16 April 2015 138 10
Total – – – 1950 377
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TABLE 15 Detailed summary of screening data for all sites
Site ID Site
Number of patients
who were assessed
for eligibility at the
screening visit
Those who met the
study inclusion
criteria at screening
prior to consent
being sought, n (%)
Those who did not
meet the study
inclusion criteria
at screening prior
to consent being
sought, n (%)
Those who
were eligible
at screening
and consent
obtained,
n (%)
Those who
were eligible
at screening
but consent
not obtained,
n (%)
Those who
provided
consent but
were not
randomised,
n (%)
Those who
provided
consent
and were
randomised,
n (%)
0149 Brighton and Sussex Hospital 43 42 (97.7) 1 (2.3) 40 (95.2) 2 (4.8) 1 (2.5) 39 (97.5)
2575 Coventry and Warwickshire 50 50 (100.0) 0 (0.0) 22 (44.0) 28 (56.0) 0 (0.0) 22 (100.0)
0187 George Eliot Hospital 60 36 (60.0) 24 (40.0) 15 (41.7) 21 (58.3) 0 (0.0) 15 (100.0)
0241 Guy’s and St Thomas’ 109 101 (92.7) 8 (7.3) 47 (46.5) 54 (53.5) 0 (0.0) 47 (100.0)
0076 Harrogate District Hospital 10 10 (100.0) 0 (0.0) 6 (60.0) 4 (40.0) 0 (0.0) 6 (100.0)
0006 James Cook University Hospital 68 67 (98.5) 1 (1.5) 27 (40.3) 40 (59.7) 0 (0.0) 27 (100.0)
0161 King’s College 84 73 (86.9) 11 (13.1) 24 (32.9) 49 (67.1) 0 (0.0) 24 (100.0)
0080 Manchester Royal Infirmary 42 41 (97.6) 1 (2.4) 20 (48.8) 21 (51.2) 0 (0.0) 20 (100.0)
0072 New Croft Clinic (Royal Victoria
Infirmary)
3 2 (66.7) 1 (33.3) 2 (100.0) 0 (0.0) 0 (0.0) 2 (100.0)
0145 North Middlesex Hospital 94 87 (92.6) 7 (7.4) 11 (12.6) 76 (87.4) 0 (0.0) 11 (100.0)
0112 Royal Bournemouth Hospital 525 123 (23.4) 402 (76.6) 50 (40.7) 73 (59.3) 36a (72.0) 14 (28.0)
0155 Royal Free, London 104 89 (85.6) 15 (14.4) 28 (31.5) 61 (68.5) 5 (17.9) 23 (82.1)
0046 Royal Liverpool Hospital 143 136 (95.1) 7 (4.9) 42 (30.9) 94 (69.1) 2 (4.8) 40 (95.2)
0230 Southmead Hospital 9 8 (88.9) 1 (11.1) 8 (100.0) 0 (0.0) 0 (0.0) 8 (100.0)
7478 St Helens Hospital 7 7 (100.0) 0 (0.0) 5 (71.4) 2 (28.6) 0 (0.0) 5 (100.0)
0050 St James’s University Hospital 134 79 (59.0) 55 (41) 11 (13.9) 68 (86.1) 0 (0.0) 11 (100.0)
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Site ID Site
Number of patients
who were assessed
for eligibility at the
screening visit
Those who met the
study inclusion
criteria at screening
prior to consent
being sought, n (%)
Those who did not
meet the study
inclusion criteria
at screening prior
to consent being
sought, n (%)
Those who
were eligible
at screening
and consent
obtained,
n (%)
Those who
were eligible
at screening
but consent
not obtained,
n (%)
Those who
provided
consent but
were not
randomised,
n (%)
Those who
provided
consent
and were
randomised,
n (%)
0016 St Stephen’s Trust at Chelsea
and Westminster
40 40 (100.0) 0 (0.0) 40 (100.0) 0 (0.0) 0 (0.0) 40 (100.0)
0361 Western General Hospital 287 72 (25.1) 215 (74.9) 12 (16.7) 60 (83.3) 0 (0.0) 12 (100.0)
9446 YorClinic 138 55 (39.9) 83 (60.1) 10 (18.2) 45 (81.8) 0 (0.0) 10 (100.0)
TOTAL 1950 1118 (57.3) 832 (42.7) 420 (37.6) 698 (62.4) 44 (10.5) 376b (89.5)
a Site had a staffing issue. They had four nurses during the recruitment period. There were gaps of around 3 months between one nurse leaving and the next starting post.
b There are three missing screening logs, see CONSORT diagram, Chapter 4, Figure 4, for further detail.
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TABLE 16 Reasons for ineligibility, by site
Site
ID
Reason for ineligibility (n)
Aged
< 18 years
Pre-existing
diagnosis
of diabetes
mellitus
Participant
has renal
disease
Participant
has known
untreated
renal artery
stenosis
Participant has
cholestasis,
biliary
obstructive
disorders or
severe hepatic
impairment
Prior diagnosis
of hepatitis C
(+ve PCR result
in previous
6 months)
Participant on
unboosted
atazanavir
Participant on
on/has been
on hormone
therapy,
anabolics and
insulin sensitisers
(previous
6 months)
Participant
on/has been
on other ARBs
and/or ACE
inhibitors
(within 4 weeks
before
randomisation)
Suspected
poor
compliance
Pregnant/
lactating
Women of
childbearing
age (unless
using reliable
contraception
that does
not interact
with their
antiretroviral
therapy)
Co-enrolment
in other drug
trials
Participant
in a trial of
an IMP likely
to influence
insulin
sensitivity
Other
reason
not
eligible
0006 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
0016 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0046 0 0 0 0 0 0 0 0 0 0 0 3 0 0 7
0050 0 2 5 0 0 4 3 0 0 6 5 2 0 0 28
0072 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
0076 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0080 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0112 5 55 26 7 7 23 16 2 42 151 10 9 11 0 40
0145 0 0 1 0 1 1 0 1 0 0 0 0 0 0 3
0149 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
0155 0 0 0 0 0 0 0 0 7 3 1 1 0 0 3
0161 0 0 0 0 0 1 0 0 5 0 0 0 0 0 5
0187 0 0 2 0 0 1 3 0 0 7 1 0 0 0 11
0230 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0241 0 1 0 0 1 0 0 0 1 0 0 0 1 0 4
0361 0 15 26 0 4 44 1 5 31 10 1 1 2 0 92
2575 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7478 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9446 0 7 12 0 6 4 0 4 12 25 1 1 1 0 13
TOTAL 5 80 73 7 19 78 23 13 99 202 19 17 15 0 208
+ve, positive; PCR, polymerase chain reaction.
A
PPEN
D
IX
6
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
90
Baseline data
TABLE 17 Reasons for exclusion
Reason
Number of
patients
Aged < 18 years 5
Pre-existing diagnosis of diabetes mellitus 80
Participant has renal disease 73
Participant has known untreated renal artery stenosis 7
Participant has cholestasis, biliary obstructive disorders or severe hepatic impairment 19
Prior diagnosis of hepatitis C (i.e. positive PCR result in previous 6 months) 78
Participant on unboosted atazanavir 23
Participant on on/have been on hormone therapy, anabolics and insulin sensitisers (previous 6 months) 13
Participant on/have been on other ARBs and/or ACE inhibitors (within 4 weeks before randomisation) 99
Suspected poor compliance 202
Pregnant/lactating 19
Women of childbearing age (unless using reliable contraception that does not interact with their
antiretroviral therapy)
17
Co-enrolment in other drug trials 15
Participant in a trial of an IMP likely to influence insulin sensitivity 0
Other reason not eligiblea 208
a Free-text field: alcohol problems, cannot commit to extra visits re travelling, multiple health issues currently under
investigation, planning pregnancy, etc.
TABLE 18 Baseline CD4 cell count and HIV viral load by treatment arm
Characteristic
Treatment arm
Arm A
(N= 105)
Arm B
(N= 84)
Arm C
(N= 82)
Arm D
(N= 106)
CD4 cell count (cells/mm3) (n= 102) (n= 83) (n = 78) (n= 101)
Median (IQR); min.–max. 598 (480–756);
200–1400
580 (425–792);
131–1501
582 (440–770);
129–1467
593 (427–783);
62–1674
CD4 cell count and HIV viral load (%) (n= 102) (n = 81)
Mean (SD); min.–max. 32.1 (7.7);
14.0–52.0
29.2 (8.6);
8.0–47.0
30.1 (9.3);
6.0–52.0
30.5 (7.9);
6.0–48.0
HIV viral load (copies/ml) (n= 35) (n= 17) (n = 31) (n= 34)
Median (IQR); min.–max.a 39 (0–40);
0–577
0 (0–39);
0–120
36 (0–44);
0–649
20 (0–39);
0–148
< 10, n (%) 2 (1.9) 1 (1.2) 2 (2.4) 1 (0.9)
< 20, n (%) 13 (12.4) 20 (23.8) 11 (13.4) 23 (21.7)
< 40, n (%) 50 (47.6) 38 (45.2) 35 (42.7) 43 (40.6)
< 45, n (%) 2 (1.9) 6 (7.1) 3 (3.7) 3 (2.8)
< 100, n (%) 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
max., maximum; min., minimum.
a Some data are presented in both continuous and categorical form as a result of there being upper and lower limits
of measurement.
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TABLE 19 Baseline liver function by treatment arm
Characteristic
Treatment arm
Arm A (N= 105) Arm B (N= 84) Arm C (N= 82) Arm D (N= 106)
ALT (IU/l) (n= 92) (n= 75) (n= 77) (n= 96)
Median (IQR); min.–max. 24.0 (17.5–33.5);
9.0–80.0
26.0 (19.0–36.0);
6.0–142.0
27.0 (20.0–35.0);
10.0–84.0
25.0 (18.0–38.0);
8.0–305.0a
ALP (IU/l) (n= 103) (n= 83) (n= 74) (n= 102)
Median (IQR); min.–max. 88.0
(71.0–107.0);
30.0–371.0
85.0
(72.0–113.0);
40.0–403.0
77.0 (62.0–98.0);
32.0–179.0
80.0
(65.0–100.0);
35.0–309.0
Albumin (g/l) (n= 102) (n= 83) (n= 81) (n= 103)
Mean (SD); min.–max. 43.7 (4.1);
33.0–51.0
44.3 (3.5);
36.0–51.0
44.2 (3.2);
37.0–54.0
44.7 (3.8);
34.0–53.0
Total protein (g/l) (n= 72) (n= 59) (n= 59) (n= 69)
Mean (SD); min.–max. 74.5 (5.3);
63.0–87.0
73.7 (4.0);
66.0–84.0
74.2 (4.6);
65.0–85.0
73.4 (3.9);
65.0–84.0
Bilirubin (µmol/l) (n= 100) (n= 78) (n= 76) (n= 98)
Median (IQR); min.–max.b 6.0 (5.0–9.5);
2.0–67.0
7.0 (5.0–9.0);
3.0–82.0
8.0 (6.0–12.0);
3.0–100.0
7.0 (5.0–14.0);
2.0–68.0
< 2, n (%) 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
< 3, n (%) 3 (2.9) 2 (2.4) 2 (2.4) 2 (1.9)
< 15, n (%) 1 (1.0) 2 (2.4) 1 (1.2) 4 (3.8)
max., maximum; min., minimum.
a Confirmed correct.
b Some data are presented in both continuous and categorical form as a result of there being upper and lower limits
of measurement.
TABLE 20 Baseline full blood count by treatment arm
Characteristic
Treatment arm
Arm A (N= 105) Arm B (N= 84) Arm C (N= 82) Arm D (N= 106)
Haematocrit (%) (n= 70) (n= 49) (n= 50) (n= 65)
Mean (SD); min.–max. 42.23 (3.29);
34.2–53.0
42.16 (6.51);
5.1–51.0
42.82 (3.18);
34.6–49.9
42.46 (5.69);
5.3–50.0
Haemoglobin (g/dl) (n= 83)
Mean (SD); min.–max. 143.77 (12.28);
114–171
144.16 (13.32);
107–173
146.73 (12.15);
114–177
145.72 (12.92);
80–171
Red blood cell count (1012/l) (n= 98) (n= 79) (n= 77) (n= 97)
Mean (SD); min.–max. 4.55 (0.44);
3.47–5.63
4.62 (0.44);
3.23–5.59
4.69 (0.41);
3.68–6.06
4.60 (0.44);
3.10–5.79
White blood cell count (109/l) (n= 105)
Median (IQR); min.–max. 5.98 (4.78–7.60);
3.5–15.3
5.61 (4.8–7.2);
3.0–13.8
5.56 (4.8–6.7);
2.04–12.9
5.7 (4.8–7.2);
2.8–14.4
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TABLE 20 Baseline full blood count by treatment arm (continued )
Characteristic
Treatment arm
Arm A (N= 105) Arm B (N= 84) Arm C (N= 82) Arm D (N= 106)
Platelets (109/l) (n= 104)
Median (IQR); min.–max. 231.5
(198.5–271.5);
128–647
223.0
(193.0–252.0);
46–406
216.5
(182.0–266.0);
119–411
219.5
(185.0–262.0);
106–368
Mean cell volume (fl) (n= 104)
Mean (SD); min.–max. 93.40 (5.65);
77.4–111.1
92.87 (5.48);
73.6–104.0
92.47 (5.48);
81.4–110.2
94.37 (5.33);
81.0–111.0
Mean cell haemoglobin (pg) (n= 80) (n= 67) (n= 60) (n = 85)
Mean (SD); min.–max. 31.49 (3.92);
3.6–39.7
31.35 (2.06);
24.1–36.7
31.34 (1.91);
26.6–36.6
31.35 (3.68);
2.59–37.0
Mean cell haemoglobin
concentration (g/dl)
(n= 68) (n= 53) (n= 53) (n = 65)
Mean (SD); min.–max. 340.71 (11.83);
309–366
335.28 (12.97);
302–366
340.57 (13.03);
315–367
336.55 (12.48);
293–357
Neutrophils (109/l)
Median (IQR); min.–max. 3.15 (2.30–4.30);
1.16–12.60
2.90 (2.24–3.90);
1.10–9.70
2.90 (2.30–3.84);
0.83–8.70
3.00 (2.10–3.80);
0.88–10.00
Lymphocytes (109/l)
Median (IQR); min.–max. 1.90 (1.60–2.55);
0.89–4.10
2.13 (1.71–2.50);
0.93–5.02
2.00 (1.62–2.31);
0.53–3.70
1.91 (1.60–2.50);
0.90–4.20
Eosinophils (109/l) (n= 104) (n= 82)
Median (IQR); min.–max. 0.11 (0.10–0.20);
0.00–1.11
0.10 (0.10–0.20);
0.00–0.60
0.12 (0.10–0.20);
0.00–0.41
0.12 (0.10–0.20);
0.00–0.50
Basophils (109/l) (n= 101) (n= 80) (n= 81) (n = 103)
Median (IQR); min.–max. 0.02 (0.00–0.05);
0.00–0.20
0.00 (0.00–0.04);
0.00–0.10
0.00 (0.00–0.03);
0.00–0.10
0.01 (0.00–0.06);
0.00–0.10
Monocytes (109/l)
Median (IQR); min.–max. 0.50 (0.34–0.60);
0.00–1.10
0.44 (0.30–0.60);
0.19–1.20
0.48 (0.38–0.60);
0.16–1.02
0.42 (0.31–0.60);
0.10–1.49
max., maximum; min., minimum.
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Numbers analysed
TABLE 21 Number of patients with missed visits and missing data because of sample issues
Visit
Treatment arm
Total
(N= 377)
Arm A
(N= 105)
Arm B
(N= 84)
Arm C
(N= 82)
Arm D
(N= 106)
No missing assessment visit 82 79 65 81 307
Complete longitudinal record 72 72 57 72 273
Study assessment at 12 weeks
Missing 13 4 11 13 41
Data invalida 3 1 2 5 11
Study assessment at 24 weeks
Missing 15 2 11 20 48
Data invalida 1 2 3 4 10
Study assessment at 48 weeks
Missing 16 2 9 24 51
Data invalida 5 4 6 3 18
Baseline
Data invalida 4 3 2 5 14
a Unfasted or haemolysed sample.
TABLE 22 Reasons for missingness or study withdrawal
Reason
Treatment arm
Total
(N= 377)
Arm A
(N= 105)
Arm B
(N= 84)
Arm C
(N= 82)
Arm D
(N= 106)
Death 1 0 0 0 1
Loss to follow-up 6 2 5 5 18
Other reasonsa 6 1 3 7 17
SAR 0 0 1 0 1
Treatment arm dropped 0 32 31 0 63
Withdrawal of consent for follow-up 1 0 3 4 8
Total 14 35 43 16 108
a Free-text field: patient moved to London – no forwarding address so unable to transfer patient; does not wish to
continue the study because of organisational reasons; not able to commit to study; advice from study team following
MRI incidental finding; to enter another clinical trial; decided to become pregnant, etc.
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Interim analysis
TABLE 23 Summary statistics for HOMA-IR at baseline and 24 weeks by treatment arm
Summary statistic
Timeline
HOMA-IR at baseline HOMA-IR at 24 weeks
Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg) Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg)
Number of patients 39 45 35 35 39 45 35 35
Mean (SD);
min.–max.
2.4 (2.0); 0.6–10.8 2.3 (1.6); 0.6–7.0 2.8 (3.9); 0.6–17.5 2.6 (2.7); 0.6–11.4 2.5 (1.9); 0.6–9.2 2.7 (1.9); 0.6–7.8 3.4 (4.4); 0.6–23.5 2.5 (1.7); 0.6–8.1
Median (IQR) 1.8 (1.0–3.5) 1.6 (1.2–2.8) 1.8 (1.2–2.5) 1.6 (1.2–2.9) 2.1 (1.2–3.2) 2.4 (1.2–3.3) 1.8 (1.4–3.4) 1.8 (1.3–3.1)
Number of patients
randomised
48 49 47 45 48 49 47 45
max., maximum; min., minimum.
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Homeostatic Model Assessment of Insulin Resistance at primary
end point
Investigation of the extreme Homeostatic Model Assessment of Insulin Resistance value
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FIGURE 10 Change in HOMA-IR at 24 weeks from baseline against HOMA-IR at baseline. (a) all values; (b) values
excluding patient 01552152.
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Excluding the outlier patient
TABLE 24 Summary statistics for HOMA-IR at baseline and 24 weeks by treatment arm
Summary statistic
Time point
HOMA-IR at baseline HOMA-IR at 24 weeks
Arm A (control) Arm D (80mg) Arm A (control) Arm D (80mg)
Number of patients (%) 100 (95.2) 99 (93.4) 89 (84.8) 81 (76.4)
Mean (SD); min.–max. 2.49 (2.08);
0.41–10.78
2.54 (2.81);
0.59–16.85
2.99 (3.25);
0.62–19.6
2.72 (2.15);
0.60–8.77
Median (IQR) 1.81 (1.12–2.90) 1.62 (1.18–2.48) 2.09 (1.29–3.17) 1.99 (1.15–3.23)
Missing (%) 5 (4.8) 7 (6.6) 16 (15.2) 25 (23.6)
Number of patients randomised 105 106 105 106
max., maximum; min., minimum.
TABLE 25 Model estimates for log-HOMA-IR at 24 weeks, excluding patient with outlier HOMA-IR
Variable Parameter estimate Standard error t-value for treatment
Intercept 0.458 0.126 –
Log-(HOMA-IR) at baseline 0.575 0.074 –
Ethnicity (non-black) –0.012 0.123 –
Arm D vs. arm A –0.034 0.099 –0.347
TABLE 26 Model estimates for log-HOMA-IR at 24 weeks, adjusted for weight change
Variable Parameter estimate Standard error t-value for treatment
Intercept 0.400 0.126 –
Log-(HOMA-IR) at baseline 0.581 0.072 –
Ethnicity (non-black) 0.031 0.122 –
Weight change 0.050 0.016 –
Arm D vs. arm A –0.039 0.097 –0.399
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Sensitivity analysis 1
We fitted the same ANCOVA model by imputing values for missing HOMA-IR values at baseline and
24 weeks using the MICE algorithm. The MICE algorithm imputed missing HOMA-IR values conditional
on available HOMA-IR values at baseline, 12 weeks and 24 weeks, treatment allocation (arm D/arm A)
and stratification factor (black/non-black).
The test statistic is –0.393, and as this value is not smaller than the critical value (–2.086), we failed to
reject the null hypothesis (i.e. no difference between arm D and arm A).
Sensitivity analysis 2
A compliance-adjusted primary outcome analysis was undertaken using IV regression, in order to estimate
the effect of actual dose on outcome. The model included patients from arm A (assumed to have received
a telmisartan dose of 0 mg) and patients from arm D who provided compliance data from both the
treatment diary and pill count. Dose is based on the average between two measures of compliance
(treatment diary and pill count).
The p-value (of 0.2885 > 0.05) implies that there is no effect of telmisartan after adjusting for dose. The test
of endogeneity indicated that there was insufficient evidence to reject the null hypothesis of exogeneity
(Durbin score, chi-squared(1) = 0.0234; p = 0.8783; Wu–Hausman F(1,138) = 0.0226; p = 0.8807), implying
that dose is independent of the error and, thus, standard regression analysis is appropriate. The randomisation
was an informative (strong) instrument in this analysis, as demonstrated by a high correlation between
compliance and randomised treatment arm (0.9928) and a highly significant p-value (i.e. < 0.0001), rejecting
the null hypothesis that randomised treatment is a weak instrument.
Same IV regression was carried out but additionally accounting for baseline HIV viral load. We assume that
baseline HIV viral load was missing at random, and there were no other factors (i.e. other than HIV viral
load) that influence whether or not patients provided compliance data.
TABLE 27 Model estimates for log-HOMA-IR at 24 weeks, imputed missing HOMA-IR
Variable Parameter estimate Standard error t-value for treatment
Intercept 0.393 0.123 –
Log-(HOMA-IR) at baseline 0.575 0.073 –
Ethnicity (non-black) 0.030 0.120 –
Weight change 0.052 0.016 –
Arm D vs. arm A –0.038 0.096 –0.393
TABLE 28 Model estimates accounting for received dose on log-HOMA-IR at 24 weeks
Variable Parameter estimate Standard error 95% CI p-value
Intercept 0.408 0.132 0.149 to 0.667 0.0020
Log-(HOMA-IR) at baseline 0.589 0.077 0.438 to 0.741 < 0.0001
Ethnicity (non-black) 0.040 0.131 –0.218 to 0.297 0.7636
Arm D dose (unit: 1000mg) –0.010 0.009 –0.028 to 0.008 0.2885
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In the next analysis, multiple imputation was used to impute missing compliance information prior to carrying
out IV regression, with HIV viral load at baseline as the key predictor in the imputation model (i.e. imputed
compliance information used for all participants who had missing compliance information but who had
baseline HIV viral load data). Twenty imputations were generated per patient using predictive mean matching
with baseline HIV viral load as predictor variable rather than including baseline HIV viral load in model.
Quantitative Insulin Sensitivity Check Index and revised Quantitative
Insulin Sensitivity Check Index at primary end point
TABLE 29 Model estimates accounting for received dose on log-HOMA-IR at 24 weeks, accounting for baseline HIV
viral load
Variable Parameter estimate Standard error 95% CI p-value
Intercept 0.431 0.167 0.103 to 0.759 0.0100
Dose (unit: 1000 mg) –0.011 0.009 –0.029 to 0.008 0.2589
Log-HOMA-IR at baseline 0.591 0.078 0.439 to 0.743 < 0.0001
Ethnicity 0.040 0.133 –0.220 to 0.300 0.7639
HIV viral load –0.001 0.003 –0.006 to 0.005 0.8288
TABLE 30 Model estimates accounting for received dose on log-HOMA-IR at 24 weeks using imputed compliance
information for patients, with missing compliance information based on baseline HIV viral load
Variable Parameter estimate Standard error 95% CI p-value
Intercept 0.458 0.125 0.213 to 0.704 < 0.001
Dose (unit: 1000 mg) –0.003 0.009 –0.020 to 0.014 0.725
Log-HOMA-IR at baseline 0.575 0.073 0.432 to 0.718 < 0.001
Ethnicity –0.013 0.122 –0.251 to 0.225 0.915
TABLE 31 Summary statistics for QUICKI at baseline and 24 weeks by treatment arm
Summary statistic
Time point
QUICKI at baseline QUICKI at 24 weeks
Arm A (control) Arm D (80mg) Arm A (control) Arm D (80mg)
Number of patients (%) 100 (95.2) 99 (93.4) 89 (84.8) 81 (76.4)
Mean (SD); min.–max. 0.117 (0.0092);
0.097–0.142
0.118 (0.0092);
0.093–0.135
0.115 (0.0093);
0.092–0.134
0.116 (0.0099);
0.099–0.134
Median (IQR) 0.117
(0.111 –0.124)
0.119
(0.113–0.123)
0.115
(0.110–0.122)
0.116
(0.110–0.124)
Missing (%) 5 (4.8) 7 (6.6) 16 (15.2) 25 (23.6)
Number of patients randomised 105 106 105 106
max., maximum; min., minimum.
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TABLE 32 Summary statistics for Revised-QUICKI at baseline and 24 weeks by treatment arm
Summary statistic
Time point
Revised-QUICKI at baseline Revised-QUICKI at 24 weeks
Arm A (control) Arm D (80mg) Arm A (control) Arm D (80mg)
Number of patients (%) 100 (95.2) 98 (92.4) 88 (83.8) 81 (76.4)
Mean (SD); min.–max. 0.132 (0.0168);
0.101–0.184
0.133 (0.0156);
0.096–0.178
0.132 (0.0176);
0.099–0.183
0.134 (0.0174);
0.103–0.187
Median (IQR) 0.13
(0.122–0.142)
0.132
(0.123–0.143)
0.129
(0.119–0.140)
0.131
(0.121–0.143)
Missing (%) 5 (4.8) 8 (7.5) 17 (16.2) 25 (23.6)
Number of patients randomised 105 106 105 106
max., maximum; min., minimum.
TABLE 33 Model estimates for QUICKI
Variable Parameter estimate Standard error t-value for treatment
Intercept 0.0493 0.0085 –
QUICKI at baseline 0.5624 0.0704 –
Ethnicity (non-black) –0.000035 0.0016 –
Weight change –0.000656 0.0002 –
Arm D vs. arm A 0.000563 0.0013 0.4471
TABLE 34 Model estimates for Revised QUICKI
Variable Parameter estimate Standard error t-value for treatment
Intercept 0.0638 0.0109 –
Revised QUICKI at
baseline
0.4932 0.0784 –
Ethnicity (non-black) 0.0028 0.0031 –
Weight change –0.0008 0.0004 –
Arm D vs. arm A 0.0017 0.0025 0.6882
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Analysis of covariance model diagnostics of primary and
secondary outcomes
The design has been constructed under the assumption that outcomes were normally distributed with a
common standard deviation, σ. Levene’s test for checking equal group variances, and histograms for
checking normality were used.
Histograms to check normality for Homeostatic Model Assessment of Insulin Resistance
at baseline and 24 weeks
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FIGURE 11 Normality of HOMA-IR (a) at baseline; (b) at 24 weeks; (c) log-transformed at baseline; and
(d) log-transformed at 24 weeks. (continued )
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FIGURE 11 Normality of HOMA-IR (a) at baseline; (b) at 24 weeks; (c) log-transformed at baseline; and
(d) log-transformed at 24 weeks.
TABLE 35 Levene’s test to check equal group variances for Homeostatic Model Assessment of Insulin Resistance at
baseline and 24 weeks
Source df Sum of squares Mean square F-value p-value
Treatment arm 1 1588.3 1588.3 1.91 0.1684
df, degrees of freedom.
A p-value of > 0.05 implies the homogeneity of variance.
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Histograms to check normality for Quantitative Insulin Sensitivity Check Index at
baseline and 24 weeks
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FIGURE 12 Normality of QUICKI at (a) baseline; and (b) 24 weeks.
TABLE 36 Levene’s test to check equal group variances for Quantitative Insulin Sensitivity Check Index at baseline
and 24 weeks
Source df Sum of squares Mean square F-value p-value
Treatment arm 1 1.268 ×10–8 1.268E-8 0.68 0.4125
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Histograms to check normality for revised Quantitative Insulin Sensitivity Check Index at
baseline and 24 weeks
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FIGURE 13 Normality of revised QUICKI at (a) baseline; and (b) 24 weeks.
TABLE 37 Levene’s test to check equal group variances for revised Quantitative Insulin Sensitivity Check Index at
baseline and 24 weeks
Source df Sum of squares Mean square F-value p-value
Treatment arm 1 2.06 ×10–11 2.06E-11 0.00 0.9928
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Longitudinal analysis: profiles, model diagnostics and estimates
Homeostatic Model Assessment of Insulin Resistance
Histograms to check normality for Homeostatic Model Assessment of Insulin Resistance
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FIGURE 14 Normality of HOMA-IR. (a) original scale; and (b) log-transformed.
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Three outlining HOMA-IR values were excluded from the longitudinal analysis [two from arm A (55.82720
at 12 weeks and 64.14336 at 48 weeks) and one from arm D (62.00064 at 24 weeks; this is the same
value excluded at the primary analysis of HOMA-IR)].
The bivariate joint model included 321 patients and 812 records. The treatment effect [arm D: telmisartan
(80 mg daily) compared with arm A: non-intervention (control)] on the longitudinal log-HOMA-IR is –0.083
(95% CI –0.247 to 0.082; p = 0.3243), implying that there is no significant difference between the
treatments on HOMA-IR.
0
2.50
2.75
H
O
M
A
-I
R
3.00
3.25
3.50
12 24
Time (weeks)
48
Treatment arm
       Arm A
       Arm D
(a)
0 12 24 48 0 12 24 48
Time (weeks)
Arm A Arm D
2
H
O
M
A
-I
R
3
4
Dropout at T12
Dropout at T24
With all data to T48
(b)
FIGURE 15 HOMA-IR mean profiles by treatment arm (original scale). (a) HOMA-IR profile plots; (b) HOMA-IR
profile plots by dropout; and (c) HOMA-IR reverse-time profile plots. (continued )
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FIGURE 15 HOMA-IR mean profiles by treatment arm (original scale). (a) HOMA-IR profile plots; (b) HOMA-IR
profile plots by dropout; and (c) HOMA-IR reverse-time profile plots.
TABLE 38 Joint model estimates: log-HOMA-IR
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.420 0.234 to 0.606 < 0.0001
Time 0.003 0.001 to 0.006 0.0159
Baseline marker 0.669 0.589 to 0.748 < 0.0001
Treatment B vs. A –0.084 –0.245 to 0.077 0.3043
Treatment C vs. A 0.010 –0.172 to 0.193 0.9106
Treatment D vs. A –0.083 –0.247 to 0.082 0.3243
Ethnicity –0.107 –0.247 to 0.033 0.1343
Longitudinal weight Intercept 1.047 –1.131 to 3.226 0.3459
Time 0.022 –0.002 to 0.045 0.0686
Baseline weight 0.987 0.965 to 1.008 < 0.0001
Treatment B vs. A 0.458 –0.551 to 1.467 0.3741
Treatment C vs. A 0.690 –0.367 to 1.746 0.2008
Treatment D vs. A 0.117 –0.842 to 1.076 0.8111
Ethnicity –0.246 –1.055 to 0.562 0.5504
Dropout Treatment B vs. A –0.355 –1.270 to 0.561 0.4477
Treatment C vs. A –0.076 –0.976 to 0.824 0.8690
Treatment D vs. A 0.081 –0.716 to 0.877 0.8427
Ethnicity –0.036 –0.847 to 0.775 0.9300
Association parameters Marker –0.262 –1.433 to 0.909 0.6611
Weight 0.044 –0.208 to 0.296 0.7337
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Quantitative Insulin Sensitivity Check Index
Histograms to check normality for Quantitative Insulin Sensitivity Check Index
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FIGURE 16 Normality of QUICKI (original scale).
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FIGURE 17 QUICKI mean profiles by treatment arm (original scale). (a) QUICKI profile plots; (b) QUICKI profile plots
by dropout; and (c) QUICKI reverse-time profile plots. (continued )
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FIGURE 17 QUICKI mean profiles by treatment arm (original scale). (a) QUICKI profile plots; (b) QUICKI profile plots
by dropout; and (c) QUICKI reverse-time profile plots.
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The bivariate joint model included 321 patients and 812 records. The treatment effect [arm D: telmisartan
(80 mg daily) compared with arm A: non-intervention (control)] on the longitudinal QUICKI is 0.001 (95% CI
–0.001 to 0.003; p = 0.3426), implying that there is no significant difference between the treatments
on QUICKI.
TABLE 39 Joint model estimates: QUICKI
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.039 0.029 to 0.048 < 0.0001
Time 0.000 0.000 to 0.000 0.0126
Baseline marker 0.649 0.572 to 0.726 < 0.0001
Treatment B vs. A 0.001 –0.001 to 0.003 0.2596
Treatment C vs. A 0.000 –0.003 to 0.002 0.9125
Treatment D vs. A 0.001 –0.001 to 0.003 0.3426
Ethnicity 0.001 –0.001 to 0.003 0.2102
Longitudinal weight Intercept 1.091 –1.066 to 3.248 0.3217
Time 0.021 –0.002 to 0.045 0.0755
Baseline weight 0.986 0.965 to 1.007 < 0.0001
Treatment B vs. A 0.479 –0.533 to 1.490 0.3537
Treatment C vs. A 0.704 –0.348 to 1.756 0.1898
Treatment D vs. A 0.135 –0.823 to 1.093 0.7823
Ethnicity –0.253 –1.053 to 0.546 0.5344
Dropout Treatment B vs. A –0.354 –1.269 to 0.561 0.4485
Treatment C vs. A –0.075 –0.982 to 0.832 0.8714
Treatment D vs. A 0.082 –0.716 to 0.879 0.8408
Ethnicity –0.037 –0.835 to 0.762 0.9279
Association parameters Marker 18.535 –75.599 to 112.668 0.6996
Weight 0.042 –0.210 to 0.295 0.7428
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FIGURE 19 Revised QUICKI mean profiles by treatment arm (original scale). (a) revised QUICKI profile plots;
(b) revised QUICKI profile plots by dropout; and (c) revised QUICKI reverse-time profile plots. (continued )
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Revised Quantitative Insulin Sensitivity Check Index
Histograms to check normality for revised Quantitative Insulin Sensitivity Check Index
The bivariate joint model included 320 patients and 808 records. Revised QUICKI scores were fitted in their
original scale.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal revised QUICKI
was 0.004 (95% CI 0.000 to 0.008; p = 0.0510). As the p-value was just above 0.05, this implies a
marginally significant difference between the treatments on revised QUICKI.
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FIGURE 19 Revised QUICKI mean profiles by treatment arm (original scale). (a) revised QUICKI profile plots;
(b) revised QUICKI profile plots by dropout; and (c) revised QUICKI reverse-time profile plots.
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TABLE 40 Joint model estimates: revised QUICKI
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.058 0.046 to 0.070 < 0.0001
Time 0.000 0.000 to 0.000 0.0402
Baseline marker 0.550 0.473 to 0.627 < 0.0001
Treatment B vs. A 0.003 –0.001 to 0.007 0.1023
Treatment C vs. A 0.001 –0.003 to 0.005 0.5993
Treatment D vs. A 0.004 0.000 to 0.008 0.0510
Ethnicity 0.001 –0.002 to 0.004 0.5071
Longitudinal weight Intercept 1.039 –1.087 to 3.164 0.3382
Time 0.020 –0.003 to 0.044 0.0899
Baseline weight 0.987 0.966 to 1.009 < 0.0001
Treatment B vs. A 0.473 –0.493 to 1.438 0.3374
Treatment C vs. A 0.690 –0.310 to 1.690 0.1765
Treatment D vs. A 0.187 –0.748 to 1.123 0.6945
Ethnicity –0.250 –1.039 to 0.539 0.5340
Dropout Treatment B vs. A –0.364 –1.272 to 0.544 0.4319
Treatment C vs. A 0.183 –0.633 to 0.999 0.6608
Treatment D vs. A 0.078 –0.726 to 0.881 0.8496
Ethnicity –0.087 –0.845 to 0.671 0.8218
Association parameters Marker 10.682 –47.031 to 68.395 0.7168
Weight 0.028 –0.206 to 0.262 0.8153
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Lipid profiles
High-density lipoprotein cholesterol
Histograms to check normality for high-density lipoprotein cholesterol
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FIGURE 20 Normality of HDL-C. (a) original scale; and (b) log-transformed.
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FIGURE 21 The HDL-C mean profiles by treatment arm (original scale). (a) HDL-C profile plots; (b) HDL-C profile
plots by dropout; and (c) HDL-C reverse-time profile plots.
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The bivariate joint model included 329 patients and 849 records. HDL-C scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-HDL-C is
0.001 (95% CI –0.046 to 0.047), implying that there is no significant difference between the treatments
on HDL-C.
TABLE 41 Joint model estimates: log-HDL-C
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.021 –0.034 to 0.076 0.4583
Time 0.000 –0.001 to 0.001 0.6088
Baseline marker 0.878 0.833 to 0.924 < 0.0001
Treatment B vs. A –0.012 –0.060 to 0.035 0.6089
Treatment C vs. A –0.038 –0.085 to 0.008 0.1086
Treatment D vs. A 0.001 –0.046 to 0.047 0.9816
Ethnicity –0.018 –0.063 to 0.028 0.4455
Longitudinal weight Intercept 0.285 –2.072 to 2.641 0.8129
Time 0.019 –0.007 to 0.045 0.1537
Baseline weight 0.994 0.971 to 1.017 < 0.0001
Treatment B vs. A 0.477 –0.627 to 1.580 0.3972
Treatment C vs. A 0.742 –0.415 to 1.899 0.2088
Treatment D vs. A 0.075 –0.975 to 1.125 0.8881
Ethnicity –0.067 –0.945 to 0.811 0.8817
Dropout Treatment B vs. A 0.089 –0.856 to 1.033 0.8540
Treatment C vs. A 0.036 –0.986 to 1.058 0.9452
Treatment D vs. A 0.329 –0.545 to 1.204 0.4608
Ethnicity –0.216 –1.078 to 0.646 0.6232
Association parameters Marker –0.638 –5.534 to 4.259 0.7986
Weight –0.046 –0.244 to 0.151 0.6465
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Cholesterol
Histograms to check normality for cholesterol
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FIGURE 22 Normality of cholesterol (original scale).
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FIGURE 23 Cholesterol mean profiles by treatment arm (original scale). (a) cholesterol profile plots;
(b) cholesterol profile plots by dropout; and (c) cholesterol reverse-time profile plots. (continued )
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FIGURE 23 Cholesterol mean profiles by treatment arm (original scale). (a) cholesterol profile plots;
(b) cholesterol profile plots by dropout; and (c) cholesterol reverse-time profile plots.
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The bivariate joint model included 329 patients and 849 records. Cholesterol scores were fitted in their
original scale.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal cholesterol is
0.013 (95% CI –0.173 to 0.199), implying that there is no significant difference between the treatments
on cholesterol.
TABLE 42 Joint model estimates: cholesterol
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 1.325 0.965 to 1.684 < 0.0001
Time 0.000 –0.002 to 0.003 0.8473
Baseline marker 0.738 0.683 to 0.794 < 0.0001
Treatment B vs. A –0.046 –0.234 to 0.142 0.6326
Treatment C vs. A 0.061 –0.117 to 0.238 0.5040
Treatment D vs. A 0.013 –0.173 to 0.199 0.8904
Ethnicity –0.031 –0.201 to 0.139 0.7219
Longitudinal weight Intercept 0.218 –2.106 to 2.541 0.8544
Time 0.021 –0.005 to 0.046 0.1115
Baseline weight 0.995 0.972 to 1.017 < 0.0001
Treatment B vs. A 0.484 –0.617 to 1.586 0.3886
Treatment C vs. A 0.746 –0.385 to 1.876 0.1960
Treatment D vs. A 0.076 –0.954 to 1.105 0.8854
Ethnicity –0.090 –0.982 to 0.802 0.8433
Dropout Treatment B vs. A 0.083 –0.872 to 1.038 0.8649
Treatment C vs. A 0.027 –0.971 to 1.026 0.9576
Treatment D vs. A 0.324 –0.549 to 1.197 0.4666
Ethnicity –0.215 –1.028 to 0.598 0.6042
Association parameters Marker –0.040 –1.197 to 1.118 0.9466
Weight –0.043 –0.249 to 0.163 0.6807
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Triglycerides
Histograms to check normality for triglycerides
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FIGURE 24 Normality of triglycerides. (a) original scale; and (b) log-transformed.
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FIGURE 25 Triglycerides mean profiles by treatment arm (original scale). (a) triglycerides profile plots;
(b) triglycerides profile plots by dropout; and (c) triglycerides reverse-time profile plots.
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The bivariate joint model included 329 patients and 849 records. Triglycerides scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-triglycerides is
0.030 (95% CI –0.056 to 0.116), implying that there is no significant difference between the treatments
on triglycerides.
TABLE 43 Joint model estimates: log-triglycerides
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.018 –0.091 to 0.128 0.7450
Time 0.001 –0.001 to 0.002 0.4220
Baseline marker 0.779 0.713 to 0.845 < 0.0001
Treatment B vs. A 0.002 –0.096 to 0.100 0.9614
Treatment C vs. A 0.101 0.010 to 0.192 0.0291
Treatment D vs. A 0.030 –0.056 to 0.116 0.4885
Ethnicity 0.005 –0.089 to 0.099 0.9156
Longitudinal weight Intercept 0.646 –1.688 to 2.980 0.5876
Time 0.021 –0.004 to 0.046 0.0962
Baseline weight 0.990 0.967 to 1.012 < 0.0001
Treatment B vs. A 0.445 –0.602 to 1.491 0.4050
Treatment C vs. A 0.676 –0.463 to 1.815 0.2448
Treatment D vs. A 0.043 –0.953 to 1.039 0.9332
Ethnicity –0.088 –0.948 to 0.772 0.8412
Dropout Treatment B vs. A 0.085 –0.876 to 1.046 0.8629
Treatment C vs. A 0.027 –0.983 to 1.036 0.9588
Treatment D vs. A 0.324 –0.547 to 1.195 0.4656
Ethnicity –0.219 –1.031 to 0.593 0.5967
Association parameters Marker –0.392 –3.779 to 2.996 0.8207
Weight –0.035 –0.269 to 0.199 0.7722
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Low-density lipoprotein cholesterol
Histograms to check normality for low-density lipoprotein cholesterol
Baseline
0.6
0.4
0.0
0.2
 24 weeks
2 4 6
12 weeks
48 weeks
LDL-C
D
en
si
ty
0.6
0.4
0.0
0.2
2 4 6
FIGURE 26 Normality of LDL-C (original scale).
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FIGURE 27 LDL-C mean profiles by treatment arm (original scale). (a) LDL-C profile plots; (b) LDL-C profile plots by
dropout; and (c) LDL-C reverse-time profile plots. (continued )
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FIGURE 27 LDL-C mean profiles by treatment arm (original scale). (a) LDL-C profile plots; (b) LDL-C profile plots by
dropout; and (c) LDL-C reverse-time profile plots.
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The bivariate joint model included 324 patients and 833 records. LDL-C scores were fitted in original scale.
TABLE 44 Joint model estimates: LDL-C
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.787 0.539 to 1.035 < 0.0001
Time 0.000 –0.002 to 0.002 0.9532
Baseline marker 0.745 0.688 to 0.802 < 0.0001
Treatment B vs. A –0.008 –0.158 to 0.142 0.9127
Treatment C vs. A 0.019 –0.135 to 0.172 0.8118
Treatment D vs. A 0.000 –0.145 to 0.144 0.9946
Ethnicity 0.029 –0.108 to 0.165 0.6820
Longitudinal weight Intercept 0.223 –2.143 to 2.589 0.8536
Time 0.021 –0.005 to 0.048 0.1170
Baseline weight 0.995 0.971 to 1.018 < 0.0001
Treatment B vs. A 0.427 –0.681 to 1.535 0.4505
Treatment C vs. A 0.626 –0.579 to 1.832 0.3086
Treatment D vs. A 0.065 –0.981 to 1.111 0.9027
Ethnicity –0.099 –1.003 to 0.806 0.8309
Dropout Treatment B vs. A –0.012 –0.970 to 0.946 0.9799
Treatment C vs. A –0.192 –1.232 to 0.848 0.7172
Treatment D vs. A 0.222 –0.645 to 1.089 0.6161
Ethnicity –0.326 –1.101 to 0.448 0.4086
Association parameters Marker 0.271 –1.151 to 1.693 0.7086
Weight –0.059 –0.253 to 0.135 0.5504
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Plasma biomarkers
Adiponectin
Histograms to check normality for adiponectin
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FIGURE 28 Normality of adiponectin. (a) original scale; and (b) log-transformed.
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FIGURE 29 Adiponectin mean profiles by treatment arm (original scale). (a) adiponectin profile plots;
(b) adiponectin profile plots by dropout; and (c) adiponectin reverse-time profile plots.
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The bivariate joint model included 324 patients and 829 records. Adiponectin scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-adiponectin is
0.035 (95% CI –0.078 to 0.148), implying that there is no significant difference between the treatments
on adiponectin.
TABLE 45 Joint model estimates: log-adiponectin
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.555 0.297 to 0.812 < 0.0001
Time –0.001 –0.003 to 0.001 0.3345
Baseline marker 0.787 0.709 to 0.865 < 0.0001
Treatment B vs. A 0.072 –0.060 to 0.204 0.2846
Treatment C vs. A 0.045 –0.077 to 0.168 0.4696
Treatment D vs. A 0.035 –0.078 to 0.148 0.5420
Ethnicity –0.043 –0.161 to 0.075 0.4731
Longitudinal weight Intercept 0.491 –1.739 to 2.720 0.6661
Time 0.020 –0.003 to 0.043 0.0941
Baseline weight 0.992 0.970 to 1.013 < 0.0001
Treatment B vs. A 0.441 –0.608 to 1.489 0.4103
Treatment C vs. A 0.683 –0.465 to 1.832 0.2437
Treatment D vs. A 0.084 –0.932 to 1.100 0.8713
Ethnicity –0.054 –0.931 to 0.824 0.9046
Dropout Treatment B vs. A 0.263 –0.665 to 1.190 0.5791
Treatment C vs. A 0.023 –1.000 to 1.046 0.9649
Treatment D vs. A 0.260 –0.625 to 1.146 0.5644
Ethnicity –0.059 –0.908 to 0.789 0.8912
Association parameters Marker 0.415 –1.394 to 2.223 0.6529
Weight –0.034 –0.242 to 0.174 0.7467
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Leptin
Histograms to check normality for leptin
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FIGURE 30 Normality of leptin. (a) original scale; and (b) log-transformed.
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FIGURE 31 Leptin mean profiles by treatment arm (original scale). (a) leptin profile plots; (b) leptin profile plots by
dropout; and (c) leptin reverse-time profile plots.
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The bivariate joint model included 325 patients and 841 records. Leptin scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-leptin is
0.004 (95% CI –0.179 to 0.187), implying that there is no significant difference between the treatments
on leptin.
TABLE 46 Joint model estimates: log-leptin
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.893 0.419 to 1.367 0.0002
Time 0.001 –0.002 to 0.003 0.6639
Baseline marker 0.906 0.857 to 0.956 < 0.0001
Treatment B vs. A –0.010 –0.198 to 0.177 0.9132
Treatment C vs. A 0.161 –0.038 to 0.359 0.1126
Treatment D vs. A 0.004 –0.179 to 0.187 0.9664
Ethnicity –0.061 –0.226 to 0.105 0.4727
Longitudinal weight Intercept 1.017 –1.224 to 3.258 0.3738
Time 0.020 –0.008 to 0.048 0.1713
Baseline weight 0.982 0.961 to 1.004 < 0.0001
Treatment B vs. A 0.386 –0.671 to 1.443 0.4739
Treatment C vs. A 0.840 –0.248 to 1.929 0.1302
Treatment D vs. A 0.148 –0.817 to 1.113 0.7637
Ethnicity 0.155 –0.682 to 0.991 0.7174
Dropout Treatment B vs. A –0.020 –1.047 to 1.007 0.9695
Treatment C vs. A 0.244 –0.724 to 1.212 0.6213
Treatment D vs. A 0.346 –0.569 to 1.260 0.4588
Ethnicity 0.122 –0.773 to 1.016 0.7893
Association parameters Marker 0.050 –1.425 to 1.524 0.9474
Weight –0.108 –0.433 to 0.218 0.5168
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Interleukin 8
Histograms to check normality for interleukin 8
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FIGURE 32 Normality of IL-8. (a) original scale; and (b) log-transformed.
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FIGURE 33 IL-8 mean profiles by treatment arm (original scale). (a) IL-8 profile plots; (b) IL-8 profile plots by
dropout; and (c) IL-8 reverse-time profile plots.
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The bivariate joint model included 327 patients and 845 records. IL-8 scores were fitted in log-transformed
scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-IL-8 is 0.041
(95% CI –0.111 to 0.193), implying that there is no significant difference between the treatments on IL-8.
TABLE 47 Joint model estimates: log-IL-8
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 1.851 1.594 to 2.107 < 0.0001
Time 0.006 0.003 to 0.009 0.0004
Baseline marker 0.297 0.246 to 0.348 < 0.0001
Treatment B vs. A 0.021 –0.145 to 0.187 0.8029
Treatment C vs. A –0.112 –0.303 to 0.078 0.2480
Treatment D vs. A 0.041 –0.111 to 0.193 0.5950
Ethnicity 0.103 –0.042 to 0.249 0.1647
Longitudinal weight Intercept 0.436 –1.841 to 2.712 0.7077
Time 0.020 –0.002 to 0.043 0.0784
Baseline weight 0.991 0.969 to 1.013 < 0.0001
Treatment B vs. A 0.506 –0.525 to 1.537 0.3361
Treatment C vs. A 0.689 –0.409 to 1.788 0.2188
Treatment D vs. A 0.194 –0.807 to 1.195 0.7042
Ethnicity –0.018 –0.864 to 0.829 0.9675
Dropout Treatment B vs. A 0.166 –0.776 to 1.108 0.7301
Treatment C vs. A 0.027 –0.964 to 1.019 0.9568
Treatment D vs. A 0.237 –0.648 to 1.122 0.6000
Ethnicity –0.353 –1.166 to 0.460 0.3948
Association parameters Marker –0.006 –1.347 to 1.335 0.9927
Weight –0.053 –0.254 to 0.148 0.6050
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Tumour necrosis factor alpha
Histograms to check normality for tumour necrosis factor alpha
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FIGURE 34 Normality of TNF-α. (a) original scale; and (b) log-transformed.
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FIGURE 35 TNF-α mean profiles by treatment arm (original scale). (a) TNF-α profile plots; (b) TNF-α profile plots by
dropout; and (c) TNF-α reverse-time profile plots.
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The bivariate joint model included 325 patients and 838 records. TNF-α scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-TNF-α is
–0.025 (95% CI –0.133 to 0.082), implying that there is no significant difference between the treatments
on TNF-α.
TABLE 48 Joint model estimates: log-TNF-α
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.154 –0.011 to 0.319 0.0682
Time 0.007 0.004 to 0.009 < 0.0001
Baseline marker 0.642 0.561 to 0.723 < 0.0001
Treatment B vs. A 0.002 –0.119 to 0.122 0.9800
Treatment C vs. A –0.058 –0.197 to 0.080 0.4093
Treatment D vs. A –0.025 –0.133 to 0.082 0.6412
Ethnicity 0.119 0.005 to 0.233 0.0415
Longitudinal weight Intercept 0.433 –1.940 to 2.806 0.7208
Time 0.020 –0.006 to 0.047 0.1374
Baseline weight 0.992 0.970 to 1.014 < 0.0001
Treatment B vs. A 0.492 –0.560 to 1.544 0.3591
Treatment C vs. A 0.736 –0.392 to 1.864 0.2010
Treatment D vs. A 0.107 –0.920 to 1.134 0.8381
Ethnicity –0.078 –0.979 to 0.824 0.8656
Dropout Treatment B vs. A 0.169 –0.826 to 1.164 0.7392
Treatment C vs. A 0.119 –0.902 to 1.140 0.8190
Treatment D vs. A 0.425 –0.495 to 1.345 0.3653
Ethnicity –0.236 –1.052 to 0.579 0.5700
Association parameters Marker 0.492 –1.269 to 2.252 0.5841
Weight –0.060 –0.259 to 0.139 0.5545
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Resistin
Histograms to check normality for resistin
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FIGURE 36 Normality of resistin (a) original scale; and (b) log-transformed.
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FIGURE 37 Resistin mean profiles by treatment arm (original scale). (a) Resistin profile plots; (b) resistin profile plots
by dropout; and (c) resistin reverse-time profile plots.
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The bivariate joint model included 326 patients and 841 records. Resistin scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-resistin is
–0.066 (95% CI –0.171 to 0.039), implying that there is no significant difference between the treatments
on resistin.
TABLE 49 Joint model estimates: log-resistin
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 3.449 2.786 to 4.112 < 0.0001
Time 0.004 0.002 to 0.005 < 0.0001
Baseline marker 0.591 0.518 to 0.665 < 0.0001
Treatment B vs. A –0.021 –0.133 to 0.091 0.7126
Treatment C vs. A –0.020 –0.131 to 0.091 0.7211
Treatment D vs. A –0.066 –0.171 to 0.039 0.2201
Ethnicity 0.038 –0.066 to 0.143 0.4699
Longitudinal weight Intercept 0.265 –1.993 to 2.522 0.8182
Time 0.021 –0.003 to 0.045 0.0877
Baseline weight 0.994 0.972 to 1.016 < 0.0001
Treatment B vs. A 0.436 –0.620 to 1.493 0.4180
Treatment C vs. A 0.699 –0.394 to 1.793 0.2101
Treatment D vs. A 0.076 –0.919 to 1.070 0.8816
Ethnicity –0.054 –0.907 to 0.799 0.9009
Dropout Treatment B vs. A 0.174 –0.750 to 1.098 0.7125
Treatment C vs. A 0.145 –0.798 to 1.087 0.7636
Treatment D vs. A 0.263 –0.608 to 1.134 0.5545
Ethnicity –0.192 –1.075 to 0.691 0.6701
Association parameters Marker 0.710 –0.679 to 2.099 0.3163
Weight –0.052 –0.251 to 0.148 0.6119
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High-sensitivity C-reactive protein
Histograms to check normality for high-sensitivity C-reactive protein
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FIGURE 38 Normality of hs-CRP (a) original scale; and (b) log-transformed.
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FIGURE 39 hs-CRP mean profiles by treatment arm (original scale). (a) hs-CRP profile plots; (b) hs-CRP profile plots
by dropout; and (c) hs-CRP reverse-time profile plots.
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The bivariate joint model included 328 patients and 845 records. The hs-CRP scores were fitted in
log-transformed scale for normality.
The treatment effect [arm D (80 mg) compared with arm A (control)] on the longitudinal log-hs-CRP is
statistically significant with an estimated effect of –0.222 (95% CI –0.433 to –0.011), implying that hs-CRP
is significantly lower among those patients randomised to arm D (80 mg).
TABLE 50 Joint model estimates: log-hs-CRP
Component Parameter Estimate 95% CI p-value
Longitudinal marker Intercept 0.582 0.293 to 0.871 0.0001
Time 0.001 –0.003 to 0.006 0.6069
Baseline marker 0.612 0.527 to 0.697 < 0.0001
Treatment B vs. A –0.207 –0.444 to 0.030 0.0867
Treatment C vs. A –0.204 –0.443 to 0.036 0.0953
Treatment D vs. A –0.222 –0.433 to –0.011 0.0388
Ethnicity –0.278 –0.501 to –0.056 0.0141
Longitudinal weight Intercept 0.378 –2.039 to 2.795 0.7593
Time 0.020 –0.004 to 0.045 0.1074
Baseline weight 0.993 0.969 to 1.016 < 0.0001
Treatment B vs. A 0.489 –0.571 to 1.549 0.3656
Treatment C vs. A 0.728 –0.419 to 1.875 0.2135
Treatment D vs. A 0.091 –0.921 to 1.103 0.8599
Ethnicity –0.095 –0.972 to 0.782 0.8317
Dropout Treatment B vs. A 0.086 –0.866 to 1.038 0.8592
Treatment C vs. A 0.046 –0.931 to 1.024 0.9257
Treatment D vs. A 0.321 –0.579 to 1.222 0.4841
Ethnicity –0.213 –1.014 to 0.588 0.6017
Association parameters Marker 0.248 –0.732 to 1.228 0.6197
Weight –0.046 –0.234 to 0.142 0.6328
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Substudies
Magnetic resonance imaging
TABLE 51 Summary statistics for the MRI and 1H-MRS measurements at baseline and 24 weeks by treatment group
Summary statistic
Time point
Baseline 24 weeks
Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg) Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg)
Internal visceral fat (dm3)
Number (%) 8 (61.5) 7 (70.0) 6 (60.0) 8 (80.0) 8 (61.5) 7 (70.0) 5 (50.0) 8 (80.0)
Mean (SD);
min.–max.
3.5 (1.1); 1.6–5.1 5.15 (2.20);
2.60–8.33
3.58 (2.70);
1.78–8.79
4.10 (2.71);
0.70–8.04
3.74 (1.43);
1.62–5.69
5.18 (2.67);
1.93–9.55
4.42 (2.06);
2.54–7.04
4.74 (2.59);
0.69–8.98
Median (IQR) 3.3 (2.8–4.2) 5.4 (2.8–7.2) 2.3 (2.0–4.2) 3.6 (1.6–5.6) 3.3 (2.9–4.7) 4.9 (2.5–7.5) 3.3 (2.9–6.2) 4.6 (2.4–5.8)
Missing (%) 5 (38.5) 3 (30.0) 4 (40.0) 2 (20.0) 5 (38.5) 3 (30.0) 5 (50.0) 2 (20.0)
Intrahepatic triglyceride content
Number (%) 12 (92.3) 10 (100.0) 8 (80.0) 10 (100.0) 8 (62.0) 7 (70.0) 4 (40.0) 8 (80.0)
Mean (SD);
min.–max.
8.2 (18.2);
0.4–64.8
6.7 (10.4);
0.4–30.7
1.9 (2.1);
0.3–6.4
2.2 (4.8);
0.1–14.0
3.0 (4.1);
0.1–12.8
7.3 (10.1);
0.2–25.1
1.2 (0.5);
0.7–1.7
1.6 (2.7);
0.3–6.9
Median (IQR) 1.7 (0.6–3.0) 1.6 (0.4–8.4) 1.2 (0.4–2.0) 1.0 (0.6–1.5) 1.8 (0.8–2.4) 2.5 (0.4–18.3) 1.3 (0.7–1.5) 0.6 (0.3–1.3)
Missing (%) 1 (7.7) 0 (0.0) 2 (20.0) 0 (0.0) 5 (38.0) 3 (30.0) 6 (60.0) 2 (20.0)
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Summary statistic
Time point
Baseline 24 weeks
Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg) Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg)
Intramyocellular triglyceride content (soleus)
Number (%) 12 (92.3) 10 (100.0) 8 (80.0) 10 (100.0) 8 (62.0) 7 (70.0) 4 (40.0) 8 (80.0)
Mean (SD);
min.–max.
19.5 (10.8);
6.2–41.8
19.0 (17.8);
6.1–65.1
12.6 (5.8);
5.0–22.4
17.3 (11.8);
7.4–44.5
19.5 (13.3);
5.2–40.0
17.1 (9.2);
7.7–33.7
22.2 (21.0);
4.8–51.9
16.6 (9.0);
8.2–33.6
Median (IQR) 17.8 (11.1–23.2) 12.4 (6.8–25.6) 11.8 (7.2–15.2) 13.7 (9.2–21.1) 16.7 (5.3–21.6) 15.8 (7.8–21.5) 16.1 (4.8–21.8) 14.5 (8.2–17.5)
Missing (%) 1 (7.7) 0 (0.0) 2 (20.0) 0 (0.0) 5 (38.0) 3 (30.0) 6 (60.0) 2 (20.0)
Intramyocellular triglyceride content (tibialis anterior)
Number (%) 11 (84.6) 10 (100.0) 8 (80.0) 9 (90.0) 8 (62.0) 7 (70.0) 4 (40.0) 8 (80.0)
Mean (SD);
min.–max.
6.3 (3.1);
0.0–11.0
8.1 (3.7);
1.4–13.9
5.3 (2.1);
3.0–9.6
7.8 (2.8);
3.0–11.0
8.1 (5.0);
2.6–18.6
10.2 (6.3);
2.5–17.7
5.1 (1.4);
3.8–6.6
7.4 (2.7);
3.4–11.2
Median (IQR) 5.9 (4.9–9.1) 8.6 (5.9–10.5) 4.9 (3.6–5.4) 7.7 (7.3–9.7) 7.4 (3.5–8.4) 9.8 (2.8–17.6) 4.9 (3.8–5.8) 7.8 (3.9–8.8)
Missing (%) 2 (15.4) 0 (0.0) 2 (20.0) 1 (10.0) 5 (38.0) 3 (30.0) 6 (60.0) 2 (20.0)
max., maximum; min., minimum.
Note
The main reason for missing MRI data at baseline is that MRI images were sent to Vardis (Vardis Limited, London, UK) for volume quantification mainly when images had been acquired at
both time points (baseline and 24 weeks). However, there was one patient for whom baseline MRI volumes were estimated by Vardis, although the patient did not attend the 24-week
follow-up visit.
D
O
I:10.3310/em
e06060
EFFICA
CY
A
N
D
M
ECH
A
N
ISM
EVA
LU
A
TIO
N
2019
VO
L.6
N
O
.6
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Pushpakom
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,U
K
.
145
TABLE 52 Summary statistics for the other MRI measures (external abdominal fat, total internal fat, total external fat and total body fat) at baseline and 24 weeks by
treatment group
Summary statistic
Time point
Baseline 24 weeks
Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg) Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg)
External abdominal fat (dm3)
Number (%) 8 (61.5) 7 (70.0) 6 (60.0) 8 (80.0) 8 (61.5) 7 (70.0) 5 (50.0) 8 (80.0)
Mean (SD);
min.–max.
5.0 (3.6);
1.7–12.2
6.4 (3.1);
2.6–10.9
4.1 (2.3);
1.3–6.7
3.4 (1.8);
0.8–6.7
5.1 (3.6);
1.2–12.1
6.7 (3.5);
2.2–11.1
5.06 (2.3);
1.8–7.5
3.8 (2.2);
0.8–8.0
Median (IQR) 3.8 (1.9–6.8) 6.1 (2.6–8.8) 4.7 (1.5–5.9) 3.2 (2.4–3.6) 3.8 (2.0–7.1) 7.4 (2.4–9.1) 5.0 (4.3–6.8) 3.2 (2.9–3.8)
Missing (%) 5 (38.5) 3 (30.0) 4 (40.0) 2 (20.0) 5 (38.5) 3 (30.0) 5 (50.0) 2 (20.0)
Total internal fat (dm3)
Number (%) 8 (61.5) 7 (70.0) 6 (60.0) 8 (80.0) 8 (61.5) 7 (70.0) 5 (50.0) 8 (80.0)
Mean (SD);
min.–max.
6.1 (1.6);
3.1–7.5
8.3 (2.7);
5.4–12.1
6.1 (3.7);
3.6–13.4
6.8 (4.1);
2.5–12.5
6.5 (1.9);
3.2–8.8
8.5 (3.2);
5.5–13.9
7.1 (2.5);
4.7–9.9
7.9 (3.3);
2.9–12.7
Median (IQR) 6.8 (4.7–7.0) 8.7 (5.8–10.8) 4.7 (3.9–6.3) 6.0 (3.0–9.4) 6.3 (5.0–7.9) 7.5 (5.6–11.9) 6.7 (4.9–9.5) 7.8 (5.0–9.3)
Missing (%) 5 (38.5) 3 (30.0) 4 (40.0) 2 (20.0) 5 (38.5) 3 (30.0) 5 (50.0) 2 (20.0)
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Summary statistic
Time point
Baseline 24 weeks
Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg) Arm A (control) Arm B (20mg) Arm C (40mg) Arm D (80mg)
Total external fat (dm3)
Number (%) 8 (61.5) 7 (70.0) 6 (60.0) 8 (80.0) 8 (61.5) 7 (70.0) 5 (50.0) 8 (80.0)
Mean (SD);
min.–max.
18.1 (11.0);
8.1–41.1
20.4 (7.3);
9.7–30.3
13.3 (5.4);
5.6–17.6
12.2 (5.4);
5.0–22.8
18.3 (11.1);
6.5–40.0
20.9 (8.3);
8.7–32.3
16.4 (5.4);
7.6–20.9
13.3 (5.1);
5.5–22.4
Median (IQR) 15.0 (9.0–20.8) 22.3 (11.4–24.4) 16.0 (7.2–17.5) 12.0 (7.3–12.8) 14.9 (9.4–22.1) 22.7 (12.1–27.8) 16.9 (16.1–20.4) 12.6 (9.4–14.9)
Missing (%) 5 (38.5) 3 (30.0) 4 (40.0) 2 (20.0) 5 (38.5) 3 (30.0) 5 (50.0) 2 (20.0)
Total body fat (dm3)
Number (%) 8 (61.5) 7 (70.0) 6 (60.0) 8 (80.0) 8 (61.5) 7 (70.0) 5 (50.0) 8 (80.0)
Mean (SD);
min.–max.
24.2 (11.5);
11.2–47.7
28.6 (9.5);
15.5–41.2
19.4 (7.4);
9.5–29.5
19.0 (8.4);
7.5–32.1
24.8 (11.6);
9.6–45.9
20.4 (11.2);
14.1–44.2
23.5 (5.9);
14.3–29.9
21.1 (7.6);
8.1–31.7
Median (IQR) 21.5
(15.9–25.5)
31.0
(16.8–36.4)
20.6
(12.4–23.9)
19.8
(10.4–24.3)
22.2
(16.0–27.0)
30.1
(17.6–41.7)
25.8
(21.7–25.9)
21.5
(15.3–25.8)
Missing (%) 5 (38.5) 3 (30.0) 4 (40.0) 2 (20.0) 5 (38.5) 3 (30.0) 5 (50.0) 2 (20.0)
max., maximum; min., minimum.
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TABLE 53 Model estimates for internal visceral fat (dm3) at 24 weeks (arm A, n= 8 patients; arm D, n= 8 patients)
Variable Parameter estimate Standard error 95% CI p-value
Intercept (in dm3) 0.129 0.333 –0.604 to 0.861 0.7063
Baseline value of internal visceral fat
(in dm3)
1.010 0.073 0.849 to 1.170 < 0.0001
Relative change in total external fat 4.161 1.423 1.029 to 7.293 0.0138
Change in weight (kg) –0.034 0.063 –0.173 to 0.104 0.5941
Treatment arm D vs. control 0.038 0.287 –0.593 to 0.670 0.8961
TABLE 54 Model estimates for intrahepatic triglyceride content in liver at 24 weeks (arm A, n= 8 patients; arm D,
n= 8 patients)
Variable Parameter estimate Standard error 95% CI p-value
Intercept 1.359 0.375 0.542 to 2.177 0.0035
Baseline value of intrahepatic triglyceride
content in liver
0.722 0.059 0.594 to 0.850 < 0.0001
Change in weight (kg) 0.365 0.102 0.141 to 0.588 0.0039
Treatment arm D vs. control –1.714 0.492 –2.787 to –0.642 0.0045
TABLE 55 Model estimates for intramyocellular triglyceride content in the soleus and tibialis anterior at 24 weeks
(arm A, n= 8 patients; arm D, n= 8 patients)
Variable Intercept Baseline value Change in weight (kg) Treatment D vs. control
Soleus and tibialis anteriora
Approximately F 170.465 4.459 0.565 0.213
Numerator df 2 4 2 2
Denominator df 9 20 9 9
p-value < 0.0001 0.0097 0.5873 0.8123
Soleusb
Parameter estimate 2.222 0.902 –0.496 –2.567
Standard error 3.589 0.143 0.724 2.559
95% CI –5.677 to 10.121 0.587 to 1.216 –2.089 to 1.097 –8.200 to 3.066
p-value 0.5480 < 0.0001 0.5070 0.3370
Tibialis anteriorb
Parameter estimate 9.882 –0.243 –0.060 –0.479
Standard error 3.087 0.420 0.522 2.472
95% CI 0.3087 to 16.678 –1.168 to 0.682 –1.089 to 1.210 –5.919 to 4.961
p-value 0.0080 0.5750 0.9100 0.8499
df, degrees of freedom.
a Multivariate test.
b Univariate models (ANCOVA).
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Urinary biomarkers
Neutrophil gelatinase-associated lipocalin
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FIGURE 40 Longitudinal NGAL mean profiles for arm A (control) and arm D (80mg) over tertile subgroups.
(a) NGAL < 2.28 at baseline; (b) NGAL > 2.28 and < 10.51 at baseline; and (c) NGAL > 10.51 at baseline.
DOI: 10.3310/eme06060 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 6
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Pushpakom et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
149
TABLE 56 Estimates from linear mixed-effect model for each subgroup for longitudinal NGAL
Variable
Tertile
First Second Third
Parameter SE 95% CI p-value Parameter SE 95% CI p-value Parameter SE 95% CI p-value
Intercept 2.271 0.469 1.345 to 3.197 < 0.0001 0.180 0.691 –1.184 to 1.543 0.7952 1.192 0.759 –0.309 to 2.693 0.1186
Time 0.005 0.004 –0.003 to 0.013 0.2545 0.006 0.004 –0.003 to 0.015 0.1854 0.003 0.004 –0.006 to 0.012 0.4670
Baseline NGAL 0.562 0.183 0.198 to 0.926 0.0028 0.480 0.227 0.031 to 0.930 0.0366 0.417 0.137 0.1460 to 0.688 0.0030
Age –0.015 0.009 –0.032 to 0.002 0.0873 0.011 0.010 –0.008 to 0.030 0.2635 –0.002 0.010 –0.022 to 0.018 0.8741
Ethnicity –0.057 0.249 –0.551 to 0.437 0.8194 0.094 0.275 –0.452 to 0.640 0.7336 –0.232 0.303 –0.833 to 0.368 0.4448
Sex (male) –0.500 0.250 –0.997 to –0.004 0.0483 0.097 0.294 –0.486 to 0.681 0.7413 0.048 0.307 –0.562 to 0.657 0.8772
Treatment B vs. A –0.511 0.224 –0.955 to –0.067 0.0247 0.075 0.234 –0.390 to 0.540 0.7490 –0.028 0.281 –0.585 to 0.528 0.9195
Treatment C vs. A –0.300 0.240 –0.776 to 0.175 0.2133 –0.563 0.262 –1.084 to –0.043 0.0343 0.080 0.291 –0.498 to 0.658 0.7846
Treatment D vs. A –0.215 0.207 –0.627 to 0.196 0.3018 –0.065 0.225 –0.512 to 0.382 0.7733 –0.347 0.275 –0.893 to 0.198 0.2093
SE, standard error.
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Albumin-to-creatinine ratio
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FIGURE 41 Longitudinal ACR mean profiles for arm A (control) and arm D (80mg) over threshold subgroups.
Note: the profile shown in ACR > 30 includes a single patient. (a) ACR < 3mg/mmol at baseline; (b) ACR between 3
and 30mg/mmol at baseline; and (c) ACR > 30mg/mmol at baseline.
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TABLE 57 Estimates from linear mixed-effect model for each subgroup for longitudinal ACR
Variable
ACR
< 3 ≥ 3
Parameter SE 95% CI p-value Parameter SE 95% CI p-value
Intercept 0.336 0.668 –0.999 to 1.672 0.6166 –1.779 0.908 –3.638 to 0.081 0.0601
Time 0.002 0.004 –0.005 to 0.009 0.5727 0.007 0.007 –0.006 to 0.021 0.2882
Baseline ACR 0.564 0.131 0.301 to 0.826 0.0001 0.877 0.221 0.406 to 1.347 0.0012
Age –0.007 0.013 –0.032 to 0.018 0.5804 0.014 0.015 –0.018 to 0.046 0.3696
Ethnicity 0.182 0.245 –0.308 to 0.672 0.4616 1.159 0.403 0.300 to 2.019 0.0116
Treatment B vs. A –0.320 0.223 –0.766 to 0.126 0.1567 –0.903 0.382 –1.718 to –0.088 0.0321
Treatment C vs. A –0.111 0.258 –0.626 to 0.404 0.6676 0.643 0.480 –0.381 to 1.667 0.2008
Treatment D vs. A –0.074 0.253 –0.578 to 0.431 0.7715 –0.665 0.303 –1.310 to –0.019 0.0443
SE, standard error.
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FIGURE 42 Scatterplots showing the correlation between NGAL and ACR at baseline and follow-up time points.
(a) All pairs; and (b) ACR 3–30.
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Safety data analysis
Adverse drug reactions by severity
The number of ARs and the number and percentage of patients affected in each category by treatment arm and by severity are provided in Table 58. For each
patient, only the maximum severity experienced for each type of AR will be displayed.
TABLE 58 Adverse reactions by severity
AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Abdominal distension Mild 0 0 0.0 2 2 2.4 1 1 0.9 3 3 0.8
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Abdominal pain upper Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Acute sinusitis Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Ageusia Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Amnesia Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Angioedema Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Anxiety Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 1 1 1.2 1 1 0.9 2 2 0.5
Severe 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Arthralgia Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Asthenia Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Back pain Mild 2 2 2.4 0 0 0.0 1 1 0.9 3 3 0.8
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Burning sensation Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Campylobacter gastroenteritis Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Chest pain Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Chromaturia Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Confusional state Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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TABLE 58 Adverse reactions by severity (continued )
AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Constipation Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Cough Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Depressed mood Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Depression Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Diarrhoea Mild 1 1 1.2 0 0 0.0 6 6 5.7 7 7 1.9
Moderate 0 0 0.0 3 2 2.4 0 0 0.0 3 2 0.5
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Disturbance in attention Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Dizziness Mild 6 6 7.1 4 4 4.9 13 13 12.3 23 23 6.1
Moderate 0 0 0.0 2 2 2.4 2 2 1.9 4 4 1.1
Severe 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Double ureter Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Dry eye Mild 0 0 0.0 0 0 0.0 2 1 0.9 2 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Dry mouth Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Dry skin Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Dysgeusia Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Dyspepsia Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 2 2 2.4 1 1 1.2 1 1 0.9 4 4 1.1
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Ear pain Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Ejaculation failure Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Epistaxis Mild 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Faeces soft Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Fall Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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TABLE 58 Adverse reactions by severity (continued )
AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Fatigue Mild 5 4 4.8 3 3 3.7 2 2 1.9 10 9 2.4
Moderate 0 0 0.0 0 0 0.0 4 4 3.8 4 4 1.1
Severe 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Feeling cold Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Feeling hot Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Haematoma Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Haematuria Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Headache Mild 3 3 3.6 5 5 6.1 5 5 4.7 13 13 3.4
Moderate 2 2 2.4 1 1 1.2 5 4 3.8 8 7 1.9
Severe 1 1 1.2 1 1 1.2 0 0 0.0 2 2 0.5
Hepatic enzyme increased Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Hyperhidrosis Mild 1 1 1.2 1 1 1.2 0 0 0.0 2 2 0.5
Moderate 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Hypertension Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Hypotension Mild 1 1 1.2 2 1 1.2 0 0 0.0 3 2 0.5
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Increased appetite Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Influenza Mild 2 2 2.4 1 1 1.2 3 3 2.8 6 6 1.6
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Influenza like illness Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Insomnia Mild 1 1 1.2 0 0 0.0 1 1 0.9 2 2 0.5
Moderate 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lacrimation increased Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Loss of consciousness Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lower respiratory tract infection Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Malaise Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
continued
D
O
I:10.3310/em
e06060
EFFICA
CY
A
N
D
M
ECH
A
N
ISM
EVA
LU
A
TIO
N
2019
VO
L.6
N
O
.6
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Pushpakom
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,U
K
.
159
TABLE 58 Adverse reactions by severity (continued )
AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Morbid thoughts Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Mouth ulceration Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Myalgia Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Nasopharyngitis Mild 0 0 0.0 1 1 1.2 1 1 0.9 2 2 0.5
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Nausea Mild 1 1 1.2 3 2 2.4 2 1 0.9 6 4 1.1
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Neck pain Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Neutropenia Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Onychomycosis Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Oropharyngeal pain Mild 0 0 0.0 1 1 1.2 1 1 0.9 2 2 0.5
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Orthostatic hypotension Mild 0 0 0.0 3 2 2.4 1 1 0.9 4 3 0.8
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Osteopenia Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Pain in jaw Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Palpitations Mild 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Paraesthesia Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Photosensitivity reaction Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Pruritus Mild 4 4 4.8 1 1 1.2 2 2 1.9 7 7 1.9
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Pulmonary fibrosis Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Pyrexia Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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TABLE 58 Adverse reactions by severity (continued )
AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Rash Mild 1 1 1.2 1 1 1.2 2 2 1.9 4 4 1.1
Moderate 0 0 0.0 0 0 0.0 2 2 1.9 2 2 0.5
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Renal impairment Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Rhinitis Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Sinus congestion Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Sinusitis Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Somnolence Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Syncope Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Tension headache Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Tongue coated Mild 0 0 0.0 0 0 0.0 1 1 0.9 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Tremor Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Trigeminal neuralgia Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Upper respiratory tract infection Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Urinary tract infection Mild 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Vision blurred Mild 1 1 1.2 1 1 1.2 2 2 1.9 4 4 1.1
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Visual impairment Mild 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Moderate 1 1 1.2 0 0 0.0 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Vomiting Mild 0 0 0.0 1 1 1.2 1 1 0.9 2 2 0.5
Moderate 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
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TABLE 58 Adverse reactions by severity (continued )
AR Severity
Treatment arm
Total randomised (n= 377)Arm B (20mg) (N= 84) Arm C (40mg) (N= 82) Arm D (80mg) (N= 106)
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Number of
events
Number of
patients
Percentage
of patients
Weight increased Mild 0 0 0.0 1 1 1.2 0 0 0.0 1 1 0.3
Moderate 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Severe 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Grand total Mild 41 20 23.8 47 18 22.0 65 27 25.5 153 65 17.2
Moderate 7 6 7.1 18 8 9.8 36 21 19.8 61 35 9.3
Severe 2 2 2.4 3 2 2.4 1 1 0.9 6 5 1.3
Patient 00162281 – arm D – dizziness (moderate and severe: included the severe AR).
Patient 01552036 – arm C – dizziness (mild and moderate: included the moderate AR).
Patient 00162174 – arm D – headache (mild and moderate: included the moderate AR).
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Serious adverse events
TABLE 59 Serious adverse events
SAE
number Description (PT) Description (SOC) Seriousness Allocation Severity Expectedness
Relationship
Withdrew
from study
drug Outcome Patient status
PI’s
assessment
Chief
Investigator’s
assessment
1 Laceration Injury, poisoning and
procedural complications
Required hospitalisation Arm C (40mg) Grade 4, potentially
life-threatening
Unexpected Unrelated Unrelated No Resolved Continuing in
trial
2 Plasmablastic
lymphoma
Neoplasms benign,
malignant and unspecified
(including cysts and polyps)
Medically significant/
important
Arm C (40mg) Grade 4, potentially
life-threatening
Unexpected Unrelated Unrelated Yes Ongoing
at final
follow-up
Withdrawn from
treatment
Plasmablastic large
B-cell lymphoma
3 Paraesthesia Nervous system disorders Required hospitalisation Arm C (40mg) Grade 2, moderate Expected Probably Probably Yes Resolved Withdrawn from
treatment
4 Mastitis Infections and infestations Required hospitalisation Arm D (80mg) Grade 1, mild Unexpected Unrelated Unrelated No Resolved Continuing in
trial
5 Infected bites Infections and infestations Required hospitalisation Arm A (control) Grade 3, severe NA NA NA No Resolved Continuing in
trial
6 Hepatitis C Infections and infestations Medically significant/
important
Arm C (40mg) Grade 3, severe Unexpected Unlikely Unrelated Yes Resolved Withdrawn from
treatment
Hepatitis C
7 Haemoptysis Respiratory, thoracic and
mediastinal disorders
Required hospitalisation Arm B (20mg) Grade 3, severe Unexpected Unrelated Unrelated No Resolved Continuing in
trial
8 Skin cancer Neoplasms benign,
malignant and unspecified
(including cysts and
polyps)
Medically
significant/important
Arm D (80mg) Grade 4, potentially
life-threatening
Unexpected Unrelated Unrelated No Not
resolved/
ongoing
Completed trial
Skin cancer recurrence
9 Limb injury Injury, poisoning and
procedural complications
Required hospitalisation Arm B (20mg) Grade 2, moderate Unexpected Unrelated Unrelated No Resolved Completed trial
10 Laceration Injury, poisoning and
procedural complications
Required hospitalisation Arm A (control) Grade 1, mild NA NA NA No Resolved Continuing in
trial
11 Pneumonia Infections and infestations Required hospitalisation Arm A (control) Grade 2, moderate NA NA NA No Resolved Continuing in
trial
12 Joint dislocation Injury, poisoning and
procedural complications
Required hospitalisation Arm D (80mg) Grade 3, severe Unexpected Unlikely Unrelated Yes Resolved Withdrawn from
treatment
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TABLE 59 Serious adverse events (continued )
SAE
number Description (PT) Description (SOC) Seriousness Allocation Severity Expectedness
Relationship
Withdrew
from study
drug Outcome Patient status
PI’s
assessment
Chief
Investigator’s
assessment
13 Groin pain Musculoskeletal and
connective tissue disorders
Required hospitalisation Arm B (20mg) Grade 3, severe Unexpected Unrelated Unrelated No Ongoing
at final
follow-up
Completed trial
14 Joint dislocation Injury, poisoning and
procedural complications
Required hospitalisation Arm D (80mg) Grade 3, severe Unexpected Unlikely Unrelated Yes Resolved Continuing in
trial
15 Convulsion Nervous system disorders Required hospitalisation Arm A (control) Grade 2, moderate NA NA NA No Resolved Continuing in
trial
16 Chest pain General disorders and
administration site
conditions
Required hospitalisation Arm D (80mg) Grade 2, moderate Unexpected Unrelated Unlikely No Resolved Continuing in
trial
17 Death General disorders and
administration site
conditions
Required hospitalisation Arm A (control) Grade 5, death NA NA NA No Fatal Death
18 Abdominal pain
upper
Gastrointestinal disorders Required hospitalisation Arm A (control) Grade 2, moderate NA NA NA No Resolved Continuing in
trial
19 Meningitis
cryptococcal
Infections and infestations Required hospitalisation Arm D (80mg) Grade 2, moderate Unexpected Unrelated Unrelated No Resolved Continuing in
trial
20 Gastroenteritis
viral
Infections and infestations Required hospitalisation Arm D (80mg) Grade 2, moderate Unexpected Unrelated Unrelated No Resolved Continuing in
trial
21 Pregnancy Pregnancy, puerperium
and perinatal conditions
Medically significant/
important
Arm D (80mg)
a
Unexpected Unrelated Unrelated Yes Not
resolved/
ongoing
Completed trial
Pregnancy
NA, not applicable (patient is in the control group).
a This is a pregnancy-related SAE; therefore, the severity cannot be completed until the baby is born. The research team have sent in several file notes. The patient moved out of the area and they have been unable to contact her to find out the
pregnancy outcome. They have also tried to contact the HIV team at the new hospital, but have received no response. The MHRA were contacted at the time and the trial co-ordinator was advised that they do not consider pregnancy to be
a SAE.
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Compliance with study drug schedule
TABLE 60 Compliance split by treatment
Variable and summary statistic
Treatment arm
Arm B (20mg)
(N= 84)
Arm C (40mg)
(N= 82)
Arm D (80mg)
(N= 106)
Total dose (mg) consumed according to the
treatment diary
n= 48 n= 42 n= 64
Mean (SD), median; min.–max. 3215.4 (558.62),
3360; 296–3360
6347.4 (396.42),
6440; 4042–6440
11,829.8 (893.53),
12,040; 5160–12,040
n (%), missing 36 (42.8) 40 (48.8) 42 (39.6)
Total dose (mg) according to total number of
returned pills
n= 70 n= 61 n= 93
Mean (SD), median; min.–max. 3290.4 (112.89),
3360; 2880–3360
6155.4 (413.91),
6440; 4680–6440
11,146.8 (1181.00),
11,840; 7620–12,040
n (%), missing 14 (16.7) 21 (25.6) 13 (12.3)
Discrepancies between these two estimates of
total dosea
n= 43 n= 37 n= 62
Mean (SD), median; min.–max. 52.7 (601.34),
0.0; –392–3064
–234.3 (604.41),
–120; –1120–2398
–964.5 (1534.06),
–605.5; –3857–6720
n (%), missing 41 (48.8) 45 (54.9) 44 (41.5)
Average of these two estimates of total dose n= 43 n= 37 n= 62
Mean (SD), median; min.–max. 3238.3 (297.51),
3330; 1828–3360
6217.7 (249.28),
6180; 5241–6440
11,340.8 (745.23),
11,512.8; 8520–12,040
n (%), missing 41 (48.8) 45 (54.9) 44 (41.5)
max., maximum; min., minimum.
a Pill count – treatment diary.
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TABLE 61 Baseline measures according to whether or not patients provided any compliance data
Variable and summary statistic
Compliance data
No (N= 36) Some (N= 236)
Systolic blood pressure (mmHg)
Mean (SD) 127.5 (13.0) 125.0 (15.0)
Median (IQR); min.–max. 126.5 (118.5–136.5); 105–161 122 (115–135); 92–172
Diastolic blood pressure (mmHg)
Mean (SD) 76.0 (8.9) 79.2 (11.0)
Median (IQR); min.–max. 74 (70–81); 56–100 79 (71–87); 54–107
CD4 cell count (cells/mm3) (n= 226)
Mean (SD) 702.4 (255.0) 603.1 (261.1)
Median (IQR); min.–max. 680 (556–846.5); 81–1417 566.5 (425–770); 62–1674
CD4 cell count and HIV viral load (%)
Mean (SD) 31.0 (8.6) 29.8 (8.5)
Median (IQR); min.–max. 30 (27.5–34.5); 6–50 30 (24–36); 6–52
HIV viral load – copies/ml (n = 13) (n= 69)
Mean (SD) 16.8 (19.0) 40.6 (85.0)
Median (IQR); min.–max.a 3.5 (0–39); 0–39 26 (0–39); 0–649
< 10, n (%) 0 (0.0) 4 (1.7)
< 20, n (%) 2 (5.6) 52 (22.1)
< 40, n (%) 20 (55.6) 96 (40.9)
< 45, n (%) 0 (0.0) 12 (5.1)
< 100, n (%) 0 (0.0) 1 (0.4)
eGFR (ml/minute/1.73 m2) (n = 18) (n= 115)
Mean (SD) 76.7 (10.6) 80.5 (12.6)
Median (IQR); min.–max.a 77.2 (69–85); 53–90 79 (71–87); 56–122
< 60, n (%) 0 (0.0) 1 (0.4)
> 60, n (%) 4 (11.1) 66 (28.1)
> 90, n (%) 14 (38.9) 52 (22.1)
max., maximum; min., minimum.
a Some data are presented in both continuous and categorical form as a result of there being upper and lower limits
of measurement.
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